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1. INTRODUCTION 
Siddha system of medicine is an endowment of healing system granted by 
Siddhars for making the people with complete physical and mental health. Siddha is 
grounded on 96 fundamental principles, based on which the physiology of humans, 
pathology and diagnostic methodology of diseases, pharmacological action of medicines 
and astute treatment of diseases are explained.  
Need for preservation of medicines, the need for long half life for medicine, the 
need for coping up the different forms of disease in various conditions  paved the way for 
rise of 32 different forms of internal medicines and 32 different forms of external 
medicines in Siddha.  In the field of pharmacology, three kinds of natural sources are 
utilized for medicine purposes which include herbs, metal &minerals and animal sources.  
The application of drugs, indicated for different group of diseases are  based on 
the taste of the drug which, in turn, based on Panchabootham. Siddha classifies diseases 
into 4448. All these diseases can be grouped under three humours- 
Vatham,Pittam,Kabam. These three, in turn, get their basics from Panchabootham. In 
common, Panchabootham are the key handled by the siddhars to diagnose the disease 
and proper apt selection of medicine for the disease. 
Herbal sources are given prior importance in Siddha among the other natural 
sources, as their availability, purification process, medicine preparation process are 
comparatively handful and easier. Herbs have a traditional history of use, with strong 
roles in cultural heritage, and in the appreciation of food and its links to health.  
Moreover, Plants have the ability to synthesize a wide variety of chemical compounds 
that are used to perform important biological functions, and to defend against attack from 
predators such as insects, fungi and herbivorous mammals. 
Phytomedicine or Herbal medicine, is the science, art and discovery of using 
botanical remedies to treat illness. The term Phytotherapy describes the therapeutic 
application of plants. This term was coined by the French physician Henri leclerc(1870-
1955) who published numerous essays on the use of medicinal plants.(Benor DJ). Many 
of these phytochemicals have beneficial effects on long-term health when consumed by 
humans, and can be used to effectively treat human diseases. At least 12,000 such 
compounds have been isolated so far; a number estimated to be less than 10% of the total. 
(Cobiac L, et al) 
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Aivaeli(Diplocyclos palmatus) is such a kind of medicinal value rich herb, 
indicated for oligospermia, female infertility, edema, worm infestation, ECZEMA and 
arthritic pain in 'Pathaartha guna vilakkam'-an important gallery of Siddha medicines. 
Skin care is the lacuna in modern medical field where herbal medicines are slowly 
making the footprint and trying to establish its therapeutic values in recent days. In that 
sake Aivaeli(Diplocyclos palmatus) can contribute its role as it is indicated for eczema in 
Siddha literature. 
Skin is the organ of beauty and protection. Eczema is one of the skin ailments 
which affect this beauty and protective function of skin. Thus it affects physically and 
mentally. Diseases of the skin account for a great deal of misery, suffering, inability and 
economic loss. Besides this, they are a great handicap in the society, because they are 
visible. 
The word ‘Eczema’ seems to have originated in AD 543 and is derived from the 
Greek word ‘ekzein’ meaning ‘to boil out’ or ‘to effervesce’ (Andrews). Baer describes 
“Eczema” as a pruritic papulovesicular process which in its acute phase is associated with 
erythema and edema and which in its more chronic phases, while retaining some of its 
papulovesicular features, is dominated by thickening, lichenification and scaling.  
Assessment of epidemiological data in the UK has also found an inexorable rise in 
the prevalence of eczema over time. (Gupta R, et al, 2004 ). The incidence and lifetime 
prevalence of eczema in England have also been reported, such that an estimated 
5,773,700 or about one in every nine people have been diagnosed with the disease by a 
clinician at some point in their lives. (Simpson CR, et al March 2009).  
Finding anti-histamine, anti-inflammatory and anti-microbial activity of 
Aivaeli(Diplocyclos palmatus) will add a feather on cap of its pharmacological activities. 
This study is not yet done before. Hence, to add a medicine of choice  for eczema and to 
add a pharmacological support for Diplocyclos palmatus, detection of anti-histamine, 
anti-inflammatory, anti-microbial activity of Diplocyclos palmatus will stand worthwhile. 
The author decided to evaluate anti-histamine, anti-inflammatory and anti-
microbial activity of Aivaeli(Diplocyclos palmatus) samoola chooranam.  
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2. AIM AND OBJECTIVES 
 
AIM: 
 
The principle aim of this study is evaluate the efficacy of the drug Aivaeli samoola 
chooranam in the management of KARAPPAN (Eczema) in pre-clinical and clinical 
aspects. Eczema is relapsing or persistent pruritic disorders that affect on the quality of 
life. 
 
OBJECTIVES: 
 
The most important objectives of the study are 
Ø To study the pharmacognostic features of the plant Aivaeli (Diplocyclos palmatus) this 
includes correct taxonomic identification of the plant with macro and microscopically 
details. 
Ø To have a collective review of the literature. 
Ø To prepare the drug according to Siddha classical text. 
Ø To subject the drug to physico-chemical standardization. 
Ø To identify the phytochemical constituents of the drug. 
Ø To subject the trial drug to chemical analysis. 
Ø To study the acute toxicity of Aivaeli samoola  Chooranam according to OECD 
guidelines. 
Ø To determine the pharmacological activity (Anti histamine, Anti inflammatory, Anti 
microbial activity) of Aivaeli samoola chooranam. 
Ø To assess the therapeutic potential of the drug through clinical trial for the              
management of  Karappan 
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3. REVIEW OF LITERATURE 
 
3.1. BOTANICAL ASPECT OF THE PLANT: 
Botanical name: Diplocyclos palmatus(L) Jeffrey 
 
Synonyms: 
Bryonia palmate L 
Bryonia laciniosa L. 
 
Family: Cucurbitaceae (T.Pullaiah 2006) 
The name Bryonia meaning ‘to sprout’ in Greek, refers to vigorous growth of herbaceous 
stems that are produced annually from large perennial roots. (Kirtikar et al 1987) 
 
SCIENTIFIC  CLASSIFICATION 
Kingdom-Plantae 
Phylum-Magnoliophyta 
Class-Angiospermae 
Order-Cucurbitales 
Family-Cucurbitaceae 
Genus-Diplocyclos 
Species-palmatus 
 
Vernacular Names 
Tamil     :  Aivaeli, Aivirali, Sivalingakkay, Aiviralkkovai, 
English  :   Lollipop climber, striped cucumber, native bryony 
Sanskrit  :  Liagini 
Hindhi    :  Sivalingi 
Kan         :  Lingatondi 
Mal     :  Neyyunni, Sivalingakkaya, Neyyurwni, Aiviralikkova, Sivavalli 
Tel             : Lingadonda 
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Description: 
Chromosome number 2n=24 
Perennial, monoecious herb climbing by bifid tendrils. Stem up to 6m long. 
Young stems spotted with darker green. Leaves alternate, simple; stipules absent; Petiole 
2-10cm long; blade broadlyovate, palmately 5-7 lobed up to 14cm x 15cm;base cordate; 
lobes narrowly elliptical, margin sinuatedentate.  
Inflorescence an axillary cluster, with usually both male and female flowers in 
same axil. Flowers unisexual,regular,5-merous corolla white to greenish-yellow; male 
flowers pedicellate with 3 free stamens; Female flowers subsessile with inferior one 
celled ovary, stigma 3-lobed.Fruit a subglobose, indehiscent berry 1.5-12.5 cm in 
diameter, solitary or clustered, red with silvery white longitudinal stripes(Grubben 2004) 
Flowers & Fruits; April  to December (T.Pullaiah et al 1998) 
 
Ecology 
Diplocyclos palmatus occurs in different types of vegetation, but usually in wet 
localities, e.g swampy forest, flood-plains and valleys at altitudes up to 1800 m. (Grubben 
2004) 
 
DISTRIBUTION 
World-Tropical Africa, Indo-China, Malaysia, Southern China, Philippines and 
Australia. 
India-In hedges and bushes all over India.( T.Pullaiah 2006) 
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Fig. No.3.A   Diplocyclos palmatus 
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3.2. SIDDHA ASPECT OF THE PLANT: 
 
It is a climber with leaves looking like palm with five fingers and there are mild 
hairy growths found in both the surfaces of leaf. Seed resembles “lingam”shape. 
Other names: Aivirali, Aiviral kovai, Linga kovai 
Taste  : Bitter 
Action  : Hot 
Classification : Pungent. 
Action  : Laxative 
Useful part : Whole plant (Gunapadam mooligai vaguppu) 
 
ெபா   ண  
வ  திைள    ெப மல  வ  க  மக கி மி 
ச   வலி      சா கர பா - வ  டலி  
ஏ க ற  ெச    ஏ திைழேய ஐேவலி 
ேபா கிவ  ெம ேற  க  
(பதா  த  ண வ ள க ) 
Character: 
Aivaeli can be used to treat Oligospermia, female infertility, oedema,intestinal 
worms, scabies, eczema, megavayu and cramps. 
 
Method of collection:  
At the time of fruit ripening, the whole plant of Aivaeli can be collected, dried in a 
sun shadow, powdered and can be used as medicine. 
 
Dose: 
1 to 2 viragan (4.2g to 8.4g) of the powder can be made into decoction or 
¼ to ½ viragan (1g to 2 g) of the powder can be given with sugar. 
If the powder is taken in excess quantity,  It will act as Laxative. 
So depending on body condition, the dose of Aivaeli powder should be chosen 
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ேச   ம   க : 
வ க   தி 
சிவ ைறயா ம ைன தின மற வாம  
சிவ ைறயா ம ைன ெதா  ேசர - சிவ ைறயா 
மாசகல ேமதின யா  வ கம  த கெமன 
மாசகல ேமதின யா  வா  
 
ெபா  -ஒ  பல  வ க  ெபா   , ஆ  பல  ஐேவலி ச ல சா வ   ஒ  
நா    வ   ெவய லி  ைவ  , ம நா   அ ேபாலேவ ெச  , இ வா  ப   
நா  வைர    ெச  ,இர   நா  சா  வ டா  உல  தி,ம ப      ேபாலேவ 
ெச  ,ப ற  ஒ  பாைன    ேம ப  வ க ைத இ  ,அதி  ஒ  ப  ஐேவலி 
சா  ஒ  மர கா  வ  , வா ெபா  த  ள பா ட தா     சீைல ெச  , 
 மிய   ழி ேதா   அத   ள  ,சா ப  எ வா    , இ ப  நா  கழி த 
ப ற  எ  க  மிய   எ   ஆவ யா  வ க  ஒ வ த  சிற த  ண ைத 
அைட   மா திைர  தலியன ெச த   ,வாத ேவைத    ஆ  . (ேதைரய  யகம 
ெவ பா) 
 
v அ ட  ம ச   க  ரண  
ேத தாவ  ேவ  ேதா   ஐவ ரலி வ    
சி நாக வ ைர டேன அ  க ேவ  ப ைட 
ஏ திேய சமபாக   ளா   ெச   
இ ேநர  ேதன ெவ  க    உ ண  
ப தி ட  ம டல தி  அ ட  ம  
பற  வ   இ ம  தி  ஆ ைமக   
  தமதா   ெபாசி  மிக உ ண ெச    
 கமள    ப திய க  ப  க தாேன 
ெபா  -ேத றா  ேவ  ேதா ,ஐவ ரலி வ ைத,சி நாக வ ைத,எ  க  ேவ  ப ைட 
இைவ நா    சமமாக எ       ெச  ேதன  கல   இர   ேநர  ெவ க  
அள  உ ெகா ள நா ப ெத   நா கள  அ ட   ம க   பற  வ  . 
(இராமேதவ  எ    யேகா   ைவ திய சி தாமண ) 
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v லி க ெம   
ைவ  ேம ஐவ ரலி ப பாக  சா   
வைகவைக   ஒ சாம      ேபா  
ஆய  ேம அர ெபா ைய பழ சா  வ   
அைர த த லி க தி  ேமேல  சி 
உ   ேம ேப   ம    கா     ைவ   
ஒ  ட தா  ேபா ெட  க    க டா   
ைத  ேம ச ன ர ேதாஷ ெம லா  
ச  ேம ெதா     ஆ  வாத  
ெச த ேம ெம  ெச ய ேவ  ெம றா  
ெச வக தி    ப ைட இ     சா  
பய  ேம ப றி ட ெந        
பா காக    கிடேவ ெம கா   ேம 
ெபா  -இலி க தி   ஐவ ரலி  சா றி  ஒ  சாம ,ப பாக  சா றி  ஒ  சாம  
      ெகா    அய ெபா ைய எ மி ச  பழ சா றி  அைர   இலி க தி  
ேம   சி, அதைன ேப   ம    கா     ைவ   ஒ   டமி   எ  க 
  ைமயான க டா  .ச ன , ரேதாச ,வாத  ெதா   றா   ேபா  .ெம   
ெச ய ேவ  ெமன    ப ைட இ  த சா றி  ப றி ெந           
ெகா  க ெம கா  .(ப ர ம ன  ைவ திய   திர ) 
 
3.3. MODERN ASPECT OF THE DRUG 
Chemical constituents of the plant  
Galactose specific lectin activity was detected in the mucilaginous coat 
surrounding the seeds of Diplocyclos palmatus. The lectin is a single polypeptide chain 
containing 2% carbohydrate. Punicic acid, a trans fatty acid that is rare in plants was 
isolated from Diplocyclos palmatus ( G.J.H Grubben 2004) 
 
Glucomannan: Extraction of defatted and decolorized seeds of Bryonia lacinosa with 1% 
aqueous acetic acid yielded a polysaccharide material, having D-glucose and D-mannose 
in the molar ratio of 1.00:1.01. Hydrolysis of the fully methylated seed gum furnished 
2,3,4,6-tetra-O-methyl-D-glucose and 2,3-di-O-methyl-D-mannose in equimolar ratio. 
Partial hydrolysis of the polysaccharide furnished three oligosaccharides namely; 
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epigentiobiose, mannobiose, and mannotriose along with the component 
monosaccharides.( Vandana Singh et al, 2006) 
 
Goniothalamin: Goniothalamin, a natural occurring styryl-lactone is a novel compound 
present in the whole plant of Bryonia lacinosa with putative anticancer activities. ( Wen-
Ying Chen et al,2005) 
 
They extracted the whole plant powder (750 g) with methanol in a Soxhlet 
apparatus. The MeOH extract was subjected to fractionation with petroleum ether (50 
ml), chloroform (50 ml) and ethyl acetate (40 ml) successively. From the ethyl acetate 
fraction goniothalamin (58 mg) was isolated by washing with diethyl ether followed by 
recrystallization. (Ashik Mosaddik M et al, 2000) 
 
Arabinoglucomannan: It is a polysaccharide material, having d-glucose, d-mannose and 
l-arabinose in the molar ratio of. 5.00:3.01:4.00. It is yielded from the extraction of the 
pulp of ripe berries of Bryonia lacinosa with 1% aqueous acetic acid. (Singh et al 2009) 
evaluated the polysaccharide Arabinoglucomannan for the microbial activity and was 
found to be active against Escherichia coli with a minimum dose of 6.25 mg/mL (Singh et 
al,  2009) 
 
The plant contains one of the Bitter principle, known as Bryonin (Dr.K.M. 
Nadkarni) 
 
Medicinal uses 
The leaves of Diplocyclos palmatus are eaten as a vegetable in Kenya and in 
South-East Asia. Young and shoots are occasionally eaten as well in South-eaten Asia. In 
Kenya the roots are used as an antivenin and fruits and leaves to cure stomach-ache. In 
Thailand stems are used as an expectorant and fruits as a laxative, and in Nepal seeds as a 
febrifuge. Diplocyclos palmatus is grown in Kenya and Zimbabwe as a garden 
ornamental because of the decorative fruits. (Grubben, 2004) 
The plant is acrid, foetid, alterant, depurative and tonic and is useful in cough, flatulence, 
skin diseases, inflammations and general debility. (T.Pullaiah, 2006) 
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Seeds - spasmolytic. Used for vaginal dysfunctions, as a fertility promoting drug. 
Powdered seeds, also roots, are given to help conception in women. Plant is also used in 
venereal diseases. (C.P. Khare) 
 
Use Of Bryonia Laciniosa To Get Male Child 
Seeds of B.laciniosa resemble to “Shivling” symbol of god Siva, were used to cure 
sterility cases as well as to get male child, in prehistoric age. Fruits are purple in colour 
with white patches and huge quantity of mucilaginous substances. 
 
Active principle of B.laciniosa has got property to regenerate germinal epithelium 
in both male and females to produce their reproductive organs like ovum and sperm. 
(H.Panda) 
 
Whole plant is used to treat adenopathy, ague, asthma, bronchitis, carbuncles, 
cholera, colic, consumption, convulsions, cough, delirium, fertility, headache, 
megalosplenia, paralysis, phthisis, snake bite.(Bonyadi Rad Ehsan et al, 2009) 
 
Fruits bitter in taste; but a common vegetable; also used medicinally for blood 
sugar.(Kumdranjan Naskar)  
 
Seed extract is taken once a day for 2-3 days during dysentery. ( SY Kamble et al, 
2008) 
Seeds are taken with water to promote conception (Dinesh jadhav et al, 2006) 
 
Traditional healers use the leaves and the seeds of this plant for treatment of 
fevers. It is also taken in impotency and used as a tonic. The leaf extract of this plant is 
also used as a cathartic and in inflammation. (Gupta et al, 2003) 
 
Seeds of Diplocyclos palmatus is used for Asthma, Cholera, Colic, Constipation, 
Post natal complaints, promotes fertility in women. ( Archana singh et al 2012) 
  
The whole plant is used to cure jaundice. 30 ml of whole plant decoction is 
administered twice a day for 3 to 5 days. ( Ratna Manjula et al, 2011) 
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Leaf decoction is taken internally to treat rheumatic pain. ( P Pandi Kumar et al, 
2007) 
 
Seeds crushed in milk are consumed to conceive especially male child. About a 
cup of it is advised for a fortnight. ( Ahirrao et al) 
 
Dried fruit powder (one teaspoonful) is mixed with spoonful powder of Sag 
(Tectona grandis Linn). This mixture is taken orally thrice a day for 3 days against 
urinary complaints. ( Dyaneswar P Ghorband et al 2002) 
 
Leaf paste is applied to relieve joint pain and rheumatism (S.Ganesan et al, 2004) 
 
Sperm count enhancement 
One teaspoonful mixture of powdered Shivlingi Putrada (Diplocyclos palmatus) 
seeds and aasoodkand (Withania somnifera) root (500mg each is taken twice a day with 
cow milk for six months. ( Bhogaonkar et al, 2006) 
 
Ovulation enhancement 
Ghanfodi Madkafodi (Cardiospermum helicacabum L) seeds and Shivlingi, 
Putrada (Diplocyclos palmatus) seeds (2 gm each) pounded with one betel leaf is eaten 
thrice a day for three days. (Bhogaonkar et al, 2006) 
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3. SIDDHA ASPECT OF THE DISEASE 
KARAPPAN 
Plagues consisting of papules and vesicles are produced on the skin and are 
surrounded by oedema, blisters and scale -like horny surface, accompanied by colour 
changes, fissures and water discharge. Itching may or may not be present. Yugi has not 
brought the Karappan under the 18 kuttams because of its aetiology and characteristic 
signs and symptoms. 
But since it is a disease of the skin it has been brought under this chapter. 
 
Aetiology 
Even though the factors cannot be underlined distinctly, this Karappan is not 
caused by pathogenic organisms. This is one of the reasons why Yugi did explain 
Karappan as distinct from Kuttam. But there may be secondary infection by microbes on 
an already Karappan affected area. 
ெப    ேசாள மி     ெப  க   
வர  கா ட  வாைழய  காெயா  
உைரெகா  பாக  ேகள  ம  உ     
வ வ தா  கர  பா மி  தேத 
Foreign authors too accept the above fact: 
Most cases of eczema especially in infants are really food allergies; they are 
reaction of the skin, at a particular time to particular foods. The treatment of such cases 
lies in prevention and identification of the causative factors and the avoidance of 
particular types of food.(Justus J.Schifferes) 
 
In Yugi 
Ø Non-vegetarian food 
Ø Pear millet (Pennisettum typhoideum) 
Ø Indian millet ( Setavia indica) 
Ø Little millet ( Paspalum scrobicerlatum) 
Ø Tuber varieties 
Ø Frequent sexual contacts with elderly women are mentioned as the causative 
factors of Karappan. Similarly Guava, eggs, fish, dried fish, eggplant and 
pumpkin are shown to cause karappan. 
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The above said products are not allergic to all persons and also they are not allergic to a 
person at all times of life. 
 
They may be allergic to a particular person  at a particular time and not throughout life 
 
Classification: 
Yugi has classified Karappan into seven main types: 
1. Vatha Karappan 
2. Kanta Karappan 
3. Varatchi Karappan 
4. Thimirvatha karappan 
5. Kabala Karappan 
6. PitthaKarappan 
7. SetthumaKarappan 
In Pathinen Siddhar Bala Vakatam, 18 types are referred to as follows: 
VathaKarappan, Pittha Karappan, SetthumaKarappan, Ari Karappan, Udhu 
Karappan, Thulai Karappan, Vedi Karappan, Mantai Karappan, Pori Karappan, 
Sattaikarappan, Otu karappan, Karum karappan, Senkarappan , Kolli karappan , Thoda 
karappan , Vaalai karappan, Varal karappan, Veengu karappan . 
 
General Features 
To start with, there is itching in the skin followed by papules, vesicles, pustule 
formation etc… 
There is spreading of Plaque and through the discharge of fluid altogether 
becoming toad skin, it will change the colour of the skin. 
The skin may be dry or may be moist with blood discharge with fleshy colour and crust 
formation. 
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CLASSIFICATION 
 
Vatha Karappan 
The body becomes hot painful, oedematous with fluid accumulation and 
ulceration. Fingers and joints become immobile and there are varicosity of veins, 
exopthalmos and dryness of skin. 
Kanta Karappan 
Head, ears and scalp become painful, oedematous, with thickening of tongue and 
gooseflesh. There are rigor itching, photophobia and throaty sensation within the throat. 
Varatchi Karappan 
The body becomes oedematous marked with pricking sensation, pruritus, 
emaciation of the body, giddiness, fatigue, discharge of fluid, fleshy colour and 
murmuring. 
Thimirvatha karappan 
While arising from seated position there is pain in legs, arms and legs and hip and 
joints become tense , ankylosed. There are paralysis, oedema, and ulceration of the body. 
Increased micturition, body pain, tremor and heat are present. 
There is tremendous pain while walking with oedema of joints, ulceration and 
fissure formation on the skin. 
Kabala Karappan 
There are pruritus of ear and eyes, hoarseness of the throat, discharges from eyes, 
rhinitis, pruritus of scalp, sneezing, palpation on forehead and inflammation of uvula. 
Pittha Karappan 
Appearance of eyes as though one is sleeping, heat and pain in the stomach, 
giddiness, fatigue, yellowish discolouration of the body , dysphasia, loss of appetite and a 
sense of itching on the body. 
SetthumaKarappan 
Pallor, Hoarseness of voice, slow –pitched voice, dyspnoea on exertion, cough, 
expectoration, asthma, dependence on others for everything. 
Karappan becomes secondary in Pittha diseases and pramegam. 
Karappan in Pittha diseases 
Pruritus, papules, sense of heat , hyperpigmentation all over the body, diarrhoea, 
borborygmi, fits, pain and fatigue of the legs and hip pain. 
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Karappan in pramegam 
Pain in the stomach, mucus discharge, micturition with a sense of heat and 
burning, ulceration of urethra and mixing of calcium largely in urine, fatigue of limbs and 
presence of large plagues all over the body. 
 
Prognosis 
Vathakarappan, pittha karappan , varatchikarappan, kabalakarappan are cured 
easily. Others are very difficult to be cured. 
நா  நிதான  
தான  ள ேச  ம தான ளகி ............ 
................கர பா  வ ரணேதாட  
சதக  53, 
சிற பான வாத தி  உ ண தாேன ேச தி கி ............ 
.................மதக  ந  கர பா ........... 
சதக  56, 
General Abstentions: 
Ø The Patient needs rest, sleep, exercise and fresh air. 
Ø Green vegetables, milk and milk products, good nutritional, cooked meat can be 
given. 
Ø Curry products, spicy foods, karappan foods and narcotics must be avoided. 
For Children, 
Ø There must be restriction in the quantity of food. 
Ø Intestinal worms have to be treated first. 
Ø Avoidance of constipation is a must. 
In washing the affected area 
Ø For blisters – wash with antiseptic solution 
Ø For inflammation – oils 
Ø For ulceration – ointments and liniments 
Ø For crusts – oil application and wash with lukewarm water. Do not use soaps. 
Green gram powder and nalungu ma can be used. To cure occupational eczema, do 
advise prevention of contact with the allergic, spurious materials. For example, in dying 
industry and painting, medical staff and doctors need to prevent contact with 
streptomycin. 
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3.5. MODERN ASPECT OF THE DISEASE 
 
SKIN 
The skin-the interface between humans and their environment-is the largest organ 
in the body. It weighs an average of 4kg and covers an area of 2m2.It acts as a barrier, 
protecting the body from harsh external conditions and preventing the loss of important 
body constituents, especially water. A death from destruction of skin, as in a burn or in 
toxic epidermal necrolysis and the misery of unpleasant acne, remind us of its many 
important functions, which range from the vital to the cosmetic. 
Function of the Skin 
  
Protection against: 
Ø Chemicals,particles 
Ø Ultraviolet radiation 
Ø Antigen, heptens 
Ø Microbes 
Ø Preservation of a balanced internal  
 environment 
Ø Prevents loss of water, electrolytes and 
macromolecules 
Ø Insulation 
Ø Sensation 
Ø Lubrication 
Ø Vitamin D synthesis 
 
Horny layer 
Melanocytes 
Langerhans cells 
Langerhans cells 
Horny layer 
 
Horny layer 
 
Subcutaneous fat 
Specialized nerve endings 
Sebaceous glands 
Keratinocytes 
 
 
IMMUNOLOGY OF THE SKIN 
The skin is an important immunological organ and normally contains nearly all 
the elements of cellular immunity; with the exception of B cells. Much of the original 
research into immunology was done using the skin as a model. 
The immunological components of skin can be separated into structures, cells, functional 
systems and immunogenetics. 
 
Structures  
The epidermal barrier is an important example of innate immunity, as most 
microorganisms that have contact with the skin do not penetrate it. Equally the generous 
blood and lymphatic supplies to the dermis are important channels through which 
immune cells can pass to or from their sites of action.  
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Cells 
Langerhans cells of the epidermis are the outermost sentinels of the cellular 
immune system. These cells plays an important role in antigen presentation. 
T Lymphocytes circulate through normal skin. Different types of T cell with 
differing functions are recognized. 
Mast cells (which release histamine and other vasoactive molecules) are normal 
residents of the dermis, as are macrophages. Both may be recruited to the site during 
inflammatory reactions. 
Keratinocyte may have an immunological function. They synthesize antimicrobial 
peptides, produce pro inflammatory cytokines. 
 
Hypersensitivity reactions and the skin 
Hypersensitivity is the term applied when an adaptive immune response is 
inappropriate or exaggerated to the degree that tissue damage results. The skin can exhibit 
all the main types of hypersensitivity response. 
Type I (Immediate hypersensitive reaction) 
Type II (Antibody-dependent cytotoxicity) 
Type III (immune complex) 
Type IV (cell mediated or delayed hypersensitive reaction) (David J.Gawkrodger) 
 
ECZEMA 
 
Definition 
Dermatitis and Eczema is non-contagious inflammation of the skin, Characterized 
by erythema, scaling, oedema, vesiculation and oozing. Hebra says, “Eczema is what 
looks like eczema”. Dermatitis literally means inflammation of the skin and as such can 
include all inflammations of the skin except by specific infections. The term ‘Eczema’ is 
a Greek word (Ec means out, and Zeo means boil.) The whole word implies ‘boil out’.  
Eczema is a specific type of allergic cutaneous manifestation of antigen-antibody 
reaction. It is characterized by superficial inflammatory oedema of the epidermis 
associated with vesicle formation. Itching varies from mild to severe paroxysms which 
may even interfere with work and sleep. (P.N.Behl,A.Aggarwal,2007)The nature history 
of eczema is diagrammatically represented as follows; 
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    Erythema 
 
 
       Papules with oedema 
                                               
        Vesicles 
                                                      
                                                       Lichenification 
  Weeping, Crusting, Pustules 
 
                                    Scaling                 
 
  Healthy skin without scars 
 
Histology 
Epidermis may show intercellular oedema (spongiosis) in an acute eczema and 
acanthosis (hyperplasia of stratum malphigi) hyperkeratosis and parakeratosis (immature 
keratinization) in the subacute and chronic phases. Dermal inflammatory infiltrate, 
polymorphonuclear or lymphocytic, may be pronounced in acute eczema, less so in 
subacute or chronic eczemas. 
 
Classification 
Dermatitis is classified into two types. Exogenous and Endogenous dermatitis. 
 
Endogenous dermatitis 
Atopic dermatitis 
Common, An itchy chronic remitting and relapsing inflammatory skin condition 
associated with other atopic dermatitis (asthma,hey fever,urticaria) in patient or family. 
Mode of genetic transmission uncertain. Serum regain, IgE levels may be raised, hence 
predisposed to anaphylactoid reactions. Delayed hypersensitivity perhaps depressed, 
hence less prone to developing allergic contact dermatitis. More prone to acquiring viral 
and some bacterial infections. Dry, generally irritable, skin that may not tolerate extremes 
of temperature or humitidy such as dry cold, excessive sweating or contact with dust or 
wool. Patients anxious and sensitive individuals. (Lalit K et al) 
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Epidemiology 
             Some 5-10% of the population of western Europe develop atopic dermatitis. The 
disease is familial, with apparent polygenic inheritance.( Wolfram Sterry et al,2006) 
Three distinct or merging phases. Infantile, childhood and adult. Itching, scratching and 
lichenification are important features. 
Each phase could start and end independently. 
 
Infantile phase 
            Common. Often first born male infant. Onset-about third month, sometimes 
earlier. Bilaterally symmetrical papulovesicular, exudative and crusted lesions. Cheeks 
predominantly involved. Later elsewhere-on the extensors of the extremities and trunk. 
Itching severe and paroxysmal. Secondary bacterial infections common. Spontaneous 
remissions and relapses. May completely remit by about 2-3 years or may evolve into 
childhood phase of atopic dermatitis. 
 
Childhood phase 
           May evolve from the infantile phase or start de novo. Intensely pruritic in the 
flexures of the elbows and knees, the wrists, ankles and sides of the neck. Symmetrical 
involvement. Lichenified and excoriated lesions. 
 
Adult phase 
            Relatively uncommon. May evolve per se or from atopic dermatitis of infancy or 
childhood. Lichenified plaques, often in the flexures. Extensor aspects of the extremities 
occasionally involved. Itching a dominant complaint and the patients thus more prone to 
develop lichen simplex chronicus. 
 
Nummular Eczema 
             A morphological diagnosis. Discoid or coin shaped lesions of uncertain, possibly 
multiple, etiology.A number of unrelated factors such as atopy, infection, 
autosensitization, physical trauma, particularly on a dry asteatitic skin may be 
responsible. 
              Erythematous, edematous discoid plaques of itchy, papulovesicular lesions 
which exude serous discharge and form crusts. Dorsa of the hand and extensor aspect of 
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upper or lower extremities preferentially affected. Bilateral but often asymmetrical. 
Relapsing and remitting. Relapses often abrupt in onset and frequent in winter. 
Dry discoid dermatitis: A nonexudative variant of Nummular eczema. Round or oval, dry, 
scaly plaques on extensors of extremities. Variable, often recurrent and chronic course. 
 
Pompholyx 
             Acute bilateral symmetrical vesicular eruption of the palms and soles. 
Multifactorial; atopic or other endogenous eczema. More common in summer. 
Hyperhidrosis a common, but causally unrelated, association. Young adult of both sexes 
affected. Itchy or painful deep seated vesicular(sago-grain like) lesions on the palms, 
sides of the fingers and soles. Occationally bullous or pustular lesions.  
 
Seborrhoeic dermatitis 
                Characterised chiefly by its distribution. Characteristic seborrhoeic look-oily 
skin with patulous, prominent follicular orifices. Sites of predilection:Scalp, retroauricular 
folds, eyebrows, nasolabial folds, beard area, interscapular and presternal regions, axillae, 
pubic region, groins, umbilicus, and folds under pendulous breasts. Generally chronic 
with remissions and exacerbations.Patients predisposed to pyococcal infections. 
 
Stasis Eczema 
               Middle aged individual with compromised venous return. Related to long hours 
continued standing. Medial aspect of ankle and lower legs involved. Slate-grey 
pigmentation. Later oedema, itching, acutely exudative and crusted or scaly and 
lichenfication areas; associated with obvious varicose veins or other evidence of venous 
stasis.  
 
Exogenous dermatitis 
Irritant contact dermatitis 
              Common, non-immunological dermatitis, secondary to contact with an irritant 
substance in ‘adequate’ concentration for a ‘sufficient’ length of the time. Individual with 
dry skin more prone. Acute irritant dermatitis sharply limited to the area of 
contact.Similar in morphology to the acute eczemas-Papules, vesicles or pustules on an 
erythematous background. Heals with hyper or hypo pigmentation. Strong irritants may 
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cause necrosis or ulcers that heal with scars. Cumulative insult dermatitis due to repeated 
contact with weak irritants, classical example: ‘housewives’ dermatitis. Slow onset.  
 
Allergic contact dermatitis 
                  A common dermatological problem, more frequent in the industrialized world. 
Type IV delayed type hypersensitivity (DTH) response. Simple chemicals (haptens) 
become complete antigens on combining with a carrier, generally epidermal protein. 
Airborne contactants affect exposed sites-face, particularly the eyelids, neck, hands and 
forearms. Textile dermatitis-axillae, flexures of elbows, thighs or other areas in intimate 
contact with clothing. Occupational dermatitis-the hands and other exposed parts. Metal 
dermatitis-sites of contact with jewellery; watch straps on the wrist. Parthenium 
hysterophorus is a common contactants. 
 
Photocontact Allergic Dermatitis 
                  Several patients with parthenium dermatitis exhibit photoaggravation of a 
purely allergic dermatitis or develop the dermatitis only on exposure to light. Sites of 
airborne allergy thereby modified. 
 
Infective Dermatitis 
                  Acute eczematous reaction to contact with purulent discharge from a 
pyococcal lesion; a boil, a discharging ear, an infected scabies or pediculosis. Exuding, 
crusted, well or ill-defined plaques of vesiculopustular lesions. Discoid or bizarre shaped. 
Auto-inoculation common. 
 
Asteatotic Eczema 
                    Elderly individual with dry xerotic skin affected. Irregular or patches of 
superficially fissured, dry, scaly, and mildly crusted lesions on the extensors of the legs, 
dorsa of the hands and the trunk. Variable itching. Frequent baths, use of soap, detergents, 
dry and cold climates worsen. 
 
Napkin Dermatitis (Diaper dermatitis) 
                      Less common in developing countries where infants frequently stay without 
occlusive napkins. Common in the developed world. Use of occlusive diapers and lack of 
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frequent changes predispose. Multifactorial etiology-irritation with feces and urine or the 
presence of irritant detergents in the napkins. 
 
Lip-licking dermatitis 
                      Not uncommon; seen in children with a habit of licking their lips and 
around. Rule out atopic diathesis. Well defined, scaly lesions around the mouth. (Lalit K 
et al) 
 
INVESTIGATIONS 
Specific IgE, Patch test, Prick test 
 
3.6. LATERAL RESEARCH VIEW OF THE PLANT 
 
Effects of Bryonia laciniosa seeds on sexual behaviour of male rats. 
Ethanolic extract of seeds of Bryonia laciniosa Linn was administered orally to 
groups of male albino rats at the dose levels of 50, 100, and 150 mg kg(-1) body weight 
per day for 28 days. The changes in sexual behaviour, reproductive organ weights, 
histology of testis and epididymis, epididymal sperm density, and androgenic hormone 
levels were evaluated. The sexual behaviour parameters studied such as mount frequency, 
intromission frequency, mount latency, intromission latency were evaluated. Increase in 
body weight as well as weight of testis, prostate, seminal vesicle, and epididymis was 
noticed. Transverse sections of testis exhibited increased spermatogenesis and a 
significant increase in sperm count in epididymis. The fructose content of seminal vesicle 
was also increased. The extract treatment also brought a significant increase in serum 
testosterone and luteinizing hormone levels. The studies clearly reflect androgenic 
activity of the extract and its effects on hypothalamic pituitary gonadal axis. (Chauhan et 
al, 2010) 
 
In Vitro cytotoxicity of Bryonia laciniosa(Linn.) Naud. On human cancer cell lines 
The water, methanol and chloroform extracts of B.laciniosa leaves were tested on 
human cancer and normal cell lines using three in vitro cytotoxicity assays i.e cell 
viability, SRB and clonogenic potential. The effect was compared with that of standard 
anticancer drugs doxorubicin and vincristine. Activation of caspase-8 and caspase-3 
enzymes was assessed to evaluate the effect of extract on induction of apoptosis in cells. 
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Of the different extracts, the aqueous extract demonstrated maximum cytotoxicity to 
cancer cells. The IC50 value was estimated to be 18 μg/mL. Nearly all cancer cells could 
be killed by the leaf extracts of B.laciniosa in vitro, where as small fraction of cells from 
cancer cell lines showed resistance to doxorubicin even at concentration much higher than 
IC50. Results of caspase assay demonstrated activation of both caspase-8 and caspase-3 
enzymes indicating induction of apoptosis in B.laciniosa leaf extract treated cells. The 
results thus show that aqueous extract of B. laciniosa leaves possess cytotoxicity to 
cancer cells and are able to kill all cancer cells without leaving residual population. 
(Alpana S Moghe et al, 2011)  
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4. MATERIALS AND METHODS 
 
4.1. PREPARATION OF THE DRUG 
 
Collection and authentication of the material: 
The plant material used in this study was collected from Anthiyur Hills, Erode 
district, Tami Nadu, India. and authenticated by Botanist, Central Research Institute for 
Siddha and Siddha experts of Gunapadam Department. The drug “Aivaeli” was selected 
from the classical Siddha literature Pathartha Guna Villakam written by Kannusamiyam 
Pillai. 
 
Preparation of Aivaeli samoola  Chooranam: 
The fresh whole plant of Aivaeli of 10 Kg was thoroughly cleaned to eliminate 
soil particles and impurities. Then the plant was cut into small pieces and dried in shade. 
Afterward they were finely powdered. The resultant powder of 7 kg was subjected to 
sieve with white cotton cloth to get finest physical form. (Vasthirakayam) 
 
Purification of Chooranam: 
The Chooranam was moistened with cow’s milk. Pots were filled with milk and 
water of equal ratio to nearly ¾ its volume. The mouth of the pot was roofed and tied with 
white cotton cloth. The Chooranam moistened by milk was placed on top of the tied 
cloth. The mouth of the pot was closed with another mud pot. The gap between the two 
mud pots was tied with a wet cloth to prevent evaporation. Then this pot was subjected to 
heat and boiled until milk level in lower pot gets reduced to ¼ volumes. Then the powder 
was taken, dried, powdered finely and preserved for usage. 
 
Preservation: 
The purified Chooranam was stored in a clean, air tight glass container. 
 
Life span : 3 Months. 
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Administration of the drug: 
Form of the medicine  : Chooranam 
Route of Administration : Enteral 
Dose    : 1 - 2 gms 
Anubanam (Vehicle)  : Sugar 
Administration  : Two times a day; after food 
 
4.2. STANDARDISATION OF AIVAELI SAMOOLA CHOORANAM: 
Standardization of drugs means evidence of its characteristics and determination 
of its quality, effectiveness and aptness to be used as medicine. Standardization of plant 
drug is based on the concentration of their active principles, physical and chemical 
standards. Plant drug has been standardized on the basis of physical characteristics, 
organoleptic properties, and phyto‐chemical properties. The process of standardization 
can be achieved by stepwise studies. 
 
Collection and identification of plant: 
The plant material viz., root, stem, leaf, flower, fruit and seeds of Diplocyclos 
palmatus. Belongs to the family Cucurbitaceae were collected from Anthiyur Hills, Erode 
district, Tamilnadu. The plant was identified with the help of Botanist, Central Research 
Institute for Siddha, Chennai-106 and by the Siddha experts of Gunapadam Department 
and a voucher specimen is kept in the Herbarium, Department of Gunapadam, 
Govt.Siddha Medical College, Arumbakkam Chennai-106. 
 
4.2.1. PHARMACOGNOSTIC STUDY  
Collection of specimens 
The plant specimens for the proposed study were collected from Anthiyur hills, 
Erode district, Tamil Nadu. Care was taken to select healthy plants and normal organs. 
The required samples of different organs were cut and removed from the plant and fixed 
in FAA (Farmalin-5ml+ Acetic acid-5ml + 70% Ethyl alcohol-90ml).After 24 hrs of 
fixing, the specimens were dehydrated with graded series of tertiary –Butyl alcohol as per 
the schedule given by Sass, 1940. Infiltration of the specimens was carried by gradual 
addition of paraffin wax (melting point 58-60 C) until TBA solution attained super 
saturation. The specimens were cast into paraffin blocks. 
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Sectioning 
The paraffin embedded specimens were sectioned with the help of Rotary 
Microtome. The thickness of the sections was 10-12 μm. Dewaxing of the sections was 
by customary procedure (Johansen, 1940). The sections were stained with Toluidine blue 
as per the method published by O’Brien et al. (1964). Since Toluidine blue is a 
polychromatic stain. The staining results were remarkably good; and some cytochemical 
reactions were also obtained. The dye rendered pink colour to the cellulose walls, blue to 
the lignified cells, dark green to suberin, violet to the mucilage, blue to the protein 
bodies etc. wherever necessary sections were also stained with safranin and Fast-green 
and IKI(for Starch) 
 
For studying the stomatal morphology, venation pattern and trichome distribution, 
paradermal sections (sections taken parallel to the surface of leaf) as well as clearing of 
leaf with 5% sodium hydroxide or epidermal peeling by partial maceration employing 
Jeffrey’s maceration fluid (Sass, 1940) were prepared. Glycerine mounted temporary 
preparations were made for macerated/cleared materials. Powdered materials of different 
parts were cleared with Naoh and mounted in glycerine medium after staining. Different 
cell component were studied and measured.] 
 
Photomicrographs 
Microscopic descriptions of tissues are supplemented with micrographs wherever 
necessary. Photographs of different magnifications were taken with Nikon labphoto 2 
microscopic Unit. For normal observations bright field was used. For the study of 
crystals, starch grains and lignified cells, polarized light was employed. Since these 
structures have birefringent property, under polarized light they appear bright against 
dark background. Magnifications of the figures are indicated by the scale-bars. 
Descriptive terms of the anatomical features are as given in the standard Anatomy books 
(Esau, 1964). 
 
4.2.2. ORGANOLEPTIC EVALUATION  
The organoleptic characters of the sample were evaluated (Siddiqui et al). 
Organoleptic evaluation refers to evaluation of the formulation by colour, odour, taste and 
texture etc. 
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4.2.3. PHYSICO-CHEMICAL INVESTIGATIONS 
Physico‐chemical studies like total ash, water soluble ash, and acid Insoluble ash, water 
and alcohol soluble extract, loss on drying at 105°C and pH have been done at Siddha Central 
Research Institute –chennai-106 as per the WHO guide lines. 
 
Determination of Total Ash: 
Incinerate about 2 to 3 g accurately weighed, of the ground drug in a tared 
platinum or silica dish at a temperature not exceeding 450º until free from carbon, cool 
and weigh. Calculate the percentage of ash with reference to the air-dried drug. 
 
Determination of Acid Insoluble Ash: 
Boil the ash obtained for 5 minutes with 25 ml of dilute hydrochloric acid; collect 
the insoluble matter in a Gooch crucible or on an ash-less filter paper, wash with hot 
water and go up in flames to constant weight. Analyze the percentage of acid-insoluble 
ash with reference to the air dried drug. 
 
Determination of Alcohol Soluble Extractive: 
Grind 5 g of the air dried drug, coarsely powdered, with 100 ml of Alcohol of the 
specified strength in a closed flask for twenty-four hours, shaking frequently during six 
hours and allowing standing for eighteen hours. Filter rapidly, taking precautions against 
loss of solvent, evaporate 25 ml of the filtrate to dryness in a tarred flat bottomed shallow 
dish, and dry at 105º, to constant weight. Calculate the percentage of alcohol-soluble 
extractive with reference to the air-dried drug. 
 
Determination of Water Soluble Extractive: 
Proceed as directed for the determination of Alcohol-soluble extractive, using 
Chloroform water instead of ethanol. 
 
Determination of Moisture Content (Loss on Drying): 
Procedure set forth here determines the amount of volatile matter (i.e., water 
drying off from the drug). For substances appearing to contain water as the only volatile 
constituent, the procedure given below, is appropriately used. Place about 10 g of drug 
(without preliminary drying) after accurately weighing (accurately weighed to within 0.01 
g) it in a tared evaporating dish. For example, for underground or un powdered drug, 
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prepare about 10 g of the sample by cutting shredding so that the parts are about 3 mm in 
thickness. 
 
After placing the above said amount of the drug in the tared evaporating dish dry at 105º 
for 5 hours, and weigh. Continue the drying and weighing at one hour interval until 
difference between two successive weighing corresponds to not more than 0.25 per cent. 
Constant weight is reached when two consecutive weighing after drying for 30 minutes 
and cooling for 30 minutes in a desiccators, show not more than 0.01 g difference. 
 
Determination of pH: 
1% solution of plant drug was prepared in distilled water and pH was determined 
using pH meter SYSTRONICS DIGITAL pH METER, MK VI. 
 
TLC estimation of Aivaeli samoola chooranam: 
Thin-layer chromatography is a technique in which a solute undergoes distribution 
between two phases, stationary phase acting through adsorption and a mobile phase in the 
form of a liquid. The adsorbent is a relatively thin, uniform layer of dry finely powdered 
material applied to a glass, plastic or metal sheet or plate. Glass plates are most 
commonly used. 
Identification can be effected by observation of spots of identical Rf value and 
about equal magnitude obtained, respectively, with an unknown and a reference sample 
chromatographed on the same plate. A visual comparison of the size and intensity of the 
spots usually serves for semi-quantitative estimation. 
Solvent system: 
Toluene : Ethyl acetate (5:0.5). 
TLC plate: 
Aluminium plate pre-coated with silica gel 60F254 of 0.2 mm thickness (Merck). 
Developing chamber: 
Camag’s twin trough chamber. 
Visualizing reagent: 
Vanillin-sulphuric agent. 
Extract Preparation: 
4 g of the chooranam was soaked overnight in chloroform. Boiled on a water bath 
for 10 mints, filtered and concentrated to 10 ml. 
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Procedure: 
The extract was applied on the TLC using capillary and developed in the solvent 
system. The developed TLC plate was air dried, dipped in vanillin-sulphuric acid reagent 
and heated in an oven at 105°C until the development of coloured spots.  
 
4.2.4 PHYTO CHEMICAL EVALUATION OF PLANT 
 
Phytochemicals are chemical compounds that take place naturally in plants. They 
are answerable for color and organoleptic properties and may have biological or 
pharmacological activity is attributed. The powdered Aivaeli samoola chooranam is 
subjected to following process. 
 
Test for Flavonoids (Shinoda test) 
Substance is dissolved in alcohol, added with magnesium bits and concentrated 
hydrochloric acid. On heating over a water bath, the appearance of magenta colour shows 
the presence of flavonoids.  
 
Triterpenoids (Noller’s Test) 
To few mg of extract, add tin and thionyl chloride and heat in water bath. Purple 
colour indicates the presence of tritepenoids. 
 
Test for Proteins (Biuret test) 
To the sample solution in a test tube, add sodium hydroxide solution and then add 
a few drops of very dilute (1 %) copper II sulphate solution and mix gently. Appearance 
of purple colour indicates the presence of protein. 
 
Test for Anthraquinones 
Few milligram of crude powder is shaken with 10 ml of benzene and filtered. To 
this filtrate, 0.5 ml of 10 % ammonia solution is added and the mixture is shaken well and 
the presence of the violet colour in the layer phase indicates the presence of the 
anthraquinone. 
 
  
31 
Test for Alkaloids (Dragendorff’s Test) 
Few mg of extract in separate test tube was warmed with 2% Sulphuric acid for 2 
minutes. And it was filtered in separate test tube and few drops of Dragendorff’s reagent 
were added. The presence of orange red precipitates indicates the presence of alkaloids. 
 
Test for Saponins 
To few mg of extract distilled water is added and shaken well. The formation of 
foam indicates the presence of saponin. 
 
Test for Steroids (Lieberman Burchard Test) 
To few mg of the extract 2 ml of chloroform is added in a dry test tube. Few drops 
of acetic acid is added, heated and few drops of acetic anhydride and 2 drops of 
concentrated sulphuric acid are added. The green colour indicates the presence of steroid. 
 
Test for Coumarin 
Extract is shaken with 10% sodium hydroxide. Yellow colour shows the presence 
of coumarin. Add concentrated sulphuric acid, original extract colour is regenerated. 
 
Test for Acids 
Extract is treated with sodium bicarbonate solution. Effervescence shows the 
presence of acid. 
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4.2.5 PRELIMINARY CHEMICAL ANALYSIS 
 
Preparation of Extract : 
Add 5 gm of the sample to 50ml of distilled water. Boil the solution for 20 minutes, cool 
and then filter. Use the Extract for the following tests. 
S.No Experiment Observation Inference 
1. 
Test for reducing Sugar : 
To 5ml of Benedicts qualitative 
reagent, add 10 drops of extract, then 
boil for two minutes 
Green / Yellow / 
Red precipitate 
Presence of 
Reducing Sugar 
2. 
Test for Starch : 
To 5 ml of extract add 2ml of acetic 
acid and then add few drops of N/50 
Iodine Solution. 
Blue Colour Presence of Starch 
3. 
Test for Proteins : 
To 2 ml of extract, add 2ml of 5% 
Sodium Hydroxide mix and add 2 
drops of Copper Sulphate Solution. 
Violet or Purple 
Colour 
Presence of 
Proteins 
4. 
Test for amino Acid : 
Place  2 drops of extract on a filter 
paper and allow to dry well. Then 
spray 1% ninhydrin over the same and 
allow to dry. 
Violet Colour Presence of Amino Acid 
5. 
Test for Albumin : 
To 2 ml of extract, add 2ml of 
Esboch’s reagent. 
Yellow 
precipitate 
Presence of 
Albumin 
6. 
Test for Phosphate : 
To 2ml of extract, add 2ml of 
ammonium Molybdate solution and 
2ml of concentrated Nitric Acid. 
Yellow 
precipitate 
Presence of 
Phosphate 
7. 
Test for Sulphate : 
To 2 ml of extract add 2ml of 4% 
ammonium oxalate solution. 
White 
precipitate 
Presence of 
Sulphate 
8. 
Test for Chloride :  
Add 2ml of extract to dilute nitric acid 
till the effervescence ceases. Then add 
2 ml of Silver Nitrate Solution. 
Cloudy White 
precipitate 
Presence of 
Chloride 
9. 
Test for Iron : 
To 2ml of extract, add 2ml of 
ammonium thio cynate solution and 
add 2ml of concentrated Nitric Acid. 
Red Colour Presence of Iron 
10. 
Test for Calcium : 
To 2 ml of extract, add 2 ml of 4% 
ammonium Oxalate Solution. 
White 
precipitate 
Presence of 
Calcium 
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11. 
Test for Sodium : 
Make a paste with 2 pinches of the 
sample with Hcl and Introduce it into 
the blue flame.  
Yellow Flame Presence of Sodium 
12. 
Test for Potassium : 
Add a pinch of the sample to 2 ml of 
Sodium Nitrate Solution. Then add 
2ml of Cobal Nitrate in 20% acetic 
acid. 
Yellow 
precipitate 
Presence of 
Potassium 
13. 
Test for Zinc : 
To 2ml of extract, add few drops of 
Sodium Hydroxide. 
White 
precipitate Presence of Zinc 
14. 
Test for Magnesium : 
To 2ml of extract, add few drops of 
Sodium Hydroxide Solution 
White 
precipitate 
Presence of 
Magnesium 
15. 
Test for Alkaloids : 
a. To 2ml of extract, add 2ml of 
Potassium Iodide Solution 
b. To 2ml of extract add 2ml of 
Picric Acid. 
c. To 2 ml of extract add 2ml of 
Phosphotunqstic Acid. 
 
Red colour 
 
 
Yellow colour 
 
White 
precipitate 
 
Presence of 
Alkaloids 
 
Presence of 
Alkaloids 
Presence of 
Alkaloids 
16. 
Test for Tannic Acid : 
To 2ml of extract add 2 ml of Ferric 
Chloride Solution 
Black precipitate Presence of Tannic Acid 
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PRECLINICAL EVALUATION OF THE TRIAL DRUG 
   Swiss albino mice of both sex weighing between (18-22 g) and 
Albino Wistar rats of the either sex (180-200 g) were grouped and housed in polyacrylic 
cages and maintained under standard laboratory conditions (temperature 24-28°C, RH, 
60-70% and 12 h light dark cycles) and were fed with standard pellet diet supplied by Sai 
durga foods, bangalore, India, and water ad libitum. All experiments involving animals 
were done according to OECD guidelines, after getting the approval of the institute 
animal Ethics committee. (XIII/VELS/PCOL/56/2000/CPCSEA/IAEC/08.08.2012). 
 
4.3. TOXICOLOGICAL STUDY OF THE DRUG: 
Acute toxicity study  
The trial drug Aivaeli samoola chooranam was subjected to acute toxicity studies 
in order to determine the safety of drug 
 Swiss albino mice were treated with foxed doses of Aivaeli Samoola Chooranam 
2000 and 5000mg/kg in 2% CMC as suspension (p.o) respectively. The mortality rate 
with a 24 h period was determined according to the OECD 425 method.  
 
4.4. PHARMACOLOGICAL ACTIVITY: 
 
4.4.1. ANTI-HISTAMINIC ACTIVITY OF AIVAELI SAMOOLA CHOORANAM 
 
Drugs And Stock Solution  
 Drug used was Histamine diphosphate (Sigma Chemical, USA). Histamine 
dihydrochloride was dissolved in distilled water and desired concentrations were 
prepared. The test drug Aivaeli Samoola chooranam concentration was 100microgram per 
ml prepared by suspending with 2% CMC and then the volume was adjusted to 10 ml 
with normal saline for making the concentration of 100 μg/ml in distilled water. 
 
Animals 
 Male albino guinea pig weighing 350– 400g was kept in fasting condition 18 
hours prior to commencement of experiment and given water ad libitum. It was housed 
under standard laboratory conditions of temperature (25 ± 2°C) and 12/12 hr light/dark 
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cycle and then sacrificed by a blow to the head and exsanguinated as per CPCSEA 
recommended guidelines. (XIII/VELS / PCOL /56 /2000/ CPCSEA /IAEC /08.08.2012). 
 
In-vitro antihistaminic study 
 Guinea pig was sacrificed and a segment from ileum (3cm) was dissected from the 
terminal ileum and mounted in an organ bath containing Tyrode solution (10 ml) between 
two stainless steel hooks under 0.5 to 1 g initial tension. The lower hook was fixed at the 
bottom of the organ bath and upper one was connected to an isotonic transducer. The 
Tyrode solution composition (pH 7.4) was (concentration in gm/lit.) NaCl 8.0, KCl 0.2, 
CaCl2 0.2, MgCl2 0.1, NaHCO3 1.0, NaH2PO4 0.05, and Glucose1.0 gm/liter.  It was 
continuously aerated and maintained at 37 ± 0.5ºC The equilibrium period was 60 min 
and the bath solution was refreshed every 15 min. After equilibrium period, a dose 
response curve for histamine in variant molar concentrations, by maintaining 45 min time 
cycle.  
 
Statistical Analysis 
 Ileum contractions induced by agonist were assumed as 100% and reductions 
induced by test drug calculated. Percentage of ileum contraction was expressed as mean ± 
SEM. Results were analyzed using one-way analysis of variance (ANOVA). Probability 
value less than 0.05 were considered as significant. 
 
4.4.2. ANTI-INFLAMMATORY ACTIVITY OF AIVAELI SAMOOLA 
CHOORANAM 
 
Animals 
Swiss albino mice of both sex weighing between (18-22 g) and Albino Wistar rats 
of the either sex (180-200 g) were grouped and housed in polyacrylic cages and 
maintained under standard laboratory conditions (temperature 24-28°C, RH, 60-70% and 
12 h light dark cycles) and were fed with standard pellet diet supplied by Sai durga foods, 
bangalore, India, and water ad libitum. All experiments involving animals were done 
according to OECD guidelines, after getting the approval of the institute animal Ethics 
committee (XIII/VELS /PCOL /56/2000 /CPCSEA /IAEC /08.08.2012). 
36 
Chemicals and Drugs used 
Formalin (S. D. Fine Chemicals Limited, Bombay), acetylsalicylic acid (Bayer 
AG), sodium carboxy methyl cellulose (Aldrich), used as drugs or chemicals. 
 
Formalin induced oedema 
 Anti-inflammatory activity was evaluated by formalin induced paw oedema 
method. Animals of all the groups were injected with 0.1 mL of 1% formalin in 0.9% 
normal saline, in the right hind foot under the plantar region.. Group I animals (formalin 
control) received a suspension of 2% of CMC p.o., 30 min prior to formalin injection. 
Group II and Group III received p.o., 250 and 500 mg/kg of Aivaeli Samoola Chooranam 
respectively, 30 min prior to formalin injection. Group IV, the standard reference group 
was given p.o., an aqueous solution of Aspirin (100 mg/kg), 30 min prior to formalin 
injection. The paw volume or the inflammation was quantified in terms of ml i.e. 
replacement of mercury by edema using a plethysmometer just before and 30, 60, 
120minutes after formalin injection. The percentage inhibition of the oedema was 
calculated for each which respect to the vehicle treated control group. 
 
Statistical Analysis  
 Values for anti-inflammatory activity were expressed as "mean increase in paw 
volume ± SEM. The results were analyzed for statistical significance using one-way 
ANOVA followed by Dunnet ‘t’ test. P<0.05 was considered significant. 
 
4.4.3. ANTI MICROBIAL ACTIVITY OF AIVAELI SAMOOLA CHOORANAM 
 
Antimicrobial assay-Isolation and maintenance of cultures 
 Esherichia coli and Bacillus subtilis were extracted from food stuffs by serial 
dilution agar plate method. In this method, serial dilutions of samples obtained from food 
stuffs were prepared and aliquots from each dilution were added to the plates containing 
nutrient agar to allow the growth of microbes. All the bacterial isolates were identified by 
cultural, morphological biochemical characteristics (Gram and endospore staining). The 
plates were kept in an incubator at 37ºC. The slants were prepared from the pure cultures 
obtained and kept in the refrigerator at 40C for further use. 
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Standardization of inoculums 
 
 The microbial inoculum was standardized at 0.5 McFarland. In microbiology, 
McFarland standards are used as a reference to adjust the turbidity of bacterial 
suspensions so that the number of bacteria will be within a given range. Original 
McFarland standards were made by mixing specified amounts of barium chloride and 
sulfuric acid together. Mixing the two compounds forms a barium sulfate precipitate, 
which causes turbidity in the solution. A 0.5 McFarland standard is prepared by mixing 
0.05 ml of 1.175% barium chloride dihydrate (BaCl2•2H2O), with 9.95 ml of 1% sulfuric 
acid (H2SO4). The standard could be compared visually to a suspension of bacteria in 
sterile saline or nutrient broth. 
 
Antimicrobial Activity 
 
 The antimicrobial activity was determined using the hole-in-plate bio assay 
procedure. The pure cultures of the microorganisms were inoculated onto Muller-Hilton 
nutrient broth incubated at temperature of 37°C for 24 hours. Using a sterile cork-borer of 
5mm diameter, three holes were made into the Petri dishes seeded with bacterial culture. 
Concentrations of 25, 50 and 100µg/ml solution were reconstituted in distilled water and 
transferred into the wells. The plates were incubated at temperature of 37°C for 18 hours. 
S. aureus, E. coli, Salmonella typhi, P.aurigunosa, St. pyogenes, and Candida albicans 
were used as the test microorganisms. All microbial cultures were maintained on nutrient 
agar slants at temperature of 4ºC and sub cultured onto nutrient agar broth for 24 hours 
prior to testing.  
 
 The plates were kept for 30 min at room temperature to allow diffusion of the test 
drug, and then were incubated at temperature of 37º C for 18 hours. After the incubation 
period, the zones of inhibition will be measured using a caliper. Studies were performed 
in triplicates and the mean value was calculated.  
 
Agar well diffusion method 
 
 Antimicrobial activity of Aivaeli Samoola Chooranam was tested using agar well 
diffusion method. 200μl of bacteria was aseptically introduced and spread using cotton 
swabs on surface of gelled sterile Muller Hilton agar plates. A well of about 6.0mm 
diameter with sterile cock borer was aseptically punched on each agar plate. 50μl of the 
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ASC were introduced into the wells in the plates. A negative control well was too made 
with 50μl of the sterile distilled water. Plates were kept in laminar flow for 30 minutes for 
pre diffusion of Aivaeli Samoola Chooranam to occur and then incubated at 37ºC for 24 
hours. Resulting zone of inhibition was measured. 
 
For determination of antimicrobial activity of three doses of Aivaeli Samoola 
Chooranam, different bacterial and fungal strains were used by agar ditch method. The 
pathogenic cultures were swabbed separately in each air dried pre-incubated Nutrient 
Agar and Sabouraud Dextrose Agar plates with help of sterile cotton swabs. Ditches were 
prepared in agar plates with the help of surface sterilized borer. After boring the Aivaeli 
Samoola Chooranam suspension of different concentrations were added separately to the 
ditches (50µl). The plates were incubated at 370C. Controls were maintained. After 24 h 
diameter of clear zone produced around the ditches were measured to the nearest mm 
with the help of the micro scales. 
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4.5 CLINICAL ASSESSMENT OF AIVAELI SAMOOLA CHOORANAM: 
Eczema is one of the skin ailments which affect this beauty and protective 
function of skin. Thus it affects physically and mentally. Diseases of the skin account for 
a great deal of misery, suffering, incapacity and economic loss. Besides this, they are a 
great handicap in the society, because they are visible. 
 
Objectives: 
To explore the efficacy of Aivaeli samoola chooranam in patients with 
Eczema.(Karappan) 
 
Design of the Study: 
The Open clinical trial – phase II B 
 
Study Centre: 
Arignar Anna, Government Hospital of Indian Medicine and Homeopathy, 
Arumbakkam, Chennai – 106. 
 
Study Participants: 
Both men and women and members of all races and ethnic groups were eligible 
for this trial. Treatment was administered on an inpatient/outpatient basis. The patients 
had been selected from the In-patient and Out-patient department of Arignar Anna 
Government Hospital of Indian Medicine and Homeopathy, Chennai – 106. 
 
Number of Subjects: 
Number of participants- 50 
 
Registration Process: 
To register a patient, the following documents should be completed by the 
investigator. 
Ø Copy of required laboratory tests 
Ø Signed patient consent form 
Ø Other appropriate forms (e.g., Trial pro-forma). 
The investigator verified eligibility and assigned a patient study number, drug dose 
and register the patient on the study. 
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Selection: 
50 patients from both sexes of various age groups were selected for clinical trial. 
Among 50 patients 40 patients were treated as out-patients, 10 patients were treated as in-
patients. The selection was based on the inclusion and exclusion criteria. They were 
clinically diagnosed on the basis of siddha principles with modern laboratory findings. 
 
Criteria for Selection: 
 
Including Criteria: 
The particular signs and symptoms like  
1. Itching 
2. Erythema 
3. Vesicles 
4. Pastules 
5. Oozing 
6. Oedema 
7. Allergic tendency 
8. Crusting 
9. Scaling 
 
Excluding Criteria: 
1. Herpes zoster 
2. Neurodermatitis 
3. Psoriasis 
4. Skin cancer 
5. Tinea pedis 
6. Scabies 
 
Criteria for Withdrawal: 
Patients were removed from study when any of the criteria listed below applies. 
The reason for study removal and the date the patient was removed must be documented 
in the Case Report Form. 
Ø Irregular medication. 
Ø Any adverse reactions during the study period. 
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Ø Patients who are all not following the diet restrictions 
Ø Patient decides to withdraw from the study, or Unwanted prolonged illness during 
the study period 
 
Investigation: 
For all the cases full clinical data were recorded and they were diagnosed on the 
basis of SIDDHA principles i.e. Envagai Thrvugal, Ezhu Udal Thathukkal Etc. 
All the patients under study were subjected to blood investigations for TC, DC, 
ESR,  Hb and Blood sugar were  investigated. 
 Urine test for albumin, sugar, deposits and motion test for ova, cysts were done. 
  The disease KARAPPAN was confirmed in the patients by means of Serum Ig E, 
skin biopsy and clinically. 
 
Criteria for Assessment of Response to Therapy: 
1) Marked Relief : 95% relief in signs and symptoms and marked 
normalcy of pathological investigations. 
2) Moderate Relief : 80% – 90% relief in the presenting signs and 
symptoms and moderate normalcy of pathological 
investigation. 
3) Mild Relief : 70% - 80% relief signs and symptoms, mild normalcy 
of pathological investigation. 
4) Poor Relief : below 60% relief of signs and symptoms and no 
marked changes in pathological investigations. 
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Table no-1  SEX DISTRIBUTION 
 
 
 
 
 
 
 
 
 
 
Inference: 
Among 50 patients, 
Ø 29 patients were male  
Ø 21 patients were female 
 
 
 
  
MALE, 29
FEMALE, 21
SEX DISTRIBUTION
MALE
FEMALE
SL. NO SEX NO. OF PATIENTS 
PERCENTAGE 
(%) 
1. Male 29 58 
2. Female 21 42 
TOTAL 50 100 
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Table No-2  AGE WISE DISTRIBUTION 
SL. NO AGE IN YEARS NO. OF PATIENTS PERCENTAGE (%) 
1. 21-30 5 10 
2. 31-40 16 32 
3. 41-50 16 32 
4. 51-60 9 18 
5. 61-70 4 8 
TOTAL 50 100 
 
 
 
 
Inference: 
5 patients belongs to the age group of 21-30 
16 patients belongs to the age group of 31-40 
16 patients belongs to the age group of 41-50 
9 patients belongs to the age group of 51-60 
4 patients belongs to the age group of 61-70 
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Table No-3  OCCUPATION STATUS 
 
SL. NO OCCUPATION NO. OF PATIENTS PERCENTAGE (%) 
1. Home makers 18 36 
2. Daily Labour 15 30 
3. Own Business 7 14 
4. Office Workers 10 20 
TOTAL 50 100 
 
 
 
 
Inference: 
 Among 50 patients 
Ø 18 patients are Home makers. 
Ø 7 patients are own business. 
Ø 10 patients are Office workers. 
Ø 15 patients are Daily Labour 
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Table No-4  DIET HABITS 
S.NO DIET NO OF PATIENT PERCENTAGE 
1. MIXED 36 72 
2. VEGETARIAN 14 28 
 
 
 
 
Inference: 
36 patients are mixed diet 
14 patients are vegetarian diet 
 
 
MIXED DIET
72%
VEGETARIAN
28%
DIET HABITS
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CLINICAL STUDY ON AIVAELI SAMOOLA CHOORANAM FOR KARAPPAN (O.P) 
Sl.No. O.P. No. Name 
Age/ 
Sex Symptoms 
 
Duration 
 
Results 
1. 7439 SHANTHAM 55/F 
Itching, erythema, lichenification, pustules, 
oozing,  varicose vein present 
18.06.2012 to 06.08.2012 
 
Marked 
2. 099 KAVITHA 37/F 
Itching, erythema, lichenification, pustules, 
oozing,   present 
25.06.2012 to 30.07.2012 Mild 
3. 782 RADHA BAI 69/F 
Itching, erythema, lichenification, pustules, 
oozing,   varicose vein present 
27.06.2012 to 12.08.2012 Marked 
4. 3189 SANGEETHA 28/F 
Itching, erythema, lichenification, pustules, 
oozing,   present 
07.07.2012 to  09.08.2012 Marked 
5. 3684 ANANDH 42/M 
Itching, erythema, lichenification, pustules, 
oozing,   present 
09.07.2012 to 15.07.2012 
 Marked 
6. 5661 SUNDHARESAN 55/M 
Itching, erythema, lichenification, pustules, 
vesicle,  varicose vein present 
17.07.2012 to 07.09.2012 Mild 
7. 5819 SAKTHI 35/M 
Itching, erythema, lichenification, pustules, 
oozing,  varicose vein present 
17.07.2012 to 27.08.2012 Mild 
8. 7315 PARTHASARATHY 64/M 
Itching, erythema, lichenification, pustules, 
oozing,   present 
23.07.2012  to 30.08.2012 Marked 
9. 7320 USHA 38/F 
Itching, erythema, lichenification, pustules, 
oozing,  varicose vein present 
23.07.2012 to 04.09.2012 Moderate 
10. 7498 VIJAYAKUMAR 47/M 
Itching, erythema, lichenification, varicose 
vein  present 
24.07.2012 to 11.09.2012 Marked 
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CLINICAL STUDY ON AIVAELI SAMOOLA CHOORANAM FOR KARAPPAN (O.P) 
Sl.No. O.P. No. Name Age/ Sex Symptoms 
 
Duration 
 
Results 
11. 887 CHANDRAN 63/M Itching, erythema, lichenification, pustules, oozing,  varicose vein present 06.08.2012 to 20.09.2012 Marked 
12. 897 BHUWANESWARI 37/F Itching, erythema, lichenification, pustules, pustule, present 
06.08.2012 to 18.09.2012 Poor 
13. 912 GAYATHRI 26/F 
Itching, erythema, lichenification, 
pustules,vesicle present 
06.08.2012 to 10.08.2012 Marked 
14. 2539 KANTHA 45/F 
Itching, erythema, lichenification, pustules, 
oozing,  varicose vein present 
13.08.2012 to 01.10.2012 Marked 
15. 969 THULASIRAMAN 48/F 
Itching, erythema, lichenification, pustules, 
oozing,   present 
06.08.2012 to 22.09.2012 Marked 
16. 4472 SAKTHIKANI 47/F 
Itching, erythema, lichenification, pustules, 
oozing,   present 
22.08.2012 to 10.09.2012 Marked 
17. 1001 ROHINI 48/F 
Itching, erythema, lichenification, pustules, 
oozing,   present 
06.08.2012 to 23.09.2012 
Moderate 
 
18. 8922 VAANI 45/F 
Itching, erythema, lichenification, pustules, 
vesicles present 
10.09.2012 to 30.10.2012 Marked 
19. 6618 DURAIVELU 55/M Itching, erythema, lichenification, pustules, oozing,  varicose vein present 
12.10.2012 to 29.11.2012 Marked 
20. 6851 DEVI 40/F 
Itching, erythema, 
lichenification,Presentesen 
13.10.2012 to 01.12.2012 Mild 
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21. 6886 PAZHANI 45/M 
Itching, erythema, lichenification, pustules, 
vesicles present 
13.10.2012 to 30.11.2012 
 
Marked 
22. 7780 KAMALAKANNAN 34/M 
Itching, erythema, lichenification, pustules, 
vesicles pain, ulcer present 
17.10.2012 to 27.11.2012 
 
Moderate 
23. 7778 SIVAKUMAR 40/M 
Itching, erythema, lichenification, pustules, 
vesicles pain, ulcer present 
17.10.2012 to 03.12.2012 
 
Marked 
24. 7711 KANNAN 40/M 
Itching, erythema, lichenification, pustules, 
oozing,  varicose vein present 
17.10.2012 to 05.12.2012 Marked 
25. 1293 RAJESWARI 55/F 
Itching, erythema, lichenification, pustules, 
vesicles present 
05.11.2012 to 20.12.2012 Marked 
26. 1517 CHELLAMAL 45/F 
Itching, erythema, lichenification, pustules, 
vesicles pain, ulcer present 
06.11.2012 to 22.12.2012 Marked 
27. 1671 KALAIARASI 42/F 
Itching, erythema, lichenification, pustules, 
vesicles pain, ulcer present 
06.11.2012  to 24.12.2012 Poor 
28. 1758 KARTHIK 28/M 
Itching, erythema, lichenification, pustules, 
vesicles present 
07.11.2012 to 20.12.2012 Marked 
29. 496 RAVI 42/M 
Itching, erythema, lichenification, pustules, 
oozing,  varicose vein present 
01.11.2012 to 18.12.2012 Moderate 
30. 1272 RAJAN 58/M 
Itching, erythema, lichenification, pustules, 
vesicles present 
05.11.2012 to 19.12.2012 Marked 
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31. 1557 JAYAKUMAR 30/M Itching, erythema, lichenification, pustules, 
vesicles present 
06.11.2012 to 16.12.2012 Poor 
32. 1805 SELVAM 35/M Itching, erythema, lichenification, pustules, 
oozing,  varicose vein present 
07.11.2012 to 20.12.2012 
 
Marked 
33. 8006 TAMIZHARASU 38/M Itching, erythema, lichenification, pustules, 
oozing,  varicose vein present 
18.10.2012 to 11.11.2013 
 
Moderate 
34. 1865 PURUSOTHAMAN 37/M Itching, erythema, lichenification, pustules, 
vesicles present 
07.11.2012 to 25.12.2012 Moderate 
35. 2083 PONVARANGAM 36/M Itching, erythema, lichenification, pustules, 
vesicles pain, ulcer present 
08.11.2012 to 24.12.2012 Marked 
36. 2260 SATHYAMOORTHY 32/M Itching, erythema, lichenification, pustules, 
vesicles present 
09.11.2012 to 27.12.2012 Marked 
37. 2287 NAVEEN 34/M Itching, erythema, lichenification, pustules, 
vesicles pain, ulcer present 
09.11.2012 to 22.12.2012 Marked 
38. 1890 KALAIVANI 32/F Itching, erythema, lichenification, pustules, 
vesicles present 
07.11.2012 to 23.12.2012 Marked 
39. 1892 REVATHI 32/F Itching, erythema, lichenification, pustules, 
vesicles pain, ulcer present 
10.11.2012 to 26.12.2012 Moderate 
40. 1894 VASUDEVAN 24/M Itching, erythema, lichenification, pustules, 
vesicles present 
07.11.2012 to 29.12.2012 Marked 
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CLINICAL STUDY ON AIVAELI SAMOOLA CHOORANAM FOR KARAPPAN (I.P) 
   Sl.No. I.P. No. Name Age/ Sex Symptoms 
 
Duration 
 
Results 
1. 1089/7184 FRANCIS 60/M Itching, erythema, lichenification, pustules, oozing,  varicose vein present 23.07.2012 to 27.08.2012 
Marked 
 
2. 1447/8001 ARUMUGAM 67/M Itching, erythema, lichenification, pustules, oozing,  varicose vein present 
06.09.2012 to 19.10.2012 
 
Marked 
3. 1152/8998 VIJAYARANI 50/F Itching, erythema, lichenification, pustules, vesicles present 
30.07.2012 to 13.08.202 
 
Marked 
4. 1216/924 MAHESWARI 46/F Itching, erythema, lichenification, pustules, vesicles present 06.08.2012 to 12.09.2012 Marked 
5. 1326/4614 USEN 37/M Itching, erythema, lichenification, pustules, vesicles pain, ulcer present 22.08.2012 to 23.09.2012 Marked 
6. 8/9848 KARNAN 43/M Itching, erythema, lichenification, pustules, vesicles present 14.09.2012 to 26.10.2012 Marked 
7. 163/4326 THULASI 38/F Itching, erythema, lichenification, pustules, vesicles pain, ulcer present 03.10.2012 to 09.11.2012 Marked 
8. 1236/1516 MAREEN 58/M Itching, erythema, lichenification, pustules, vesicles present 08.08.2012 to 10.09.2012 Marked 
9. 1342/5169 BHASEER 51/M Itching, erythema, lichenification, pustules, vesicles pain, ulcer present 25.08.2012 to 10.10.2012 Marked 
10. 1363/5792 KUMAR 40/M Itching, erythema, lichenification, pustules, vesicles pain, ulcer present 28.08.2012 to 10.10.2012 Marked 
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Sl. 
No. 
O.P. 
No. 
Name 
Age/ 
Sex 
HAEMATOLOGICAL REPORT  URINE ANALYSIS 
BEFORE TREATMENT AFTER TREATMENT ESR (mm) Hb(Gm) B.S BT AT 
TC 
CU/m
m 
DC 
TC 
CU/
mm 
DC BT AT 
BT AT 
Mg/dl 
Alb Sug Dep Alb Sug Dep 
P L E P L E 
½ hr 1 
hr 
½ hr 1h
r 
BT AT 
1. 7439 SHANTHAM 55/F  9400 57 38 5 9300 58 39 3 13 33 10 30 12  12.4 113 109 NIL NIL OPC NIL NIL NIL 
2. 099 KAVITHA 37/F 9300 56 38 6 9400 57 39 4 14 34 10 18 10 10.2 96 92 NIL NIL NIL NIL NIL NIL 
3. 782 RADHABAI 69/F 9000 55 40 5 9100 55 12     3 16 37 10 18 11 11 115 101 NIL NIL FPC  NIL NIL NIL 
4. 3189 SANGEETHA 28/F 9200 56 32 12 9200 59 35    6 20 42 10 22 11.2 11.4 92 96 NIL NIL FPC NIL NIL FPC 
5. 3684 ANANTH 42/M 8700 58 36  6 9800 60 36    4 18 40 14 28 12 13 109 87 NIL NIL FPC NIL NIL FPC 
6. 5661 SUNDHARESAN 55/M 8800 56 38  6 9000 56 40   4 18 38 12 26 14 14.2 110 100 NIL NIL NIL NIL NIL NIL 
7. 5819 SAKTHI 35/M 9200 58 35 7 9400 57 40 3 5 11 5 10 14.6 15 99 96   NIL NIL FPC NIL NIL NIL 
8. 7315 PARTHASARATHY 64/M 8900 60 35 5 9000 59 38 3 7 17 6 14 7.2 8.8 89 94 NIL NIL FPC NIL NIL FPC 
9. 7320 USHA 38/F 9200 59 33 8 9200 60 35    5 13  28 8 17 9.8 10.1 102 99 NIL NIL FPC NIL NIL FBC 
10. 7498 VIJAYAKUMAR 47/M 8800 57 34   9 9000 60 35      5 16 30 10 22 13.5 14 112 108 NIL NIL NIL NIL NIL NIL 
11. 887 CHANDRAN 63/M 9200 59 35 6 9900 60 36 4 26 48 12 35 12 13 108 89 NIL NIL NIL NIL NIL NIL 
12. 897 BHUWANESWARI 37/F 10000 66 28 6 9900 62 34 4 33 63 18 38 12 12.8 83 80 NIL NIL FPC NIL NIL NIL 
13. 912 GAYATHRI 26/F 9300 55 39   6 9400 58 39     3 12 39 8 20 12 12.5 83 90 NIL NIL NIL NIL NIL NIL 
14. 2539 KANTHA 45/F 9900 60 36 4 9900 60 37 3 12 33 9 18 12.6 13.2 101 98 NIL NIL FPC NIL NIL NIL 
15. 969 THULASIRAMAN 48/F 9700 59 38 3 9800 60 37 3 3 8 4 8 12.8 13 106 102 NIL NIL NIL NIL NIL NIL 
16. 4472 SAKTHIKANI 47/F 9400 55 41  4 9500 56 41 3 18 34 10 18 9.8 10.2 118 106 NIL NIL FPC NIL NIL FPC 
17. 1001 ROHINI 48/F 9200 62 30  8 9400 66 30    4 14 30 7 15 10.2 11 95 90 NIL NIL NIL NIL NIL NIL 
18. 8922 VAANI 45/F 9000 52 31 7 9300 54 32    4 16 40 12 36 9.6 10.4 110 102 NIL NIL FPC NIL NIL NIL 
19. 6618 DURAIVELU 55/M 9700 55 37 8 9800 59 38 3 12 26 6 14 11.8 12.2 118 111 NIL NIL NIL NIL NIL NIL 
20. 6851 DEVI 40/F 9800 53 40 7 9900 56 39    5 19 28 11 22 10 10.8 98 94 NIL NIL NIL NIL NIL NIL 
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Sl. 
No. 
O.P. 
No. 
Name 
Age/ 
Sex 
HAEMATOLOGICAL REPORT URINE ANALYSIS 
BEFORE TREATMENT AFTER TREATMENT ESR (mm) Hb(Gm) B.S gm/dl BT AT 
TC 
CU/mm 
DC 
TC 
CU/mm 
DC BT AT 
BT AT BT AT Alb Sug Dep Alb Sug Dep 
P L E P L E 
½ hr 1 
hr 
½ hr 1hr 
21. 6886 PAZHANI 45/M 9800 53 41 6 9900 54 43 3 12 26 6 14 13 13.5 110 106 NIL NIL NIL NIL NIL NIL 
22. 7780 KAMALAKANNAN 34/M 7600 58 37 5 7800 58 39 3 16 32 7 14 12.4 13 104 98 NIL NIL FPC NIL NIL FPC 
23. 7778 SIVAKUMAR 40/M 8900 61 31 8 9100 63 33 4 14 28 8 16 14 14.8 115 101 NIL NIL   NIL NIL NIL NIL 
24. 7711 KANNAN 40/M 9100 63 31 6 9300 64 33 3 8 16 4 8 12 12.8 112 102 NIL NIL FPC NIL NIL FPC 
25. 1293 RAJESWARI 55/F 9000 54 38 8 9200 57 39 4 20 45 12 18 11.8 12.4 133 109 NIL NIL FPC NIL NIL NIL 
26. 1517 CHELLAMAL 45/F 8900 53 40 7 9000 56 41 3 27 55 20 40 13 13.5 80 94 NIL NIL FPC NIL NIL FPC 
27. 1671 KALAIARASI 42/F 9000 51 43 6 9200 52 44 4 20 44 14 26 11.5 12.2 88    90 
         
NIL 
NIL NIL NIL NIL NIL 
28. 1758 KARTHIK 28/M 7900 55 37 8 8100 57 38 5 22 46 10 18 11.5 12 96 94 NIL NIL NIL NIL NIL NIL 
29. 496 RAVI 42/M 7900 61 31 8 9800 62 34 4  22 44 12 18 13 13.5 82 84 NIL NIL FPC NIL NIL FPC 
30. 1272 RAJAN 58/M 8100 59 34 7 8000 61 35    4 16 32 8 16 12 13 102 100 NIL NIL NIL NIL NIL NIL 
31. 1557 JAYAKUMAR 30/M 9200 58 35 7 9100 60 36 4 24 38 12 24 10 11 106 98 NIL NIL NIL NIL NIL NIL 
32. 1805 SELVAM 35/M 9500 61 33 6 9600 62 35 3 12 26 8 14 13 14 92 88 NIL NIL NIL NIL NIL NIL 
33. 8006 TAMIZHARASU 38/M 9200 57 36 7 9400 59 37 4 14 28 6 12 12 15 102 106 NIL NIL FPC NIL NIL FPC 
34. 1865 PURUSOTHAMAN 36/M 9700 55 37 8 9800 57 44 4 24 42 13 20 10 12 98 96 NIL NIL NIL NIL NIL NIL 
35. 2083 POVARANGAM 36/M 9300 53 40 7 9400 55 42 3 22 44 12 18 12 14 110 104 NIL NIL NIL NIL NIL NIL 
36. 2260 SATHYAMOORTHY 32/M 9500 54 38 8 9600 58 38 4 12 28 9 14 13 14 98 94 NIL NIL NIL NIL NIL NIL 
37. 2287 NAVEEN 34/M 9900 61 33 6 9800 61 36 3 14 26 8 12 12 14 102 104 NIL NIL FPC NIL NIL FPC 
38. 1890 KALAIVANI 32/F 7600 59 34 7 7900 60 37 3 22 44 14 22 10 10.5 106 98 NIL NIL NIL NIL NIL NIL 
39. 1892 REVATHI 32/F 7500 58 35 7 7700 60 36 4 16 28 7 15 9.5 10 98 92 NIL NIL FPC NIL NIL FPC 
40. 1894 VASUDEVAN 24/M 8900 55 37 8 9100 57 44 4 14 28 8 16 12 12.5 102 98 NIL NIL FPC NIL NIL FPC 
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Sl. 
No
. 
I.P. No. Name Age/ Sex 
HAEMATOLOGICAL REPORT URINE ANALYSIS 
BEFORE 
TREATMENT 
AFTER TREATMENT ESR (mm) 
Hb(Gm) B.S gm/dl BT AT 
TC 
CU/
mm 
DC TC 
CU/m
m 
DC BT AT 
BT AT BT AT Alb Sug Dep Alb Sug Dep 
P L E P L E 
½ 
hr 
1 hr ½ hr 1hr 
1. 1089/7184 FRANCIS 60/M 9300 62 32 6 9400 63 33 4 12 24 6 10 11 11.5 115 110 NIL NIL NIL NIL NIL NIL 
2. 1447/8001 ARUMUGAM 67/M 9700 61 32 7 9800 63 33 5 15 28 10 14 13 14 120 108 NIL NIL FPC NIL NIL NIL 
3. 1152/8998 VIJAYARANI 50/F 9800 53 41 6 9900 55 41 4 14 28 8 14 10 11 98 92 NIL NIL  PC  NIL NIL FPC 
4. 1216/924 MAHESWARI 46/F 8800 55 38 7 8900 59 38 3 15 30 7 14 9.8 10 101 98 NIL NIL NIL NIL NIL NIL 
5. 1326/4614 USEN 37/M 9700 53 40 7 9800 55 41 4 12 24 6 12 12 12.5 111 99 NIL NIL FPC NIL NIL NIL 
6. 8/9848 KARNAN 43/M 9500 62 32 6 9600 63 33 4 10 28 5 10 14 14 110 102 NIL NIL FPC NIL NIL FPC 
7. 163/4326 THULASI 38/M 9300 54 38 8 9400 57 38 5 12 32 8 16 11 11.5 98 96 NIL NIL NIL NIL NIL NIL 
8. 1236/1516 MAREEN 58/M 9500 55 38 7 9600 59 38 3 16 34 9 16 10.5 11 102 98 NIL NIL FPC NIL NIL FPC 
9. 1342/5169 BHASEER 51/M 9200 58 36 6 9400 59 38 3  2 26 4 8 10 10.5 104 100 NIL NIL NIL NIL NIL NIL 
10 1363/5792 KUMAR 40/M 9100 61 32 7 9200 63 33    5 14 22 6 12 12.4 13 110 98 NIL NIL NIL NIL NIL NIL 
 
 
54 
ECZEMA AREA SEVERITY INDEX SCORE 
  
S.NO O.P NO NAME 
AGE/SE
X 
EASI  SCORE 
BT AT 
1. 7439 SHANTHAM 55/F 3.8 0.8 
2. 099 KAVITHA 37/F 4.6 1.8 
3. 782 RADHA BAI 69/F 4 0.2 
4. 3189 SANGEETHA 28/F 10.8 1.6 
5. 3684 ANANDH 42/M 3.6 0.2 
6. 5661 SUNDHARESAN 55/M 0.6 0.2 
7. 5819 SAKTHI 35/M 7.2 2.8 
8. 7315 
PARTHASARATH
Y 
64/M 5.2 0.4 
9. 7320 USHA 38/F 3.2 0.8 
10. 7498 VIJAYAKUMAR 47/M 0.8 0.2 
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ECZEMA AREA SEVERITY INDEX SCORE 
  
S.NO O.P NO NAME 
AGE/SE
X 
EASI SCORE 
BT AT 
11. 887 CHANDRAN 63/M 4.0 1.0 
12. 897 BHUWANESWARI 37/F 2.8 1.8 
13. 912 GAYATHRI 26/F 4.2 0.4 
14. 2539 KANTHA 45/F 12 1.8 
15. 969 THULASIRAMAN 48/F 5.4 1 
16. 4472 SAKTHIKANI 47/F 15 3 
17. 1001 ROHINI 48/F 10 1.8 
18. 8922 VAANI 45/F 4 0.8 
19. 6618 DURAIVELU 55/M 8 1.2 
20. 6851 DEVI 40/F 6 2.8 
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ECZEMA AREA SEVERITY INDEX SCORE 
 
 
  
S.NO O.P NO NAME AGE/SEX 
EASI SCORE 
BT AT 
21. 6886 PAZHANI 45/M 3 0.2 
22. 7780 KAMALAKANNAN 34/M 6 0.4 
23. 7778 SIVAKUMAR 40/M 8 1.4 
24. 7711 KANNAN 40/M 15.4 3 
25. 1293 RAJESWARI 55/F 10 1.2 
26. 1517 CHELLAMAL 45/F 14 1.6 
27. 1671 KALAIARASI 42/F 6 3.4 
28. 1758 KARTHIK 28/M 14 2 
29. 496 RAVI 42/M 4 0.1 
30. 1272 RAJAN 58/M 12 2.2 
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ECZEMA AREA SEVERITY INDEX SCORE 
 
                       
            
 
  
S.NO O.P NO NAME AGE/SEX 
EASI SCORE 
BT AT 
31. 1557 JAYAKUMAR 30/M 8 1.6 
32. 1805 SELVAM 35/M 18 3 
33. 8006 TAMIZHARASU 38/M 18 3.8 
34. 1865 PURUSOTHAMAN 37/M 10.5 2.6 
35. 2083 PONVARANGAM 36/M 10 2.2 
36. 2260 SATHYAMOORTHY 32/M 8 2.2 
37. 2287 NAVEEN 34/M 3 0.2 
38. 1890 KALAIVANI 32/F 6 1.4 
39. 1892 REVATHI 32/F 5.8 0.6 
40. 1894 VASUDEVAN 24/M 5 2.6 
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ECZEMA AREA SEVERITY INDEX SCORE 
 
S.NO I.P NO NAME AGE/SEX 
EASI SCORE 
BT AT 
1 1089/7184 FRANCIS 60/M 12 2.4 
2. 1447/8001 ARUMUGAM 67/M 4 0.6 
3. 1152/8998 VIJAYARANI 50/F 6.4 1.4 
4. 1216/924 MAHESWARI 46/F 7.4 2.0 
5. 1326/4614 USEN 37/M 4 0.8 
6. 8/9848 KARNAN 43/M 14 2.8 
7. 163/4326 THULASI 38/F 10.2 2.2 
8. 1236/1516 MAREEN 58/M 9.2 1.8 
9. 1342/5169 BHASEER 51/M 11.4 2.4 
10. 1363/5792 KUMAR 40/M 9.6 1.4 
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5. RESULTS AND DISCUSSION 
 
Many types of studies had been focused on Aivaeli samoola Chooranam to 
demonstrate its superiority and therapeutic efficacy. Explorations like literary collections, 
pharmacognostic study, physicochemical and phyto chemical analysis, toxicological 
study, pharmacological study and clinical study are carried to sustain the aim and 
objective of the study 
Literary review of Aivaeli samoola chooranam shows that it has bitter in taste. 
Siddha have unique methodology of selecting a drug of choice for a disease based 
on humoral pathology of the disease and suvai of the drug. Suvai based medicine 
selection could give better result as at is in successful practice from ancient days. 
ைக    ைவய  ப   
 ட      ட  ெகா ய ந   
வா ந  ற  அழ சி   தண    
-ம   வ தன பாட - 
As per literature, Bitter taste has the property to reduce the skin manifestations. Because 
of its bitter taste, it has a specialty in treating skin disease like Karappan. 
 
STANDARDIZATION OF PLANT DRUG  
 
Pharmacognostic Study of Aivaeli samoola chooranam: 
Macroscopic 
Perennial, monoecious herb climbing by bifid tendrils. 
Stem up to6m long. Young stems spotted with darker green. 
Leaves alternate, simple; stipules absent; petiole 2-10cm long; blade 
broadlyovate, palmately 5 lobed up to 14cm x 15cm;base cordate; lobes narrowly 
elliptical, margin sinuatedentate. 
Inflorescence an axillary cluster with usually both male and female flowers in 
same axil. 
Flowers unisexual,regular,5-merous corolla white to greenish-yellow;male 
flowers pedicellate,with 3 free stamens;female flowers subsessile,with inferior ,1 celled 
ovary,stigma 3-lobed. 
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Fruit a subglobose, indehiscent berry 1.5-12.5 cm in diameter, solitary or 
clustered, red with silvery white longitudinal stripes. 
 
Microscopic 
T. S of Leaf 
Leaf is dorsiventral with prominent aboxical part of the midrib bifacial lamina 
(Fig 1.1). The midrib consists of small, blung adaxial cone and widet thick somewhat 
labed abaxial part. The midrib is 440mm thick and 400mm broad. The epidermal layer of 
the midrib consists of small, squorish, thin walled cells within the adaxial cone occurs 
small, compact, mass of collenchimpa cells. The ground tissue is homogeneous 
parenchypmatous, thin walled, angular & compact (Fig 1.2). The vascular strand is single, 
small and bowl shaped. It consists of a cluster of wide, angular, thick walled refen and a 
thin layer of phloem on the lower part of the xylem strand (Fig 1.3). 
 
Lamina: 
The Lamina is 100mm thick. The adaxial epidermis includes fairly thick 
rectangular cells with thin cuticle. The aboxial epidermis is also fairly thick with 
rectangular thin walled cells. The Palirade tissue consists of a single band of thick, 
cylindrical, less compact cells. The spongy mesophyll consists of 3 or 4 layers of 
spherical or lobed cells which form narrow air chambers (Fig 1.4) 
 
Root 
Both thin and thick roots are studied. The thin root (Fig 2.1) and thick root (Fig 
3.1) are basically similar in structure. The root consists of outer narrow, less district 
periderm layer and thick parenchymatous cortex. Fig (2.1 & 1 & 2, 3.1).  
 
The vascular cylinder is unusual (anamelous) in structure. In thin root there are 4 
radiating fan shaped wings of vessel elements with broad vascular rays inbetween the 
radial wings. (Fig 2.1) In case of thick root the xylem elements occur in about 6 radial 
wings with wide parenchumatous rays in between the wing (Fig 3.1) Instead of having 
solid, dense xylem cylinder in this case xylem elements are broken in radiating wings by 
wide parenchymatous rays. So, this feature is considered to be anamolous structure. The 
vessel elements are very wide, circular and fairly thick walled, within the vessel elements 
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are seen thin vesicles called thyloses, which are broken and collapsed (Fig 2.2 & 2.3, 3.2). 
The vessel elements are ensheathed by thin layer of fibers. Phloem occurs at the accouter 
ends of radial segments of xylem. The vessel elements in the centre are narrow, those 
towards the periphery are wider, The outer vessel elements are 200-250µm wide. 
Flowers 
The flowers are unisexual and the plants are monecious Male and Female flowers 
occur in the axils of same plant. The petals and sepals are 5 lobed, stamens three 1 
stamens has one celled another, the other two have 2 celled anther. The stamers are 
attached on the throat of the sepals (Fig 4.1). The another wall is 2 layered and thin 
walled (Fig 4.2). The Pollen Grains are circular with thick and smonth exicts (Fig 4.2 & 
3) 
The Pollen Grains are 50µm in diameter. 
 
Female Flower 
The Ovary is ovoid. It is tricarpellary, syncarpous with parietal Placentation. 
Ovules are many, the ovary develops into ovoid, pulpy many seeded berry. The ovule is 
cylindrical with elongated cylindrical embryo (Fig 5 & 6.1). The pericarp is 400µm thick. 
It consists of thick walled epidermal layer and the mesocarp having outer small, thick 
walled ground cells & Inner Larger, thin walled parenchyma cells. Vasuclar bundles are 
seen in the thin walled parenchyma zone. The vascular bundles are bicollatoral with 
central xylem and phloem on outer & Inner parts of xylem strand (Fig 6.3). 
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Fig: 1.1- T.S of  leaf through midrib & lamina 
 
 
Fig: 1.2- T.S of midrib-enlarged 
 
 
Fig: 1.3-Vascular strand of the midrid enlarged 
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 Fig: 1.4- T.S of lamina 
 
Abe - Abaxial epidermis,   Adc - Adaxial core 
Ep - Epidermis,    GT - Ground tissue 
La - Lamina,    MR - Midrib 
Ph - Phloem,    PM - Palisade mesophyll 
SM - Sponcy mesophyll,   VB - Vascular bundle,   
X - Xylem 
 
 
 
Fig: 2.1 T.S of thin root-Entire view 
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Fig: 2.2 & 2.3-Vascular cylinder showing radiating segments 
Co - cortex    Sph - Secondary phloem 
SX - Secondary xylem  XR - Xylem ray 
 
 
Fig: 3.1 T.S of thick root-Entire view 
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Fig: 3.2-Vessel elements with broken Tyloses 
 
Cx - central Xylem   Ox - Outer xylem 
Pa - Parenchyma   PF - Paratrachial fibers 
VR - Vascular ray   Ty - Tyloses 
 
 
 
Fig: 4.1-L.S of Male flower 
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Fig: 4.2 -T.S of  Anther-Enlarged 
 
 
Fig: 4.3-Pollen grarins enlarged 
 
An - Anther   AW - Anti-clinal wall 
N - Nucleus  Po - Pollen 
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Fig: 5.1 T.S of Fruit 
 
Ca - carpel,   Em - Embryo 
Pe - Pericarp,  OV - Ovule 
 
 
 
 
Fig: 6.1 L.S of seed with embryo 
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z  
Fig: 6.2-Pericarp of the fruit 
 
 
 
Fig: 6.3-Vascular bundle of the pericarp 
 
Em - embryo,  OV - Ovule 
Ph - Phloem,  X - Xylem 
Ep - Epidermis,  IC - Inner cortex 
OC - Outer cortex,  VB - Vascular bundle 
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Pharmacognostic study shows   microscopical structures of the herb Diplocyclos 
palmatus. It is used to recognize the plants in fresh and dried samples and to identify the 
adulteration of the drug. 
 
ORGANOLEPTIC CHARACTERS 
The following organoleptic characters are noted in Aivaeli samoola chooranam 
Table No 5 
Appearance Powder 
Colour light brown 
Odour Odourless 
Taste Bitter 
Texture Fine 
 
PHYSICO-CHEMICAL INVESTIGATIONS OF DRUG 
S.No Parameter Mean Value 
1. Loss on Drying at 105°C 8.573 % 
2. Total Ash 12.572 % 
3. Acid insoluble Ash 1.075 % 
4. Water Soluble Extractive 26.0 % 
5. Alcohol Soluble Extractive 14.85 % 
6. Particle size Completely passes through sieve no.44 
7. Ph 6.2 
 
Ø Loss on drying (LOD) gives the total of volatile content and moisture present in the 
drug. The stability of a drug and its shelf-life is dependent on moisture –content. 
Moisture increases can adversely affect the active ingredient. Low moisture content, 
drug could get maximum stability and better shelf life. 
Ø Total ash value measures the total inorganic content (ammonium, potassium, calcium, 
chloride, iron, etc.) present in the drug. 
Ø Acid insoluble ash value of a drug says the amount of siliceous matter present in the 
plant. Lower the acid insoluble value better will be the drug quality. (1.075%) 
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Ø Water extractive and ethanol extractive values give the percentage of soluble matters 
present in the drug. Suitable solvent could be selected based on the extractive value. 
Also it gives the percentage of drug which will interrelate with the metabolism 
reactions. 
Ø pH value indicates the nature of the drug whether it is alkaline or acidic. pH value 0 to 
less than 7 shows the drug is acidic in nature. 
 
TLC Estimation of Aivaeli samoola chooranam 
 
After spray with visualizing agent 
 
 
 
 
 
 
 
 
 
 
 
Sl.No 
After Dipping in Vanillin-Sulphuric acid 
Rf value Colour of the spot 
1 0.19 Bluish grey 
2 0.27 Bluish grey 
3 0.53 Violet 
4 0.66 Violet 
5 0.73 Greenish yellow 
6 0.81 Greyish blue 
7 0.97 Violet 
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Thin Layer Chromotography is used for precise identification and adulterant of 
the plant drug. Identification was effected by study of spots of identical Rf value and 
about equal magnitude obtained, respectively, with an unknown and a reference sample 
chromatographed on the same plate. The visual similarity of the size and intensity of the 
spots supported in semi-quantitative estimation of plant. 
Standardization of drugs aids in confirmation of identity and determination of 
quality, effectiveness of Diplocyclos palmatus. 
 
PHYTO CHEMICAL EVALUATION OF AIVAELI SAMOOLA CHOORANAM 
The qualitative analysis on phyto chemical substance on Aivaeli  Shows 
presence of Alkaloids, Flavonoids, Triterpenes,, Steroids, Saponins, and Proteins. 
1. Alkaloids + ve 
2. Triterpenes + ve 
3. Flavonoids  + ve 
4. Saponin   + ve 
5. Steroids + ve 
6. Protein + ve 
7. Anthraquinones - ve 
8. Acid  - ve 
9. Coumarin - ve 
 
INTERPRETATION 
Saponin have Fungitoxic activity (David R.Gang 2011) and terpenes have anti-
inflammatory activity (Iris F.Benzieet al -2011). These two phytochemical activity is 
essential for a drug to manage Eczema. As these are present in the Aiveli samoola 
chooranam, its indication to karappan is justified phytochemically. 
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PRELIMINARY CHEMICAL ANALYSIS OF AIVAELI SAMOOLA 
CHOORANAM 
 
S.NO TEST FOR CHEMICALS RESULT 
1. Reducing sugar Absent 
2. Starch Absent 
3. Protein Absent 
4. Amino acid Present 
5. Albumin Absent 
6. Phosphate Present 
7. Sulphate Present 
8. Chloride Present 
9. Iron Present 
10. Calcium Present 
11. Sodium Absent 
12. Potassium Absent 
13. Zinc Present 
14. Magnesium Present 
15. Alkaloids Present 
16. Tannic acid Present 
 
INTERPRETATION 
From the preliminary chemical analysis ,we came to know  that the trial drug have 
Amino acid, Phosphate, Sulphate, Chloride, Iron, Calcium, Zinc, Magnesium, Alkaloids, 
Tannic acid.  
Zinc has potent wound healing activity (Sathyanarayana). Zinc in Aiveli samoola 
chooranam might be the reason for its action in healing ulcers seen in Eczema. 
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Elemental Analysis of Drug: 
Fourier Transforms Infrared Spectroscopy (FT-IR): 
 
 
 
FT-IR is the acronym for Fourier Transform Infrared Spectroscopy. FT-IR is a 
spectroscopic technique that utilizes lower energy radiation to induce vibration and 
rational excitation of atoms and groups of atoms within molecules. Because of the variety 
of symmetry of atomic groups and their differences in atomic masses and electronic 
structure the absorption patterns for a specific species will be unique, which allows for 
their identification. Infrared spectroscopic technique used to identify the functional 
groups in organic and inorganic compounds. 
 
Principle 
IR interacts with the sample and the bonds between atoms in the molecule stretch 
and bend, absorbing infrared energy and creating the infrared spectrum. It is of two types 
bending and stretching. 
FT-IR is a very useful tool in the detection of the functional groups of bio molecules, thus 
aiding in their structural elucidation, thereby confirming the presence of active molecules 
responsible for the therapeutic activity of Siddha drugs. 
Aivaeli samoola chooranam have following functional groups. 
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PEAK VALUES FUNCTIONAL GROUPS 
3394.1 Phenols and Alcohols 
2921.6 Alkanes 
2368.2 Amine 
2344.9 Amine 
1637.0 Alkens 
1420.1 Aromatic groups 
1075.5 Esters 
620.4 Alkynes 
 
Scanning Electron Microscope (SEM): 
 
 
 
Electron Microscopes are scientific instruments that use a beam of highly 
energetic electrons to examine objects on a very fine scale. This examination can yield 
information about the topography (surface features of an object) morphology (shape and 
size of the particles making up the objects) composition (the elements and compounds 
that the object is composed of the relative amounts of them) and crystallographic 
information (how the atoms are arranged in the object). 
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TOXICOLOGICAL EVALUATION OF AIVAELI SAMOOLA CHOORANAM 
 
Acute toxicity study 
Swiss albino mice were treated with foxed doses of Aivaeli Samoola Chooranam 
2000 and 5000mg/kg in 2% CMC as suspension (p.o) respectively. The mortality rate 
with a 24 h period was determined according to the OECD 425 method. Acute toxicity for 
Aivaeli samoola chooranam had been studied in mice and their behavioral changes are 
normal. Hence Aivaeli samoola chooranam is a safe herbal drug. 
According to the results of acute toxicity test, the doses of 250 and 500 mg/kg were 
chosen for further experiments. 
Table 7: Dose finding experiment and behavioral Signs of Toxicity of ASC 
N
o 
Dose 
mg/k
g 
1 2 3 4 5 6 7 8 9 
1
0 
1
1 
1
2 
1
3 
1
4 
1
5 
1
6 
1
7 
1
8 
1
9 
2
0 
1. 500 + - - + - + - - - - - - - - - - - - - - 
2 1000 + - - + - + - - - - - - - - - - - - - - 
3 2000 + - - + - + - - - - - - - - - - - - - - 
4 5000 + - - + - + - - - - - - - - - - - - - - 
1. Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch Response 7. Decreased Motor 
Activity      8. Tremors 9. Convulsions 10. Muscle Spasm 11. Catatonia 12. Muscle relaxant 13. Hypnosis 14. Analgesia 
15.Lacrimation 16. Exophthalmos 17. Diarrhoea 18. Writhing 19. Respiration 20. Mortality. 
 
ANTI HISTAMINIC ACTIVITY OF AIVAELI AMOOLA CHOORANAM 
 
 In the present investigation, histamine produced dose dependent contraction as 
indicated in the kymograph. Aivaeli Samoola chooranam produced antagonistic effect on 
histamine induced contraction. Significance was observed at dose of 20, 40, 80μg/ml for 
histamine. The modified physiological salt solution containing Aivaeli Samoola 
chooranam (1000μg/ml) significantly inhibited (p<0.01) the contractile effect of 
histamine. Histamine is one of the important mediators of allergy, inflammation and 
bronchoconstriction. Targeting histamine, either prevention of its release from mast cells 
or use of histaminergic receptor antagonists becomes part of antihistaminic therapy in 
eczema. Histamine is an autocoid having profound physiological effect in the body.  
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Table-7: Effect of Aivaeli Samoola Chooranam on isolated Guinea pig ileum 
preparation  
Values are expressed in mean ± SEM, *p< 0.05 compared with histamine induced 
contraction (42mm as 100%); n=3. 
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Antihistaminic Effect of Aivaeli Samoola 
Chooranam 
Hist alone Hist+ASC
S. No 
Dose of Histamine 
(μg/ml) 
Maximum response in cms 
Histamine alone 
Histamine+Aivaeli 
Samoola Chooranam 
(1mg/ml) 
1. 20 μg/ml 3.2±0.14 1.40±0.15** 
2. 40 μg/ml 3.5±0.12 1.82±0.12** 
3. 80 μg/ml 4.2±0.10 1.90±0.14** 
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Fig No-5.A-Anti -histamine activity of ASC 
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ACUTE ANTIINFLAMMATORY ACTIVITY OF AIVAELI SAMOOLA 
CHOORANAM USING FORMALIN INDUCED METHOD IN RATS 
 
Pain and inflammation are associated with the pathophysiology of various clinical 
conditions such as inflammation, arthritis, cancer and vascular diseases. Inflammatory 
reactions are not only the response of living tissues to injury and infection, but also are 
relevant to disease developments, such as asthma, multiple sclerosis, colitis, inflammatory 
bowel disease and atherosclerosis. Many natural products are used in traditional medical 
systems to relieve the symptoms from pain and inflammation. Formalin has been widely 
used as a noxious agent able to induce experimental inflammation for the screening of 
compounds possessing anti-inflammatory activity. This phlogistic agent, when injected 
locally into the rat paw, produced a serve inflammatory reaction, which was discernible 
within 30 min. The development of edema induced by formalin corresponds to the events 
in the acute phase of inflammation, mediated by histamine, bradykinin and prostaglandins 
produced under an effect of cyclooxygensase. 
 
 Oral administration of Aivaeli Samoola Chooranam significantly inhibited 
(p<0.01) the Formalin induced paw oedema in rats at both doses (250 and 500 mg/kg). At 
250 mg/kg dose, 50% inhibition and at 500 mg/kg dose, 63.15% inhibition was observed. 
The group treated with Aspirin showed maximum inhibition of oedema, which was 
69.23%. Inflammation is a complex process and various mediators e.g. prostaglandins, 
leukotrienes and kinins, platelet activating factor, etc. have been reported to be involved 
in the development if inflammatory diseases. Formalin assay is well studied for 
comparative bioassay of anti-inflammatroy agents, since the relative potency estimates 
obtained from most drugs tend to reflect clinical experience. Prostaglandins play a major 
role in the development of the second phase of inflammatory reaction which is measured 
around 3h of time.  
 
 The presence of prostaglandin in the inflammatory exudates form the injected foot 
has been well demonstrated. It is well known the that inhibition of formalin– induced paw 
oedema in rats is one of the most suitable test procedure to screen anti-arthritic and anti-
inflammatory agent as it closely resembles human arthritis. Injection of formalin 
subcutaneously into hind paw of rats produces localised inflammation. The nociceptive 
effect of formalin is biphasic, an early neurogenic component followed by a later tissue 
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mediated response. The formalin induced paw oedema model in rats is known to be 
sensitive to cyclooxygenase inhibitors and has been used to evaluate the effect of non-
steroidal anti-inflammatory agents which primarily inhibit cyclooxygenase involved in 
prostaglandin synthesis.  
 
 Based on these reports, it is inferred that the inhibitory effect of Aivaeli Samoola 
Chooranamon formalin- induced inflammation in rats in the present study may be due to 
inhibition of the enzyme cyclooxygenase, leading to inhibition of prostaglandin synthesis. 
The Aivaeli Samoola Chooranam exhibited significant dose dependent anti-inflammatory 
activity in the acute model of inflammation involving the induction of oedema in rat hind 
paw, comparable to the reference drug aspirin.  
 
Table No-8 Anti-inflammatory effect of Aivaeli Samoola Chooranam in Formalin–
induced paw edema 
Group Dose 
(mg/kg) 
Increase of Paw volume in ml and % Inhibition 
30min 60min 120min 
Control ---- 0.38±0.08 0.65±0.07 0.80±0.09 
Aspirin 100 0.13±0.04** 
(65.78%) 
0.20±0.04** 
(69.23%) 
0.26±0.05** 
(67.50%) 
ASC 250 0.19±0.04** 
(50%) 
0.47±0.06* 
(27.69%) 
0.42±0.04** 
(47.50%) 
ASC 500 0.14±0.03** 
(63.15%) 
0.28±0.04** 
(56.92%) 
0.35±0.04** 
(56.25%) 
 
n = 6 animals in each group *p<0.05 **p<0.01 
 
 From this study, it can be concluded that the Aivaeli Samoola Chooranam possess 
anti-inflammatory activity. The findings justify its use in traditional medicine to treat 
inflammatory and painful conditions. 
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ANTI MICROBIAL ACTIVITY OF AIVAELI SAMOOLA CHOORANAM 
 
 
 
Fig.No.5.B  Anti-microbial activity of ASC 
 
The antibacterial and antifungal activity of Aivaeli Samoola Chooranam was 
tested. The maximum inhibition zone was observed for the E.coli, S. typhi and Candida 
albicans 7-9mm at the concentration range of 25-100µg/ml.  
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CLINICAL ASSESMENT 
CLINICAL ASSESMENT OF AIVAELI SAMOOLA CHOORANAM: 
50 patients from both sexes of various age groups were selected for clinical trial. 
Among 50 patients 40 patients were treated as out-patients, 10 patients were treated as in-
patients. The selection was based on the inclusion and exclusion criteria.  They were 
clinically diagnosed on the basis of siddha principles with modern laboratory findings. 
 
Table No-9 Gradation result 
SL. NO 
LEVEL OF 
IMPROVEMENT 
NO.OF 
PATIENTS 
PERCENTAGE (%) 
1. Marked Response 37 74 
2. Moderate Response 7 14 
3. Mild Response 4 8 
4. Poor Response 2 4 
TOTAL 50 100 
 
 
Inference: 
Among 50patients, 
Ø 37 patients had marked response. 
Ø 7 patients had moderate response. 
Ø 4 patients had mild response. 
Ø 2 patients had poor response. 
MARKED 
RESPONSE
74%
MODERATE 
RESPONSE
14%
MILD RESPONSE
8%
POOR 
RESPONSE
4%
PERCENTAGE
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Table No. 10  (Improvement in signs and symptoms) 
SL.NO 
SIGNS AND 
SYMPTOMS 
No of Patients  
BT AT IMP IMP % 
1. Itching 50 9 41 82 
2. Erythema 42 7 35 83 
3. Oedema 26 5 21 80 
4. Vesicles 36 9 27 75 
5. Pustules 36 9 27 75 
6. Oozing 20 4 16 80 
7. Scaling 28 6 22 78 
8. Lichenification 44 16 28 63 
9. Ulcer 10 2 8 80 
      10. Pain & burning 
sensation 
10 2 8 80 
 
 
Inference 
Ø 41 out of 50 patients were relieved from Itching 
Ø 35 out of 42 patients were relieved from Erythema 
Ø 21 out of 26 patients were relieved from Oedema 
Ø 27 out of 36 patients were relieved from Vesicles 
Ø 27 out of 36 patients were relieved from Pustules 
Ø 16 out of 20 patients were relieved from Oozing 
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Fig.No.5.C- Comparison of before and after treatment with ASC in Karappan 
patient   
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STATISTICAL ANALYSIS 
 
DESCRIPTIVE STATISTICAL FOR IMPROVEMENT IN SIGN & SYMPTOMS 
IN KARAPPAN (ECZEMA) PATIENTS 
 
PAIRED “t” TEST RESULT: 
 
EASI (ECZEMA AREA SEVERITY INDEX) SCORE 
 
P value and statistical significance: 
The two-tailed P value is less than 0.0001 
By conventional criteria, this difference is considered to be extremely statistically 
significant. 
 
Confidence interval: 
The mean of Before treatment minus After treatment equals 6.200 
95% confidence interval of this difference: From 5.160 to 7.240 
 
Intermediate values used in calculations: 
  t = 11.9769 
  df = 49 
  standard error of difference = 0.518  
 
 
 
 
 
 
 
 
 
 
 
 
 
Group Before 
treatment 
After 
treatment 
Mean 7.762 1.562 
SD 4.326 0.985 
SEM 0.612 0.139 
N 50 50 
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                                                 6. CONCLUSION 
 
The plant Diplocyclos palmatus (Aivaeli) is selected from the Siddha text  
'Pathaartha guna vilakkam’ for the evaluation of  its therapeutic efficacy on 
Karappan(Eczema). The plant of Diplocyclos palmatus (Aivaeli) authenticated by 
experts was subjected to step wise procedure of analysis like pharmacognostic study, 
physicochemical, phytochemical, chemical analysis to account the creditability of 
drug. 
From the preliminary chemical analysis ,we came to know  that the trial drug 
have Amino acid, Phosphate, Sulphate, Chloride, Iron, Calcium, Zinc, Alkaloids, 
Tannic acid. Zinc has potent wound healing activity. Zinc in Aiveli samoola 
chooranam might be the reason for its action in healing ulcers seen in Eczema. 
Toxicological studies comprised of the evaluation of non-toxic dosage, acute 
toxicity on Swiss albino mice according to OECD guidelines.  
Pharmacological study revealed the Anti-histamine, Anti-inflammatory, 
Anti-microbial activity of Aivaeli Samoola Chooranam. 
The biologically active Aivaeli Samoola chooranam inhibiting the histhamine 
induced contraction on isolated guinea pig ileum preparation. Thus, the Aivaeli 
Samoola chooranam confirms the antihistaminic effect in presence of agonist like 
histamine which justify the H1 antagonistic traditional claim of Aivaeli Samoola 
chooranam in siddha system of medicine. 
The antimicrobial activity of Aivaeli Samoola Chooranam was tested. The 
maximum inhibition zone was observed for the E.coli, S. typhi and Candida albicans 
7-9mm at the concentration range of 25-100µg/ml.  
The drug has shown significant improvement in Eczema patients. Overall 
result revealed that out of 50 patient 37 patient had marked response, 7 patient had 
moderate response, 4 patient had mild response and 2 patient had poor response. 
There were no new or unexpected safety events noticed during the course of the 
treatment. 
From the above listed studies of Aiveli samoola chooranam, it can be concluded that 
the drug is safe and  excellent medicine for management of Karappan. 
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7. SUMMARY 
The plant Diplocyclos palmatus (Aivaeli) is selected from the Siddha text  
'Pathaartha guna vilakkam’ for the evaluation of  its therapeutic efficacy on 
Karappan(Eczema). The dissertation has started with an introduction in which Siddha 
fundamental theory behind selection of drugs for a disease, essentiality of  Phytotherapy,  
the  need for preclinical and clinical study on  Aiveli for Karappan is  signified.  
The plant of Diplocyclos palmatus (Aivaeli) had been collected from Anthiyur 
Hills, Erode district, Tamilnadu and authenticated by experts. 
  Drug review disclosed the collection of Botanical aspect, Siddha aspect and 
Modern scientific aspects about the trial drug. Disease review explored the collection of 
siddha and modern literature about Eczema. 
The drug was subjected to step wise procedure of analysis like pharmacognostic 
study, physicochemical, phytochemical, chemical analysis to account the creditability of 
drug.  
Toxicological studies comprised of the evaluation of non-toxic dosage, acute 
toxicity on Swiss albino mice according to OECD guidelines.  
Pharmacological study revealed the Anti-histamine, Anti-inflammatory,               
Anti-microbial activity of Aivaeli Samoola Chooranam. 
Open clinical trial was conducted in 50 patients at Arignar Anna  Government  
Hospital of Indian Medicine and Homeopathy, Chennai. The drug has shown significant 
improvement in Eczema patients. Overall result revealed that out of 50 patient 37 patient 
had marked response, 7 patient had moderate response, 4 patient had mild response and 2 
patient had poor response. There were no new or unexpected safety events noticed during 
the course of the treatment. 
The final Discussion and conclusion chapters analyzed the dissertation. The 
conclusion chapter also provides a nutshell impact created by the study on Aiveli and 
made Aivaeli samoola chooranam as a scientifically proven drug of choice for 
Karappan(Eczema) to the medical society. 
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1. INTRODUCTION 
Siddha system is the treasure dedicated to world by Siddhars for keeping the 
people at the state of physical, mental and social well being. Siddha strongly advocacies 
every physician to look into “what kind of person is affected by an ailment is most 
important than what kind of illness he has”. This perspective devises the protocol of every 
treatment in Siddha. This unique fundamental is the subtle strength and rationale behind 
the existence of this system since antiquity. The proper combination and harmony of the 
three humours- Vali, Azhal, Iyam in their qualities and right proportion are responsible for 
maintaining good health. When these three humours are disturbed by food, life style 
modification or any other disorders, they are provoked and disease manifest. 
Regularizing the deranged these three humours (Mukkutram), Strengthening them, 
balancing the distribution of them by food, life style and medicine is the treatment 
methodology followed in Siddha to handle a diseased patient. As per 
T.V.Sambasivampillai Dictionary, Marunthu (medicine) is a substance that helps to 
alleviate or eradicate the disease, gives strength to the body and normalises the function 
of the body. Making use of natural sources like plants, metal and minerals, animal 
products, medicines are prepared. Depending upon mode of application, these medicines 
are grouped under two categories: 
1. Agamarunthugal ( Internal medicines) - 32 
2. Puramarunthugal (External medicines) - 32 
In addition, Muppu, Rasavatham, Thiravagam, Seyaneer, Maranam, etc., are 
some special wings under Siddha pharmacology to prepare a medicine at its peak 
therapeutic efficient form. Siddha answers for many of challenging diseases of present 
world using these kinds of wide ranged medicine preparations. One such medicine is 
NAVACHARA CHUNNAM which is suggested for Soothagakattu, Soothagakatti, 
Magotharam, Neerambal And Pandu mentioned in Anuboga Vaithiya Navaneetham. 
Chunnam is a form of internal medicine, placed superior than Parpam and 
Chenduram, has 500 years shelf life. Chunnam are medicaments prepared by heat and 
calcinations following the procedure stipulated in the recipes. They possess alkaline 
properties similar to that of lime stone. Navacharam, one of Karasaram (Mineral) with 
more therapeutic effects, when made into Chunnam, can stand as potent medication for 
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Soothagakatti. It is a disorder mentioned in Siddha, which is closely related to polycystic 
ovarian syndrome (PCOS), one of the most common female endocrine disorder and an 
important cause of female infertility. 
The W.H.O defines reproductive health as “it is a condition in which the 
reproductive process is accomplished in a state of complete physical, mental and social 
well-being and is not merely the absence (or) disorders of the reproductive process”. 
Polycystic ovarian syndrome (PCOS), which affects female reproductive health, is a 
multisystem endocrinopathy with ovarian expression of metabolic disturbance and a wide 
spectrum of clinical features, such as hyperandrogenism and obesity along with metabolic 
disorders (Shaw et al, 2007). It occurs mostly in the age group between 20 and 30 
(Potemkin) The prevalence of PCOS is estimated at 5–10% of women in childbearing 
age. (Franks S, 1995). 
The syndrome was described by Stein and Leventhal in 1935, although Polycystic 
degeneration of the ovaries had been reported by Slavyansky in 1893, Lesnoi in 1928 and 
Gigoisky in 1930 (V.Potemkin,) The need to establish universally accepted diagnostic 
criteria led to the Rotterdam criteria for PCOS in 2003 (The Rotterdam ESHRE/ASRM- 
Human Reproduction, 2004) but no optimal treatment was defined for infertile women 
with PCOS even then. 
Several studies have recommended that insulin resistance plays a significant role 
in the pathogenesis of the syndrome. Insulin resistance is now recognized as a major risk 
factor for the development of type II diabetes mellitus (Reaven GM. 1988). As an effect 
of insulin-resistance, women affected by PCOS often present abnormalities of glucose 
metabolism and lipid profile, and have an increased risk of type II diabetes and 
cardiovascular disease over-time. Women with PCOS are at increased risk of endometrial 
cancer. (K Bhasker rao et al, 1996) 
The drug of choice available for management of this female endocrine disorder, in 
present medical world, is very less. Clomiphene citrate is the commonly prescribed drug 
to PCOS women for its ovulation inducing activity. The common adverse reaction of 
Clomiphene citrate is hot flushes. The important drawback is that it causes (i) Ovarian 
enlargement and cyst formation due to overstimulation, which may lead to rupture and 
internal hemorrhage. (ii) Multiple ovulation, resulting in multiple pregnancies and fetal 
wastage. Rarely it may cause restlessness, blurring of vision and alopecia. (R.S.Satoskar) 
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In this present scenario, the need of hour is to explore a drug with high therapeutic 
efficacy for treatment of PCOS with no or less side effects. Siddha answers this challenge 
with “Navachara Chunnam”. The author hopes that studying the effect of Navachara 
Chunnam on PCOS will discover a new drug of choice to add strength for the fight of 
medical world against PCOS, in turn female infertility. 
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2.AIM AND OBJECTIVES 
AIM 
To justify the ancient Siddha drug for remedial of Polycystic Ovarian Syndrome 
with its supreme formulation and provide good progress. The purpose of the present study 
was aimed at evaluating the activity of Navachara Chunnam for its naturally curing 
PCOS through pre clinical and clinical aspects. In present medical world there is a need 
for proper treatment for PCOS. The aim of this study is a new drug evaluation for 
treatment of PCOS.  
OBJECTIVES 
The key objectives of the study are: 
Ø To have a collective review of the literature. 
Ø To prepare the drug according to Siddha classical text. 
Ø To subject the drug to physico-chemical standardization. 
Ø To analyze the drug chemically for detection of acid and basic radicals. 
Ø To focus the drug for analytical assessment. 
Ø To study the toxicity profile of Navachara  Chunnam according to OECD 
guidelines. 
Ø To determine the pharmacological activity (Ovulogenic effect) of Navachara 
Chunnam. 
Ø To assess the therapeutic potential of the drug through clinical trial for the 
management of PCOS 
Ø To analyze all the above study results to evaluate the advantage of Navachara 
Chunnam. 
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3. REVIEW OF LITERATURE 
 
     3.1. LITERATURE REVIEW OF DRUG 
 
v நவ சார  
 
Ø நவ சார  காரசார வ  க திைன  சா  த .  
 உ க தா    வைக இ ப ைத    
எ   ேபாக    வதிலி    காரசார  இ ப ைத   எ   அறியலா . 
 
“ெபா   கி ற நவ சார  ச தி  சார  
............................................................................ 
..............................................த  ய  க ப  
க  ெதாைகய  லிைவய ப  ைத    வாத 
காரசா ர  ைறயா   க ட வாேற”   
                                                                                (ேபாக  காரசார  ைற) 
Ø நவ சார  அ  வ   றா  .  
“ ............ஆண  பா  நவ சார  ச தி  சார  
அ  ெவ   ெசா வா க ளறி   ெகா ேள” 
                                                                                                        (ேபாக  கார  ைற)                         . 
Ø ெசயந    ஆதி ெபா    நவ சார  ஆ  . 
 
v நவ சார  ெபய க  
ஆ ேம நவ சார  ேபைர ேக  
அ  கா   நவசி தி சாரமாேனா  
வா ேம சல   ைம வா  தி    க ப  
வழ கிேனா  ஒ பதிட வ  யாேனா  
ேவ  மா   தர  ேமகநாத  
ெம யான வாத    ெகா பா  நினேறா  
ேபா ேம வாதெம ற வா தி    நாத  
ேபரான ெசயந    நாதனாேம 
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ஆெம ற வாத தி   சிேராமண யா  நி ேறா  
அ ரனா  சகல  அ  கின த  ேயா  
ேவெம ற      ேம   வாேனா  
வ ப ட நவசா  க  சா  யாேனா  
ேபாெம ற வாத ைத சைம  கி ேறா  
ேபரான ெக ைக கட ண  ேளானா  
நாெம ற ச திய ட றா  நி ேறா  
நவ சார  ேபெர லா  நா  ேனேன.  
                                                                                 (ேபாக  நிக  -1200) 
 
ேவ  ெபய க  
· இ  ைக 
· ச லிைக 
·  ள ைக 
· ப  
- (டா ட  இரா.தியாகராஜ ,L.I.M ;2004) 
 
v நவ சார தி  நிற , ைவ ம    மண  
§ நிற -அ     ப  த நிறமாக   அ ல  கப ல நிறமாக   இ     
§  ைவ- ள    ைவ ட  கச பாக இ     
§ மண -  திர ெவ  ட ைடயதாக   இ     
§ நவ சார -ஆ  சர  . இத   ெப சர   ெவ கார .  
                                                                           -(சி.க  சாமி  ப ைள,2011) 
 
v நவ சார -  தி ைறக  
v நவ சார ைத ெவ ந   கைர  ,  டாய    ேபா  வ க  ,  ள ர 
ஆறியப  வா  அக ற பா திர தி  வ   ெவ ய லி  ைவ க உ   
உைற  .  றிமண  ேவைர இ  ட  இ      ய  ைவ க 
ெவ  ட  ேபா  . 
v ேகா  திர தி  கைர  , வ க      ட எ    ெவ ய லி  உல  தி 
எ  க   தி ஆ  .    -(டா ட  இரா.தியாகராஜ ,L.I.M ;2004). 
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ெச ைக 
· உட  ேத றி ( ைற த அளவ  நா பட  ெகா  தா ) 
· ெவ ப  டா கி (அதிகளவ  ெகா  க) 
· ேகாைழயக றி 
· வ ய ைவெப  கி 
· வ ரண  டா கி 
· ப தமக றி 
·   கியமாக நிண நர  க , மாமிச  கிர திக  ம  த  ேவக ைத  
ெச    . 
 
சார தி    ச    
க    , இ    , ப கார , வைளய   , இ   , கா த , 
வ க ,அ ட ேதா ,  கா க , சிைல, அ ப ரக , ச     , கிள ச . 
 
சார தி   மி    
 ர , மேனாசீைல, கப , நிமிைள, ப ைண,ெகௗ , இலி க .                                   
(சி.க  சாமி  ப ைள, 2011) 
 
ெபா  ண  
       “  ம  ட  ைல ெகா    மேகாதர ைத 
         வ ைம    க லைட ைப மா   கா -ச ம  
         கவ  ச   ேதாட க கனவாத ந    
         நவ சார மாேத நவ . 
 
ெபா  : 
வய  வலி, டலி    த ,ெப வய ,க லைட  , ச ம தி  
 லா  நா ற ,தி ேதாட ,கனவா  ேபா   .ேம  ,உ ப ச , க ல ர  
வ  க ,ப ல க ேநா , க ச தி,இர த காச ,  யாவ  த வாத , தக க  , 
க கி ம ,வ டா  கா  ச ,இைவக    உபேயாகி கலா .(டா ட  
இரா.தியாகராஜ ,L.I.M ;2004). 
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அள  
21/2   றி(325மி.கிரா )  த  71/2   றி (975 மி.கிரா ) 
வைரயா  .அதிக அளவ  ெகா  க ேபதியா  .(டா ட  இரா.தியாகராஜ ,L.I.M 
;2004). 
                    உபேயாக  
க  பவா ,க  ைபய வலி,க  ைபய வ  க , தகக  ,ப தவா தி, 
வா தி   ப  கா   தைலேநா , தைல   த  இைவக    
நவ சார ைத  க   ர கல த ந   தின  இர        ைற ெகா  க 
ந ல  ண  டா  .(டா ட  இரா.தியாகராஜ ,L.I.M ;2004). 
 
VERNACULAR NAMES OF NAVACHARAM 
 
Tamil                  – Nava-charam;Nava-charum 
Sanskrit – Navasara, Navasagara, Chulika lavana.  
English – Sal Ammoniac.  
Arabic – Armina,  Milhunnar.  
Punjabi – Noshadar.  
Kashmiri – Nausadan.  
Hindi – Navasadara, Nousadar.  
Bengali – Navasagara, Nishadal, Duk.  
Gujarati, Mah. & Kon. – Navsagar.  
Malayalam. & Telugu  –   Navasaram 
Burm. – Lovas; Zarasa 
 
As obtained in the bazaars is generally very impure in dirty white or 
brownish translucent cakes, “as it is manufactured from a kind of clay found at 
Karnal in the Punjab” – (Chopra). It is obtained by the combustion of excretions of 
various animals or of animal matters or by burning coals or common salt. It is a 
secondary product in the manufacture of coal gas. It is generally obtained in India 
from unburnt extremities of brick-kilns in which manure of animals, especially 
camel’s dung is used as fuel. To this, coal and common salt are added and sublimed. 
It is thus obtained in white granular crystals or transparent masses. 
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It is readily soluble in water and is highly deliquescent. It has a saline, 
disagreeable, nauseous and pungent taste. It can be purified and made into a powder 
by dissolving in hot water and evaporating to dryness and then bottling. 
 
ACTION  
Alterative,  expectorant and cholagogue in small doses. 
In large doses purgative. It has a marked stimulating action on the mucous 
membranes, increasing their secretion also on the absorbent system and on gland 
structures.  
 
MEDICINAL USES 
It relieves hepatic congestion and modifies hepatic secretions; useful is cases 
of hepatic abscess, chronic hepatic congestion and in dropsy connected with the liver 
and ovarian diseases; in cirrhosis and in jaundice from catarrh of the bile ducts.  
For hepatitis, sal-ammoniac 8 to 15 grains, mixed with 105 grains of 
Absinthium (worm wood)  rubbed well in a mortar with a little water and given in a 
single dose will give relief (Hakim & Vaidyan). 
In gastric catarrh in biliousness with coated tongue, foetid breath, flatulence 
etc., in bronchial and vesical catarrh, in chronic pharyngitis with glairy mucous 
secretions and whooping cough it is valuable, combined with liquid extract of 
glycyrrhiza syrup of Country liquorice and with a few grains of powdered cinnamon, 
in cases of whooping cough.  
In amenorrhoea, dysmenorrhoea,  gleet, leucorrhoea, chronic dysentery and 
other similar chronic discharges from lungs, stomach and other internal organs it is 
given dissolved in conjee water (2 drachms to a pint) in wineglassful doses every 
second or third hour. “In hysteria, nervousness, jaundice and other live complaints 
and gastric catarrh, doses of 10-20 grains three times daily are beneficial. It is often 
prescribed as a stimulating expectorant in chronic bronchitis and in pneumonia in the 
stage of resolution- (Chopra).  
 
In various forms of neuralgia, in chronic liver diseases, organic or functional, 
in rheumatic affections of the face etc., it is given in infusion of Indian Sarsaparilla; in 
intermittent fever, in sick or nervous headaches, acute alcoholism   and in delirium 
tremens its action is very marked, given dissolved in camphor julep. In dropsy due to 
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liver disease and in that following fevers, it is administered with infusion of Moringa 
or decoction of Astercantha. 
 
  As an alterative it acts slowly modifying the nutrition of the tissues; it is a useful 
agent in chronic inflammatory diseases of the glands such as thyroid body, liver and 
spleen and in induration of the uterus, ovaries and the prostate and externally for 
fomentation in the form of a lotion (1 in 80). In urinary diseases chiefly where the 
urine is full of lithates it is very useful.  
 
Externally its solution combined with nitre is a nice cooling and stimulant 
application to the head in headache, “sprains, rheumatism, lumbago, sciatica” 
(Chopra), mania and apoplexy, and for inflamed erysipelas and hernia tumours; in 
inflamed hydrocele, indolent tumours, in enlarged glands, in (mammary) milk 
abscesses occurring after confinement and abscesses in other parts of the body before 
formation of matter, in chronic skin diseases and as a dressing for bruises and blows 
on the eye (black eye). For milk abscesses etc., it is used as lotion. 
 
With Arrack and rose-water (1 in 8 and 160 parts respectively). Mixed with 
sulphide of arsenic, it is used as an application to scorpion bites. As an inhalation in 
affections of the air passages its vapours produced by heating a drachm of it on a dish, 
are useful. Ammonium Chloride is recommended for local application in case of 
cataract.(Dr.K.M. Nadkarni) 
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ேச   ம   க  
 
v ேபாஜன ச சீவ  ேலகிய  
தி ப லிகா சாமிள  சீ ெவ   ேபாம  
ெச ப  ெதா ய    ேச  க -  ேபா  
ேசா     ெவ கார  ெசா நவா  சார ட  
ஏ ற ச  கார ெம . 
 
எ    ெப  காய  ஏ க கி ரா ேபா  
உ   ேகா ட    ய ேமா -ந ண ப 
ைநய  ெபா    ந       ேதா     
உ யபல ேமாைர தா ேவா  
 
ஓத  பன க   ஓ க ந  ேத   
வ  த  பலைம   வ டைர   -ேசதமிலா  
  ைட கா  ேபாலள  ெசா ல வ ேநர  
ெகா ட பய றாேன  . 
 
    மடவா   ேகா  வ  ர தி  
சீ   வாலிேயா  ேச வா   – வ    
வலி  ம  ப த மதிக  த வா வா  
நலிேயா  ெம றதைன நா . 
வ ள க  
ேச   சர  க  
தி ப லி,க சா,மிள ,ெவ    ,ஓம ,வைளய   ,இ    ,க    ,ேசா   
 ,ெவ கார ,நவ சார , உழம , ெப  காய ,கிரா  , ேகா ட ,   , ேமா   
வைக   1 பல , உ  த    பல -5, ேத  பல -5 
இைவகைள  க வ திலி   ேலகிய பதமாக அைர   ைவ    ெகா   
ேவைள   சி    ைட கா  ப ரமாண  தின  இ ேவைள உ ெகா ள 
 தி க    மாத வ ல க தி  வ    தகவா வ  வலி,   மவய  வலி, 
ப தவா  , ம த , அஜ  ரண  த   . 
                                                                                         (சி.க  சாமி  ப ைள;2009) 
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v ப சலவண  திராவக  
பாரா   ெவ      ெக  பா ெயா   
     பா  கேவ சீலமைர  கார  காலா  
ேநரா   சாரமதி  கைர கா ேலா  
     நிக   கறி  ப ேவ வ  சமா   
சீரா   திராவகேம ய ன  வா கி  
     ேச  கேவ சல திெல  ள யா  கா   
 ரா    தகேனா  வா    ம  
     ெதா தி த மா  ேநா  ெதாைல   தாேன. 
ெபா    
ெவ    -1 ேச  
ப கார -1/2 ேச  
ெவ கார -1/4 ேச  
நவ சார -1/8 ேச  
கறி    வ  ச  ேச  அளவாக  க  ரலி  ேபா   கட பாைறயா  
 ளாக இ   , ம கட தி  இ   ம  வாைலைய  ெச கி சீைல 
ெச  ,கா  தப  திராவக  வா க  . 
அள ; 7 ள  ள   தசல தி  கல   இ ேவைள 
த    ேநா க  - தி க    டா    தகவலி, வா  ,  ம , மா  ேநா  
ந   .(சி.க  சாமி  ப ைள;2009) 
v சார ெம   
ேச   சர  க  
சார     பல  3 
ெகா   க ள மர பா  பல  1 
  தி ெச த வாள   பல  1 
சி றாமண   பா   பல  3 
ெச பாக ;  
 தலி  சார ைத  க வ தி  இ   ெகா   க ள மர பா  வ   
அைர   அத ப  வாள   சி றாமண    ப        ந   அைர   
ெம  பத தி  வழி   வாயக ற    ய  ப திர ப  த  . 
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ப ரேயாக ; 
 ேதக திட தி   ஏ றவா 1-2 மிள   ப ரமாண  பைனெவ ல தி  
ைவ    காைல ேநர தி  ெகா  க 7-8 தடைவ ேபதியா  .இ த ெம கா  ேபதி 
அதிகமாய  ம நா  அளைவ  ைற   ெகா க.ேபதி ச வர ஆகாவ   சிறி  
அளைவ அதிகப  தி  ெகா க. 
 
த    வ யாதி; வாத ந ைர ெவள ப  தி கா  வ  க , அ ட வாத , 
வய றி  ள க  , பா  , மேகாதர , தக வா  ந   . 
(சி.க  சாமி  ப ைள;2012) 
 
கலி காதி ெய ெண  
 
  மவைக த  த    கலி காதி  ெந  
     ணமாக  ெசா  கிேற   ல தியேன ேகளா  
க ம ெம ற  ம    கா  சா ற பா 
     க வாக  ப ய ர  டாவ  ன  தா  
த மெம ற ப ய ர   ெவ ளா   ந தா  
      த பாம  ப ெயா       ேச     
ப மென ற வாமண கி ென   ம பா  
      பகராேத ப ய ர   ட வாேர. 
 
வா  த பா  க  கா   க   ேராண  
      வளமான வா வ ள க  தி க   ேமல  
ஏ த பா வ      வைளய    
      இதமான க      ச       
கா த பா நவா சார ெமவா சார க கார  
      கல காேத ய பளா கார      
பா  த பா வா மிள  யாைன  தி ப லி   
      பா கான ெவ   ள  ப    மாேம. 
 
 
ஆம பா நிலவாைக க ட  க தி  
      அ பேன ெவ ைள சா ரைணய  ல  
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நாம பா ச தி சா ரைணய  ல  
       நலமாக வைர பலமா யைர    ெகா   
தாம பா ெநா சி சா  ப ம ச  சா   
       தளமான வ சி சா  ம   சா  
ேவம பா ப யைரயா   ட வ   
       வ தான கைட சர    கழ    ேற. 
 
  ற பா லைர த தெந  தன  கைர    
  திராம ல   ேப றி ெம  பத மானா  
ஏ ற பா கலசமதி  வ    ைவ ேத 
 எ னெசா ேவ  னைர கா ேச  வ  த மாக  
கா ற பா ெகா  வர  ப   நா தா  
 கவ ைசெயா  ப லிைக   கைர   ேபா   
ஆ ற பா ெப வய  வா   க   
 அ கா  மேகாதர க ள    ேபா ேம 
 
அ  ேபா  வா ெவ ற திர சி ெய லா  
 அ பேன ணமா  ெம   வா  
ந   ேபா  க  பவலி க  ப ைல 
 நாடாேத ய சி    ந வ  வ    
க   ேபா  ைககாலி  க    ைல 
 கட        வலி காண ேதா   
ப   ேபா  வய றி  ள வ யாதி ெய லா  
 பற  மடா வ னெமா   பகர  ேகேள. 
 
வ ள க ;  
ஆ     ம   கா  ப -2, ஆவ  ந  ப  -2, ெவ ளா   ந  ப -1, 
ஆமண ெக ெண  ப -2 இைவகைள ஒ       ஒ  ைதல 
பா ட திலி  ,அதி  க  கா , க   ேராகிண , வா வ ள க  ,   ,  மிள ,  
தி ப லி, ஏல , இ    , வைளய   , க    , ச     , நவ சார , எவா சார , 
அ பளாகார , வா மிள , ஆைனதி ப லி, ெவ ைள    , நிலவாைக, 
க ட க தி , ெவ ைள சாரைண, ச தி சாரைண கிழ  , வைக   பல  ½ வ  த  
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பா  வ டைர    ேச   , ெநா சி சா , ப ைசம ச  சா , இ சி சா , ேசா   
க றாைழ  சா , வைக    ப -1/2 ேச     கல  , 3 கழ   ெப  காய ைத   
அைர    கல   அ  ப ேல றி எ    வ ட  ெம   பதமா   பத தி  
வ    ெகா க.இதி  1/2 த  1 பல  வ  த  10-நா  ப திய  ட  அ  த கவ ைச, 
ப ல ைக, ெப வய , வா  க  , மேகாதர , வாத ப ண , க  ைபவலி, 
க  ைப ைல, க  ப கி மி,  ம க  , வய  ச ப தமான ப ண க  தலியன 
ந   . (அக திய ன வ  அ ள ெச த ைவ தியர தின    க ) 
 
v லவண  திராவக  
ஓத  பா ெவ   ப  சீன   
த  தி லா தி  ேச  தி  சார   
 தி லா கறி  ப ய ைவ பாதிேய 
ேவைத யா    திராவக  ேவ  ேம 
 
ேவ   திராவக  த ைன வ  ப ட  
பா    ம  பறி தி  ப ல ைக 
ஈ   ேராெம  ெற  ப  யைலகட  
தா   ெம   தவ ன  ெசா றேத 
 
ெபா  - ெவ     6 எைட 
ப கார  3 எைட 
சார  11/2 எைட 
கறி    11/2 எைட 
 
க  ரலி  ேபா   ந றா  இ   , ம கட தி  இ  ,வா     
ெபா  தமான வாைலைய  ெச கி ம சீைலெச  , கா  தப  திராவக  
வா க  .     அள -3-5  ள  வைரய  ஒ  வா  சல தி  வ ளாவ  தின  
இ ேவைள உ  வ   ஜ  ர க  ,  தக க  ,   ம , பா  ,  தலிய 
ேராக க  நிவ  தியா  . இ சாப திய . 
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ஊம ைத 
Botanical name - Datura innoxia 
 ைவ   - ைக   
த ைம  - ெவ ப  
ப     - கா    
 
ெச ைக 
வா தி  டா கி (Emetic) 
இசிவக றி (Antispasmodic) 
 யரட கி (Anodyne) 
   ைச  டா கி (Narcotic) ( ணபாட  லிைக வ   ) 
ெபா  ண  
நா  க யா  வ   நலிெச  வ ரண  ேபா  
வா   ழி    க  க  மா    கா -த   ண ைத  
ேசம தி  ைவ திலிட  த    ேதா ட கள   
ஊம ைத ய  ண ைத   . 
                                                            (அக திய  ணவாகட ) 
 ண  
இத  இைலைய உல  தி  ெபா  ெச   32 மி.கி அ ல  100 மி.கி அள  
உ     ெகா  க,இைர   ந   . சிைத த வ ைத 42 கிரா   , எ ெண  
325 மி.லி ேச    ஏ  நா  வைரய  அைர தைர   ெவய லி  ைவ  , 8-  நா  
வ   , அ வய றி  தடவ, தக வய  வலி, ந  தாைர எ   ந   . 
ேச   ம   க  
Ø ேதைரய   ைறப  இரசப ப  ெச ய க  ம ைத பய ப கிற . (டா ட  
இரா.தியாகராஜ ,L.I.M ;2004) 
Ø  ரா  ச  எ    மா திைர ெச ய பய ப கிற .(சி.க  சாமி  
ப ைள,2011) 
Ø ேகாேமதக ப ப  க  ம த  சா வ   அைர   ெச ய ப கிற . 
(சி.க  சாமி  ப ைள,2011) 
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ேசா   
Botanical name -  Pimpinella anisum 
 ைவ   - மண ட    ய கா    , இன    
த ைம  - ெவ ப  
ப     - கா    
 
ெச ைக 
அக  வா வக றி 
பசி த      
 ண - தகவா ைவ க     .( ணபாட  லிைக வ   ) 
 
  ண  
  ணம   (calcined compound) 
In Tamil medicine  several kinds of lime are used. They go by the name of the 
substance used to prepare the lime. They are lime from calcined Bivalve shells, snail 
shells, conch shell, crab shell, egg shell, pearl oxyster shell  etc(T.V. Sambasivam 
pillai) 
 
  ண தி  ஆ  கால  
                              “...................................... 
ெற ள டா   ண ஐ   க  ப ச   
................................ 
ஆ  கால  ஐ     ஆ  க  ஆ  .” 
                                                                                       (டா ட  இரா.தியாகராஜ ,L.I.M ;2004) 
 
  ண தி   ஆதி 
  “        ................................................... 
வா திடேவ வ  ரெமா      சீன  
   ம கேள ய ைவ      ண  தாதி” 
                                                                                                                   (காரசார  ைற) 
  ண  ெச ய பய ப   க வ க  
§ ம   ைச 
§ வ சிர  ைச 
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§ ஆ   ேதாலி  ெச ய ப ட ஒ ைற     தி 
§ ப ச  ண  ைக. (ேபாக  நிக  -1200) 
§   ணமா     லிைக 
§ ேவலிப  தி ( ணபாட   லிைக வ   )  
v   ண  ெச   கால க  
§ ப  ன  
§ சி திைர (டா ட  க. .உ தமராய )  
 
v   ண தி  த ைமக  
                “பா ந  னெம லா  
                     பற தி   கன மி ைல 
                ேகா ந ய ட..............” 
  ண  எ றா  மிக   ேலசாக   கா றி  பற க    யதாக   
இ    .(ெகா கணவ  3000) 
       ண தி  நிற  
§ தவள நிற -(ச ைட ன  நிக  ) 
§ ெவ ைம நிற (ெகா கண  வாதகாவ ய ) 
   ணவைககள  தர  
“ஊதிய  ண    த த றர  
மாதிய ந  ம   ெர டா தர  
மாதி  பரச ம    றா தர  
ேகாதிய ெசயந  ெகா நாலா  வ ைதேய” 
 த றர -                              ஊதி எ  கி ற  ண  
இர டா  தர -                   ந ட  ேச    ெச     ண  
  றா  தர -                       உபரச  ட  ேச    ெச     ண  
நாலா  தர -                           ெசயந ட  ெச     ண   (ச ட ன  நிக  ) 
 
v   ண  ெவ ைமயாக இ லாம  க ைமயாக இ  தா  அைத 
ெவ ைமயாக மா  வத  கான  ைற 
க       ண ைத ஒ  ேத கா  அள  எ    அத ட  க   ைப 
ஒ  பல  ேச  க ேவ   .ேச  த இர   சர  கைள   ந றா  அைர   
சிமி  ேபா  இர   ெச   ெகா .இ சிமிழி   க  ேபறிய   ண ைத 
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வ ைல த   ைவ   ம ெறா  சிமிழா     ைக    ைவ   ஊதினா  
  ன தி  க    நிற  அக   ப   ேபா  ெவ    . 
v   ண தி கான ேசாதைன 
 ....................................................... 
     ெபா  தேவ ம சளதி  ேபா   த   
  ஆடேவ ெர த ேபா  சிவ  ேபா   
      ..................................................................(யாேகா   ணகா ட ) 
   
3.2 SIDDHA ASPECT OF THE DISEASE 
நவ றிடேவ ய   வய  ெப     கா   
   நலமான ேமன ய  தி  கா   
 வ றிடேவ  ம    வய றி  ேதா    
   ணவதியா  ேதவதா ெப ணா னா   
நவ றிடேவ ச ம தி  மலேட யா   
   சதாகால  க  பம  த யா ெத   
 வ றிடேவ கி ன  சிகி சா சார  
    க றி டா  ேலாக   மா த  காேம. 
                                                     - கி ைவ திய சி தாமண - 
 
     
ெபா  - உடலி  ம ற பாக கைளவ ட இ     வய   ெப  தி  த , உட  
அைத    காண , உ திய     ம   க  கா த  ஆகிய  றி  ண கைள  
ெகா   எ  ேம க  த  காமலி     த ைம   நிர தர மல  எ   ெபய . 
                                                                                                                 
 தக ேநா  வ  வழி 
............................................................... 
      தரண ய  ெப க    ெக பேநா க  
நய கேவ வ   ெத னெவ றா  ைம தா 
      ந ைம ட   வா   நாள றாேன 
மய கேவ மா  பா ட  பா  பழ தினாேல 
      வ  தடா தக தி  வா  தாேன 
 
தாென ற க   ழிய  வா   த கி 
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      தள  த ெதா  ேசாைரய னா  தைசதா    
ஊென ற ேதகெம லா  மத    ந ல 
     உ ைம  ள அ வய றி  வலி  டா   
பாென ற க   ழிதா  வ ள க ம றி 
     பரமான வ   வ ேக அ காைதயா 
ஏென றா  ஆதிய ேல வா   ெகா    
     இ  ததினா  ெக பம  இ ைல தாேன 
 
ெபா  -தரண ய  க ப ேநா  வ வத   காரண  எ னெவ றா ,   வா   
நாள  மா  பா ட , பா . பழவ  க  உ பதினாேல  தகவா  
உ டா  .க   ழிய  வா  த கி,தைசயா    , அ வய றி  வலி 
உ டா   .க   ழிய  வ   ைவ அ க வ டா . 
                                                                                         -அக  திய  அ த கைல ஞான  
 
ெபா மிர த தைன மறி   ேபாதமிக   வலி  டா க 
  திேசரா வய வலிேபா  ெகா    க  ப தைன யழி    
வ   ய     ைட  ைள    மல ைதமிக   மி  கி 
ெப க  பைன    என ெப ேயா  ேப  க  பவா வ ேத 
 
ெபா  -வா வான  ெபா மி  தக  ச வர ெவள வரவ டாம  த    .மிக   
வலி  டா  .க  ப  உ டாகா .இள  க  ப ைத அழி  வ  .இ     ைட   
உைள  .மல ைத மிக   க  கி வரள  ெச   .இைவ க  பவா வ  
 ண களா  . 
                                                   -அக திய  ஆ  ேவத  1200 
     
 
சி தான க  ப தி  ேச  தி   இர த தா  
வ தா      வா ேபா  ஓ    
வ ற பசிேபா   உழ ேற இைர தி   
வ றாக கழி சலா  வ  தக வா ேவ. 
ெபா  ;க  ப   ழிய  வா  ட  இர த   ேச    உ    அ  மி    ஓட  
ெச   பசிைய அக றி கழி ச  டா  .இத   தக வா  எ   ெபய . 
                                                                                       -தி  ல  க  கிைட வய திய  600 
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ேக ேம தக தில கின  வா   
   ெக   வ   மாதவ டா  க  ேபா   
ஆ ேம க   ழி       ேதக  
     அ பேன திரம  அ  ல தி  
ந ேம தக தி  வா   ேதா றி 
    ேநரான அ வய  வலி    கா   
பா ேம தைலவலி    இ    ைள ச  
    ப  வமா  ம    ண  த   தாேன 
 
ெபா  - தக தி  வா    ப த     ற  அைட   மாதவ டா  க  யாகி 
க   ழி        ேபா  . தைலவலி, இ    வலி, அ வய  வலி 
ஏ ப  .ம    ண ணமா  . 
                                                                                            -ஆவ யள    அ த ைற    க - 
 
இைச தெதா  ெப மல  எ  மி ைல 
     ......னாேல மலடான ேசதிேக  
அைச தி     ேபயா   ப த தா   
     அ வய  ெநா  வ   வா வா   
ப ைச தக  ப    வா   கிரக தா   
     ப ண யா   ேமகைவ  யா   
 ச ெக ட  கலவ ய னா  ெவா  கி  
     ல காம  ப ைளய ைல ெசா ல ேகேள 
ெபா  -ப த தா  ,வா வா  , க  ப    வா  , கிரக தா  , ைவ  யா   
 ச ெக ட  கலவ ய னா   ெப க    ழ ைதய ைம உ டா  . 
                                                           -பதிென  சி த க  பா ய ைவ திய சி லைற  ேகாைவ- 
 
 தக க   –    ந  க   – T.V.Sambasivam pillai 
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3.3.MODERN ASPECT OF THE DISEASE 
 
PHYSIOLOGY OF FEMALE REPRODUCTIVE SYSTEM 
The ovary orchestrates the development and release of a mature oocyte and also 
elaborates hormones (e.g., estrogen, progesterone, inhibin) that are critical for pubertal 
development and preparation of the uterus for conception, implantation, and the early 
stages of pregnancy. To achieve these functions in repeated monthly cycles, the ovary 
undergoes some of the most dynamic changes of any organ in the body. 
Primordial germ cells can be identified by the third week of gestation and their 
migration to the genital ridge is complete by 6 weeks' gestation. Germ cells can only 
persist within the genital ridge and are then referred to as oogonia. Starting at ~8 weeks' 
gestation, oogonia begin to enter prophase of the first meiotic division and become 
primary oocytes. This allows the oocyte to be surrounded by a single layer of flattened 
granulosa cells to form a primordial follicle. 
The oocyte persists in prophase of the first meiotic division until just before 
ovulation, when meiosis resumes. The quiescent primordial follicles are recruited to 
further growth and differentiation through a highly regulated process that limits the size 
of the developing cohort to make sure that folliculogenesis can continue throughout the 
reproductive life span. 
This initial enrollment of primordial follicles to form primary follicles is 
characterized by growth of the oocyte and the transition from squamous to cuboidal 
granulosa cells. The theca interna cells that surround the developing follicle begin to form 
as the primary follicle grows. Acquisition of a zona pellucida by the oocyte and the being 
there of several layers of surrounding cuboidal granulosa cells mark the development of 
secondary follicles. It is at this stage that granulosa cells develop follicle-stimulating 
hormone (FSH), estradiol, and androgen receptors and communicate with one another 
through the development of gap  junction. 
 
Development of a Mature Follicle 
 The early stages of follicle growth are primarily driven by intraovarian 
factors, whereas maturation to the state required for ovulation, including the resumption 
of meiosis in the oocyte, requires the combined stimulus of FSH and luteinizing hormone 
(LH). Recruitment of secondary follicles from the resting follicle pool requires the direct 
action of FSH. Accumulation of follicular fluid between the layers of granulosa cells 
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creates an antrum that divides the granulosa cells into two functionally distinct groups: 
mural cells that line the follicle wall and cumulus cells that surround the oocyte . 
             A single dominant follicle emerges from the growing follicle pool within 
the first 5–7 days after the onset of menses, and the majority of follicles fall off their 
growth trajectory and become atretic. Autocrine actions of activin and bone morphogenic 
protein 6 (BMP-6), derived from the granulosa cells, and paracrine actions of GDF-9, 
BMP-15, and BMP-6, derived from the oocyte, are involved in granulosa cell 
proliferation and modulation of FSH responsiveness.  
               Differential exposure to these factors may explain why one follicle is 
selected for continued growth to the preovulatory stage. The dominant follicle can be 
distinguished by its size, evidence of granulosa cell proliferation, large number of FSH 
receptors, high aromatase activity, and elevated concentrations of estradiol and inhibin A 
in follicular fluid. 
 
                                  Fig 2.Development of ovarian follicles 
Regulation of Ovarian Function 
Hypothalamic and Pituitary Secretion 
              Gonadotropin-releasing hormone (GnRH) neurons develop from epithelial cells 
outside the central nervous system and migrate, initially alongside the olfactory neurons, 
to the medial basal hypothalamus. GnRH is secreted into the pituitary portal system in 
discrete pulses to stimulate synthesis and secretion of LH and FSH from pituitary 
gonadotropes. 
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              At the onset of puberty, pulsatile GnRH secretion induces pituitary gonadotropin 
production. In the early stages of puberty, LH and FSH secretion are apparent only during 
sleep, but as puberty develops, pulsatile gonadotropin secretion occurs throughout the day 
and night. 
 
Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) are increased 
during the neonatal years but go through a period of childhood quiescence before 
increasing again during puberty. Gonadotropin levels are cyclic during the reproductive 
years and increase dramatically with the loss of negative feedback that accompanies 
menopause. 
Ovarian steroid 
            Ovarian steroid–producing cells do not store hormones but produce them in 
response to LH and FSH during the normal menstrual cycle. The sequence of steps and 
the enzymes involved in the synthesis of steroid hormones are similar in the ovary, 
adrenal, and testes. However, the specific enzymes required to catalyze specific steps are 
compartmentalized and may not be abundant or even present in all cell types.  
            Within the developing ovarian follicle, estrogen synthesis from cholesterol 
requires close integration between theca and granulosa cells—sometimes called the two-
cell model for steroidogenesis. FSH receptors are confined to the granulosa cells, whereas 
LH receptors are restricted to the theca cells until the late stages of follicular 
development, when they are also found on granulosa cells. The theca cells surrounding 
the follicle are highly vascularized and use cholesterol, derived primarily from circulating 
lipoproteins, as the starting point for the synthesis of androstenedione and testosterone 
under the control of LH.  
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              Androstenedione and testosterone are transferred across the basal lamina to the 
granulosa cells, which receive no direct blood supply. The mural granulosa cells are 
particularly rich in aromatase and, under the control of FSH, produce estradiol, the 
primary steroid secreted from the follicular phase ovary and the most potent estrogen. 
Theca cell–produced androstenedione and, to a lesser extent, testosterone are also 
secreted into peripheral blood, where they can be converted to dihydrotestosterone in skin 
and to estrogens in adipose tissue. The hilar interstitial cells of the ovary are functionally 
similar to Leydig cells and are also capable of secreting androgens. Although stromal 
cells proliferate in response to androgens [as in polycystic ovarian syndrome 
(PCOS)], they do not secrete androgens. 
Estrogen production in the ovary requires the cooperative function of the theca 
and granulosa cells under the control of luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH). HSD, hydroxysteroid dehydrogenase; OHP, hydroxyprogesterone. 
 
  Steroid Hormone Actions 
            Both estrogen and progesterone play critical roles in the expression of secondary 
sexual characteristics in women. Estrogen promotes development of the ductile system in 
the breast, whereas progesterone is responsible for glandular development. In the 
reproductive tract, estrogens create a receptive environment for fertilization and support 
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pregnancy and parturition through carefully coordinated changes in the endometrium, 
thickening of the vaginal mucosa, thinning of the cervical mucus, and uterine growth and 
contractions.  
              Progesterone induces secretory activity in the estrogen-primed endometrium, 
increases the viscosity of cervical mucus, and inhibits uterine contractions. Both gonadal 
steroids play critical roles in the negative and positive feedback controls of gonadotropin 
secretion. Progesterone also increases basal body temperature and has therefore been used 
clinically as a marker of ovulation. 
Modulations in binding protein levels by insulin, androgens, and estrogens contribute to 
high bioavailable testosterone levels in PCOS and to high circulating estrogen and 
progesterone levels during pregnancy. 
Hormonal Integration of the Normal Menstrual Cycle 
     The sequence of changes responsible for mature reproductive function is coordinated 
through a series of negative and positive feedback loops that alter pulsatile GnRH 
secretion, the pituitary response to GnRH, and the relative secretion of LH and FSH from 
the gonadotrope.  
        For the majority of the cycle, the reproductive functions in a classic endocrine 
negative feedback mode. Estradiol and progesterone inhibit GnRH secretion, and the 
inhibins act at the pituitary to selectively inhibit FSH synthesis and secretion. This 
negative feedback control of FSH is critical to development of the single mature oocyte 
that characterizes normal reproductive function in women. 
          In addition to these negative feedback controls, the menstrual cycle is uniquely 
dependent on estrogen-induced positive feedback to produce an LH surge that is essential 
for ovulation of a mature follicle. The neural signaling pathways that distinguish estrogen 
negative versus positive feedback are incompletely understood. 
 The Follicular Phase 
           This phase is characterized by recruitment of a cohort of secondary follicles and 
the ultimate selection of a dominant preovulatory follicle .The follicular phase begins, by 
convention, on the first day of menses. follicular recruitment is initiated by the rise in 
FSH 
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            Increasing levels of estradiol are answerable for proliferative changes in the 
endometrium. The exponential rise in estradiol results in positive feedback on the 
pituitary, leading to the generation of an LH surge (and a smaller FSH surge), thereby 
triggering ovulation and luteinization of the granulosa cells. 
The Luteal Phase 
              This phase begins with the formation of the corpus luteum from the ruptured 
follicle in response to ovulation signals. Progesterone and inhibin A are produced from 
the luteinized granulosa cells, which continue to aromatize theca-derived androgen 
precursors, producing estradiol. The combined actions of estrogen and progesterone are 
responsible for the secretory changes in the endometrium that are necessary for 
implantation.  
Clinical Assessment of Ovarian Function 
               Menstrual bleeding should become regular within 2 to 4 years of menarche, 
although anovulatory and irregular cycles are common before that. For the remainder of 
adult reproductive life, the cycle length counted from the first day of menses to the first 
day of subsequent menses, is ~28 days, with a range of 25–35 days. However, cycle-to-
cycle variability for an individual woman is ± 2 days. 
                  Luteal phase length is relatively constant between 12 and 14 days in normal 
cycles; thus, the major variability in cycle length is due to variations in the follicular 
phase. The duration of menstrual bleeding in ovulatory cycles varies between 4 and 6 
days. There is a gradual shortening of cycle length with age such that women over the age 
of 35 have cycles that are shorter than during their younger reproductive years. 
Anovulatory cycles increase as women approach the menopause, and bleeding patterns 
may be erratic.(HARRISON’S  principles of INTERNAL MEDICINE) 
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POLYCYSTIC OVARIAN SYNDROME 
Introduction 
                 The polycystic ovary syndrome was characterized by symptoms of excessive 
androgenisation, such as hirsutism and acne, and obesity in addition to infertility in the 
presence of bilateral polycystic ovaries (PCO). These ovaries were described as being 
enlarged,having a markedly thickened tunica albuginea with hyperplasia of the theca 
interna cells.( Gautam N et al;2007) 
Stein-Leventhal syndrome, the association of amenorrhea with bilateral polycystic ovaries 
and obesity was first described in 1935 by Stein and Leventhal. Its complex genetic 
origins are likely polygenic and/or  multifactorial. 
Pathogenesis 
        Polycystic Ovaries develop when the ovaries are stimulated to produce 
excessive amounts of male hormones (androgens), particularly testosterone, either 
through the release of excessive luteinizing hormone (LH) by the anterior pituitary gland 
or through high levels of insulin in the blood (hyperinsulinaemia) in women whose 
ovaries are sensitive to this stimulus. 
                  The syndrome acquired its most widely used name due to the common sign on 
ultrasound examination of multiple (poly) ovarian cysts. These "cysts" are actually 
immature follicles, not cysts ("polyfollicular ovary syndrome" would have been a better 
name). The follicles have developed from primordial follicles, but the development has 
stopped ("arrested") at an early antral stage due to the disturbed ovarian function. The 
follicles may be oriented along the ovarian periphery, appearing as a 'string of pearls' on 
ultrasound examination. A majority of patients with PCOS have insulin resistance and/or 
are obese. Their elevated insulin levels contribute to or cause the abnormalities seen in 
the hypothalamic-pituitary-ovarian axis that lead to PCOS. 
 Aromatase is an enzyme that converts androstenedione to estrone and testosterone 
to estradiol and this is found in adipose tissue. The excess of adipose tissue in obese 
patients creates the paradox of having both excess androgens (which are responsible for 
hirsutism and virilization) and estrogens. The development of PCOS is described by all 
these steps; LH over FSH dominance, increased ovarian androgen production, 
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hyperinsulinemia increases GnRH pulse frequency, decreased SHBG binding and 
decreased follicular maturation. Insulin resistance is a common finding among patients of 
normal weight as well as those overweight patients. PCOS may be found with chronic 
inflammation, several investigators correlating inflammatory mediators, anovulation and 
with other PCOS symptoms. The risk of PCOS development was shown to be higher in 
lesbian women than in heterosexuals. 
Symptomatic presentation of the polycystic ovary syndrome 
v Obesity 
The occurrence of obesity in PCOS is relatively common, with more than 50% being 
overweight (BMI >25kg/m2 or obese (BMI >27kg/m2). The weight distribution is 
classically with a central deposition of fat in the truncal region and manifest in an 
increased waist/hip ratio. 
v Acne 
Acne is an inflammatory disorder of the hair follicle and its associated sebaceous and 
apocrine gland. It is present in up to one third of the women with PCOS. 
v Hirsutism 
Hirsutism is the growth of terminal hair on the body of a women, in the same pattern as in 
an adult male. The cause of hirsutism is androgen action upto the hair follicle.  
v Androgenic alopecia 
Androgenic is a progressive pattern of hair loss of scalp terminal hair, which is a common 
finding in men 
v Acanthosis nigricans 
Acanthosis nigricans is a mucocutaneous eruption that occurs most frequently in the 
axillae, skin flexures and the nape of the neck. It is manifest by increased pigmentation 
and papillomatosis. 
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Diagnostic Criteria 
         Diagnostic criteria have been established by the modified consensus of the National 
Institutes of Health and Child Health and Human Development (1990) and by consensus 
criteria established during the ESHRE/Rotterdam Conference in 2003 
NIH Criteria (both required) 
1. Chronic anovulation 
2. Clinical or biochemical signs of hyperandrogenism 
Minor NIH Criteria 
1. Insulin resistance 
2. Perimenarchal onset of hirsutism and obesity 
3. Elevated LH/FSH ratio 
4. Intermittent anovulation associated with hyperandrogenemia 
5. Ultrasound evidence of polycystic ovaries 
Rotterdam Criteria-two of three required 
1. Oligo and /or anovulation 
2. Clinical or biochemical signs of hyperandrogenism 
3. Polycystic ovaries 
Differential diagnosis 
 Other causes of irregular or absent menstruation and hirsutism, such as congenital 
adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia, androgen secreting 
neoplasms, and other pituitary or adrenal disorders, should be investigated. PCOS has 
been reported in other insulin resistant situations such as acromegaly. 
Long-Term risks of PCOS 
         Endometrial carcinoma-ovarian carcinoma: In chronic anovulatory patients with 
PCOS, persistent estrogen stimulation, unopposed by progesterone, increases the risk of 
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endometrial carcinoma. Additionally, a hyperestrogenic  state in PCOS is associated with 
an increased risk of breast cancer as well as a two to threefold increase in ovarian cancer( 
Catherine J). The incidence of insulin resistance in PCOS women is  25%-70% .In 
women with PCOS, the rate of early pregnancy loss has been reported to be as high as 
40%.The early pregnancy loss rate in women with PCOS has been attributed to elevated 
LH concentrations, Higher androgen levels, insulin resistance and obesity. 
                 Cardiovascular disease-hypertension, an unfavorable lipid profile, and reduced 
endothelial elasticity are all more common in obese women with PCOS. (Sabaratnam 
Arulkumaran Lesley Regan) 
Radiologic Studies in PCOS 
                 Ultra sonographic examination of PCOS women reveals an increase in ovarian 
size and an increased number of immature follicles. The Rotterdam criteria include 
enlarged ovaries measuring >10 cm3 and more than 12 follicles measuring 2-9 mm in 
diameter.PCOS is a disorder comprising multiple clinical variants and apparent genetic 
propensities grouped together into the “PCOS phenotype” (Catherine J et al) 
Epidemiology 
                  PCOS is the commonest endocrine disorder in women of reproductive age and 
an estimated prevalence of 5-10% in this age group. By contrast, 23% of asymptomatic 
women will have the ultrasound finding of polycystic ovarian morphology(Poison et 
al.1988). 
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4. MATERIALS AND METHODS 
 
4.1 PREPARATION OF NAVACHARA CHUNNAM 
The trial drug Navaachara Chunnam was formulated based on the ‘Anuboga 
Vaithya Navaneetham’. The ingredients are Navacharam, juice of Oomathai (Datura 
innoxia). The raw material was obtained from country drug shop, Chennai and the plant 
was collected from in and around Chennai. Both materials were identified and 
authenticated by the botanist and the experts of Gunapadam (Pharmacology) at Govt 
Siddha Medical College, Arumbakkam, Chennai. After identification, the samples of raw 
materials have been preserved in the laboratory of the department for future reference. 
Purification 
Dissolve the Navacharam in hot water. Filter the solution and cool it to room 
temperature. Then place the solution in a vessel in the sunlight. The solution turns into 
salt due to sunlight. Collect the purified salt. 
Preparation of Chunnam: 
Materials Required : 
Ø Navacharam 35g 
Ø Datura innoxia leaf juice 1.3 litre 
Ø Datura innoxia leaves   
Procedure 
Place the Purified Navacharam on a sand plate and heat up with Datura leaf 
juice(Surukku koduththal). Then grind the leaves of datura and make a kavasam of 
thickness 0.5 inch for the Navacharam. Dry the kavasam. Grind the limestone using 
Datura leaf juice and make a moosai and lid. Place the dried kavasam within this moosai 
and close it with lid and seal it with sanded cloth five times .Dry it and Put  the Pudam 
with dung cakes of weight six times the kavasam. After finishing the pudam let the 
moosai undisturbed to give away the heat. Finally  Chunnam is prepared. 
Storage: 
The drug Navachara Chunnam was stored in a clean air tight container. 
Dosage: 260 mg – two times a day 
Form of medicine: Chunnam 
Route: Enteral 
Vehicle: Soembu kudineer 
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ANALYSIS AS PER CLASSICAL LITERATURE 
· Reaction with turmeric: According to the Siddha Pharmacopoeia, “Chunnam become 
red when turmeric powder is added to it because of the presence of Lime in it (calcium)”. 
Addition of small quantity of turmeric powder with water and prepared Navachara 
Chunnam turned white colour to red which confirmed that the preparation was perfect 
and complete. 
· Floating on Water: If the Chunnam is well prepared, it floats on water. A small amount 
of Navachara Chunnam was sprinkled over the water in a glass container. It was found 
that the Chunnam particles floated over the surface of water indicated lightness of the trial 
drug. 
· Lines on fingers: Chunnam in well prepared form should be fine. When taken between 
thumb and forefinger, the fine powder will fill the lines of the fingerprint. A pinch of 
Chunnam was taken in between the thumb and index finger and rubbed. It was observed 
that the Navachara Chunnam entered into the lines of the finger, and was not easily 
washed out from the cleavage of the lines confirmed its fineness. 
· Lustre: If any shining or sparkly particles present in Chunnam, it indicates that the drug 
is not prepared properly and contains unchanged substances like metals and other toxic 
substances. There should be no shining and sparkling particles present in the well 
prepared Chunnam. The Navachara Chunnam was taken in a Petri dish and observed for 
any lustre in daylight through magnifying glass. No lustre was observed in the Chunnam. 
· Taste: The well prepared Chunnam should be completely tasteless. Presence of any taste 
like sweet, sour or bitter indicate incomplete preparation which required another 
calcination process. When a small amount of Navach Chunnam was kept on the tip of the 
tongue, no specific taste was observed rather than a mild irritation due to its alkaline 
nature. 
The finished product, Navachara Chunnam was analysed for quality control as above 
based on the classical Siddha literature and found suitable for further studies 
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4.2. STANDARDIZATION OF NAVACHARA CHUNNAM: 
Standardization of drugs helps to confirm its identity and determination of its 
quality, effectiveness .Standardization of herbo mineral drug is based on qualitative and 
quantitative analysis through physico‐chemical properties and instrumental studies. The 
physico-chemical analysis and elemental analysis of this herbomineral formulation have 
been done at SCRI (Siddha Central Research Institute) and Anna university (FTIR in 
Dept. of Chemistry and SEM in Dept. of Mechanics) 
 
4.2.1 Physico‐Chemical Investagations: 
               Physico‐chemical studies like Total ash, Water soluble ash, and Acid Insoluble 
ash, Loss on drying at 105°C and pH have been done at Siddha Central Research Institute 
as per the guide lines of WHO.  
 
Determination of Total Ash: 
Incinerate about 2 to 3 g accurately weighed, of the ground drug in a tared 
platinum or silica dish at a temperature not exceeding 450º until free from carbon, cool 
and weigh. Calculate the percentage of ash with reference to the air-dried drug. 
 
Determination of Acid Insoluble Ash: 
Boil the ash obtained for 5 minutes with 25 ml of dilute hydrochloric acid; collect 
the insoluble matter in a Gooch crucible or on an ash-less filter paper, wash with hot 
water and ignite to constant weight. Calculate the percentage of acid-insoluble ash with 
reference to the air dried drug. 
 
Determination of Moisture Content (Loss on Drying): 
Procedure set forth here determines the amount of volatile matter (i.e., water 
drying off from the drug). For substances appearing to contain water as the only volatile 
constituent, the procedure given below, is appropriately used. Place about 10 g of drug 
(without preliminary drying) after accurately weighing (accurately weighed to within 0.01 
g) it in a tared evaporating dish. For example, for underground or un powdered drug, 
prepare about 10 g of the sample by cutting shredding so that the parts are about 3 mm in 
thickness. 
122 
After placing the above said amount of the drug in the tared evaporating dish dry at 105º 
for 5 hours, and weigh. Continue the drying and weighing at one hour interval until 
difference between two successive weighing corresponds to not more than 0.25 per cent. 
Constant weight is reached when two consecutive weighing after drying for 30 minutes 
and cooling for 30 minutes in a desiccator, show not more than 0.01 g difference. 
 
Determination of pH: 
1% solution of plant drug was prepared in distilled water and pH was determined 
using pH meter SYSTRONICS DIGITAL pH METER, MK VI. 
 
4.2.2 Preliminary Chemical Analysis  
Preparation of Extract : 
Add 5 gm of the sample to 50ml of distilled water. Boil the solution for 20 minutes, cool 
and then filter. Use the Extract for the following tests. 
S.No Experiment Observation Inference 
1. 
Test for reducing Sugar : 
To 5ml of Benedicts qualitative 
reagent, add 10 drops of extract, 
then boil for two minutes 
Green / yellow / red 
precipitate 
Presence of 
Reducing Sugar 
2. 
Test for Starch : 
To 5 ml of extract add 2ml of acetic 
acid and then add few drops of N/50 
Iodine Solution. 
Blue colour 
Presence of 
Starch 
3. 
Test for Proteins : 
To 2 ml of extract, add 2ml of 5% 
Sodium Hydroxide mix and add 2 
drops of Copper Sulphate Solution. 
Violet or purple 
colour 
Presence of 
Proteins 
4. 
Test for amino Acid : 
Place  2 drops of extract on a filter 
paper and allow to dry well. Then 
spray 1% ninhydrin over the same 
and allow to dry. 
Violet colour 
Presence of 
Amino Acid 
5. 
Test for Albumin : 
To 2 ml of extract, add 2ml of 
Esboch’s reagent. 
Yellow precipitate 
Presence of 
Albumin 
6. 
Test for Phosphate : 
To 2ml of extract, add 2ml of 
ammonium Molybdate solution and 
2ml of concentrated Nitric Acid. 
Yellow precipitate 
Presence of 
Phosphate 
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7. 
Test for Sulphate : 
To 2 ml of extract add 2ml of 4% 
ammonium oxalate solution. 
White precipitate 
Presence of 
Sulphate 
8. 
Test for Chloride :  
Add 2ml of extract to dilute nitric 
acid till the effervescence ceases. 
Then add 2 ml of Silver Nitrate 
Solution. 
Cloudy white 
precipitate 
Presence of 
Chloride 
9. 
Test for Iron : 
To 2ml of extract, add 2ml of 
ammonium thio cynate solution and 
add 2ml of concentrated Nitric 
Acid. 
Red colour Presence of Iron 
10. 
Test for Calcium : 
To 2 ml of extract, add 2 ml of 4% 
ammonium Oxalate Solution. 
White precipitate 
Presence of 
Calcium 
11. 
Test for Sodium : 
Make a paste with 2 pinches of the 
sample with HCl and Introduce it 
into the blue flame.  
Yellow flame 
Presence of 
Sodium 
12. 
Test for Potassium : 
Add a pinch of the sample to 2 ml 
of Sodium Nitrate Solution. Then 
add 2ml of Cobal Nitrate in 20% 
acetic acid. 
Yellow precipitate 
Presence of 
Potassium 
13. 
Test for Zinc : 
To 2ml of extract, add few drops of 
Sodium Hydroxide. 
White precipitate Presence of Zinc 
14. 
Test for Magnesium : 
To 2ml of extract, add few drops of 
Sodium Hydroxide Solution 
White precipitate 
Presence of 
Magnesium 
15. 
Test for Alkaloids : 
 To 2ml of extract, add 2ml of 
Potassium Iodide Solution 
 To 2ml of extract add 2ml of Picric 
Acid. 
 To 2 ml of extract add 2ml of 
Phosphotunqstic Acid. 
 
Red colour 
 
 
Yellow colour 
 
White precipitate 
 
Presence of 
Alkaloids 
 
Presence of 
Alkaloids 
Presence of 
Alkaloids 
16. 
Test for Tannic Acid : 
To 2ml of extract add 2 ml of Ferric 
Chloride Solution 
Black precipitate 
Presence of 
Tannic Acid 
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4.3. ACUTE AND SUB ACUTE TOXICITY STUDY ON NAVACHARA 
CHUNNAM 
Animals 
 Mice of either sex weighing 25-30g and rats weighing 210-240g were obtained 
from the animal house of Vels University. The animals were used with the approval of the 
Institute animal ethics committee and obtained from Vels University, Chennai. They were 
fed with a balanced standard pellet diet and maintained under standard laboratory 
conditions, providing 24-280C temperature, standard light cycle (12 h light, 12 h dark) 
and water ad libitum. Animals were kept in cages with raised floors of wide mesh to 
prevent coprophagy. Animal welfare guidelines were observed during the maintenance 
period and experimentation. The rats were randomly assigned to control and different 
treatment groups, six animals per group. The animals were acclimatized for one week 
under laboratory conditions.  
 
ACUTE TOXICITY STUDY-OECD 425 GUIDELINES 
Acute oral toxicity test for the Navachara Chunnam was carried out as per OECD 
Guidelines 425. As with other sequential test designs, care was taken to ensure that 
animals are available in the appropriate size and age range for the entire study. The test 
substance is administered in a single dose by gavage using a stomach tube or a suitable 
intubation cannula. The fasted body weight of each animal is determined and the dose is 
calculated according to the body weight. After the substance has been administered, food 
was withheld for a further 2 hours in mice. The animals were observed continuously for 
the first 4 h and then each hour for the next 24 h and at 6 hourly intervals for the 
following 48 h after administering of the test drug, to observe any death or changes in 
general behaviour and other physiological activities. Single animals are dosed in sequence 
usually at 48 h intervals. However, the time interval between dosing is determined by the 
onset, duration, and severity of toxic signs. Treatment of an animal at the next dose was 
delayed until one is confident of survival of the previously dosed animal.  
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Observation of toxicity signs: 
General behavior, respiratory pattern, cardiovascular signs, motor activities, 
reflexes, change in skin and fur, mortality and the body weight changes were monitored 
daily. The time of onset, intensity, and duration of these signs, if any, was recorded.  
 
SUB-ACUTE TOXICITY 
 In a 28-days sub acute toxicity study, twenty four either sex rats were divided into 
four groups of 6 rats each. Group I that served as normal control was administered with 
distilled water (p.o.) while groups II, III and IV were administered daily with the 
Navachara Chunnam (p.o.) for 28 days at a dose of 25, 50 and 100mg/kg respectively. 
The animals were then observed daily for gross behavioral changes and any other signs of 
subacute toxicity. The weight of each rat was recorded on day 0 and weekly throughout 
the course of the study, food and water consumption per rat was calculated. At the end of 
the 28 days they were fasted overnight, each animal was anaesthetized with diethyl ether, 
following which they were then dissected and blood samples were obtained by cardiac 
puncture into heparinised tubes. The blood sample collected from each rat was 
centrifuged with 3000 X g at 4oC for 10 min to separate the serum and used for the 
biochemical assays.  
 
Hematological and blood biochemical analyses: 
At the end of the study, all animals were kept fasted for 16-18 h and then 
anesthetized with anesthetic ether on the 28th day. Blood samples for hematological and 
blood chemical analyses were taken from retro orbital vein. Heparinized blood samples 
were taken for determining complete blood count (white blood cell count, differential 
white blood cell count, platelet count, red blood cell count, hematocrit, and hemoglobin) 
by semiautomated hematology analyzer. The serum from non-heparinized blood was 
carefully collected for blood chemistry and enzyme analysis (glucose, creatinine, total 
protein, albumin, total and direct bilirubin, serum glutamate-oxaloacetate transaminase 
(SGOT), serum glutamate pyruvate transaminase (SGPT), and alkaline phosphatase 
(ALP)) were automatically determined using autoanalyzer. 
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Necropsy: 
All rats were sacrificed after the blood collection. The positions, shapes, sizes and colors 
of internal organs were evaluated. The Spleen, Testes, Pancreas, Lung, Liver, Brain, 
Heart, Stomach, Intestine, Bone, Ovary, and Kidney tissues were excised from all rats to 
visually detect gross lesions, and weighed to determine relative organs’ weights and 
preserved in 10% neutral formalin for histopathological assessment. The tissues were 
embedded in paraffin, and then sectioned, stained with haematoxylin and eosin and were 
examined microscopically. 
 
Statistical analysis 
           Values were represented as mean ± SEM. Data were analyzed using one-way 
analysis of variance (ANOVA) and group means were compared using the Tukey-Kramer 
Multiple Comparison test using GraphPad Instat-V3 software. P values < 0.05 were 
considered significant. 
 
4.4 EVALUATION OF OVULOGENIC EFFECT OF NAVACHARA CHUNNAM 
IN RATS 
Animal Selection 
 Mice of either sex of wistar strain weighing 28-32gms and Female albino rats of 
wistar strain weighing about 95–135 gm were used. Pregnant animals were excluded. 
Animals were fed on conventional diets and water ad libitum and they were maintained 
under standard conditions of humidity, temperature (20- 24°C) and light (12 h light: 12 h 
dark cycle). Animals were kept in polycarbonate cages with laced steel roofs. The 
animals were acclimatized for one week under laboratory conditions. The study was 
conducted at the Vel’s University, Chennai after obtaining Institutional Animals Ethical 
Committee clearance bearing the number XIII/VELS/PCOL/57/2000/CPCSEA/ 
IAEC/08.08.2012. 
 
Drug and stock solution 
The Navachara Chunnam was accurately weighed using electronic balance and 
suspended in 2% carboxy methyl cellulose solution to so as to get 200mg/kg of main 
stock solution and this was used in this study. All the chemicals and standard drugs were 
procured from authorized suppliers. 
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Acute toxicity study: 
Acute oral toxicity test was carried out as per OECD Guidelines 425 up and down 
method. Animals are observed individually after dosing at least once during the first 30 
minutes, periodically during the first 24 hours, with special attention given during the first 
4 h, and daily thereafter, for a total of 14 days. Initially starting at a dose of 2000 mg/kg 
of Navachara Chunnam was given. Body weight and behavioral changes were noted. 
Animals are observed individually and were systematically recorded. The acute toxicity 
was occurred at 250mg/kg after 48 hours of oral drug treatment. Hence, one-tenth and one 
fifth dose was selected as therapeutic dose from maximum tolerable dose for further 
pharmacological study. 
 
Ovulation stimulation activity: 
 In the present study, twenty four Virgin female wistar rats weighing of around 
(88- 130 gm) of 2 month old were obtained from the animal house at Vel’s University, 
Chennai. Before starting drug treatment, the reproductive cycles of the rats were 
synchronized by the following method. 100μg estradiol dissolved in 2 ml olive oil was 
injected subcutaneously. All rats after a 24 hr period, received intramuscular injections of 
50 μg progesterone dissolved in olive oil. After few hours, Vaginal smears were obtained 
by vaginal lavage to monitor ovulation and oestrous cycle. Vaginal smears were prepared 
by washing vaginal opening with 0.9% w/v of sodium chloride with a glass dropper and 
placed in a clean glass slide and viewed under light microscope at 40X magnification. 
Examination of vaginal smears showed that all the animals were in the estrous stage. All 
the animals were weighed daily after drug administration for 10 days. The suitable 
sensitive rats were divided into four groups of six each as follows:  
Ø Group I Normal Control animals given only 2ml/kg of CMC solution.  
Ø Group II animals were administered 25 mg/kg of Navachara Chunnam for 
10days,  
Ø Group III rats were received 50mg/kg of Navachara Chunnam for 10 days  
Ø Group IV received clomiphene 10mg/kg and served as standard. All the drugs 
were given orally. 
 2ml of blood was collected by retro orbital puncture. Blood samples were 
centrifuged for 15 minutes at 4000 rpm and the separated serum samples were frozen at -
20°C and kept for later estimation of LH, FSH and estradiol by ELISA method. At the 
end of experiment, the animals were sacrificed using ether anesthesia and the uteri were 
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removed and weight was recorded. The oviduct was dissected out from the rats, 
suspended in normal saline and placed on a microscopic slide with a cover slip to count 
the number of ova analysis.  
 
Histological analysis 
 At the end of the treatment, the ovary was removed and placed in formalin 
fixative for 20-24 hours. Fixed tissue samples were placed in ascending concentrations of 
alcohol and embedded in paraffin. Slices of tissue, 5-7 μm thick, were prepared and 
stained with hematoxylin and eosin, and then monitored and evaluated with a light 
microscope. To study folliculogenesis all tissue blocks were serially sliced. Follicle 
identification was based on the detection of a nucleus. The numbers of follicles 
(primordial, primary, etc.) were counted. Follicle recognition criterion on the slides was 
based on the type of epithelial cells surrounding them. For example, primordial follicles 
have squamulose cells whereas primary follicles are surrounded by cuboidal cells. The 
numbers of follicles per slide were randomly counted. 
 
Statistical analysis  
 Statistical significance of data was assessed by analysis of variance (one-way 
ANOVA) followed by a comparison between different groups using Dunnet test. 
 
 
129 
4.5. CLINICAL ASSESSMENT:   
Siddha system had been survived through centuries and cannot be lightly 
condemned as being unscientific. This ancient system offers simple, cost effective and 
nature friendly therapy. Special interest had laid on women’s health since status of 
women is an index of the community. Nowadays change in lifestyle, food habits and 
stress women tend to develop polycystic ovarian syndrome due to hormonal imbalance 
with ovulation disorder. So Navachara chunnam was focused to trial for remedy of  
PCOS (Sudhagakatti). 
Objectives 
To explore the efficacy of Navachara chunnam in women with Polycystic ovarian 
syndrome. 
Study Design 
The Open clinical trial – Phase II B 
Study Centre 
Arignar Anna Government Hospital of Indian Medicine and Homeopathy, 
Arumbakkam, Chennai – 106. 
Study Participants 
Women members of all races and ethnic groups are eligible for this trial. 
Treatment administered on an outpatient  and inpatient basis. The patients  selected from 
Out-patient and In-patient department of Arignar Anna Government Hospital of Indian 
Medicine and Homeopathy, Chennai – 106. 
Number of Subjects 
No of  participants   44 
Registration Process 
To register a patient, the following documents should be completed by the 
investigator. 
· Copy of required laboratory tests 
· Signed patient consent form 
· Other appropriate forms (e.g., Trial Pro forma) 
The investigator verified  eligibility and  assigned a patient study number, drug dose 
and register the patient on the study. 
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Inclusion criteria 
44 women with PCOS, ages between 16-38 year were selected for open label 
clinical trial by using Rotterdam Criteria 
Rotterdam Criteria-two of three required 
Ø Oligo and /or anovulation 
Ø Clinical or biochemical signs of hyperandrogenism 
Ø Polycystic ovaries 
 
Exclusion criteria 
Ø Cushing syndrome 
Ø Late-onset 21-hydroxylase deficiency 
Ø Thyroid dysfunction 
Ø Androgen secreting tumours 
Before and at the end of study, the following investigations were carried out; 
Ø Assessment of menstrual history(Regularity of the cycle, Length of the cycle, 
Duration of menstruation, Level of blood flow) 
Ø Physical examination for body weight, BMI, waist/hip ratio and Blood pressure. 
Ø Laboratory investigation for Hormonal assay (LH, FSH, Free testosterone, 17-
hydroxyprogesterone, estradiol, insulin (fasting and post prandial) and lipid 
profile. 
Ø USG pelvis 
Ø Follicular Study 
          Each woman was asked to report any side-effect during the treatment. Safety 
parameter (hematology, liver and renal function, serum electrolytes and uric acid) were 
assessed before and at 2 month intervals during the study. 
All subjects gave their informed consent before entering the study. 
 
      Withdrawal Criteria 
Patients were  removed from study when any of the criteria listed below applied. The 
reason for study removal and the date of removal of patient had been documented in the 
Case Report Form. 
Ø Irregular medication. 
Ø Patients who are all not cooperating to take blood samples. 
Ø Any adverse reactions during the study period. 
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Ø Patient decides to withdraw from the study, or  
Ø Unwanted prolonged illness during the study period. 
 
Evaluation of Clinical Parameters 
Patients are clinically evaluated by the following parameters: 
History Taking 
Age, occupation, socio economic status, complaints and its duration, menstrual 
history, marital history. History of parity, family history, previous illness, and personal 
habits were recorded in the case sheet for every patient at the time of first visit to the OP. 
Investigations 
All the patients were subjected to the laboratory investigations before and after the 
treatment. 
Blood: Complete haemogram, Blood sugar fasting & post prandial, Blood urea, Serum 
creatinine, Serum cholesterol  and hormonal assay. 
Urine: Albumin,Sugar,Deposits, 
Ultrasound Sono Gram: Whole Abdomen and Pelvis. 
 
Criteria for Assessment of Response to Therapy: 
1. Marked response  : 90% relief in signs and symptoms and improvement                          
.                                in lab investigations. 
2. Moderate response : 70 - 80 % relief in the presenting signs and symptoms and          
.                                improvement in lab investigations. 
3. Mild response : 60-70% relief signs and symptoms. 
4. Poor response : 50% relief of signs and symptoms no marked changes 
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Table No.1- (MARITAL STATUS) 
 
SL. NO Marital 
Status 
NO. OF 
PATIENTS 
PERCENTAGE (%) 
1. Single 24 55 
2. Married 20 45 
TOTAL 44 100 
 
 
 
Inference: 
Out of 44 patients 20 (45%) are married  
Out of 44 patients 24 (55%) are Single. 
 
 
 
 
 
  
Single, 24
Married, 20
MARITAL STATUS
Single
Married
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Table No.2-(AGE DISTRIBUTION) 
 
SL. NO AGE IN YEARS NO. OF 
PATIENTS 
PERCENTAGE 
(%) 
1. 16-20 11 25 
2. 21-25 8 18 
3. 26-30 17 39 
4. 31-38 8 18 
TOTAL 44 100 
 
 
 
 
Inference: 
Among 44 patients, 
Ø 11 patients belongs to the age group of 16-20  years 
Ø 8  patients belongs to the age group of 21-25 years 
Ø 17  patients belongs to the age group of 26-30 years 
Ø 8  patients belongs to the age group of 31-38 years 
 
11
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CLINICAL STUDY ON NAVACHARA CHUNNAM  FOR  PCOS
Sl.No. O.P. No. Name Age/ Sex Symptoms 
 
Duration 
 
Results 
1. 7349 DIANA 27/F Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, Constipation,weight gain  present 
18.06.2012 to 
20.08.2012 
 
Marked 
2. 3517 KALAIMAGAL 20/F Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, Acanthosis nigricans, hirsutism present 
09.07.2012 to 
08.09.2012 
Marked 
3. 3182 VALARMATHI 16/F Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, Constipation present 
07.07.2012 to 
17.102012 
Marked 
4. 7464 UMAMAHESWARI 37/F 
Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation, Infertility present 
24.07.2012 to 
28.09.2012 
Marked 
5. 4189 RAJESWARI 27/F Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, Constipation, hirsutism present 
21.08.2012 to 
01.11.2012 
 
Moderate 
6. 2396 NITHYA 19/F Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, Constipation present 
13.08.2012 to 
13.11.2012 
Marked 
7. 4283 DEEPAPRIYA 17/F Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, weight gain present 
21.08.2012 to 
18.11.2012 
Marked 
8. 5245 SUGANYA 26/F Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, Constipation present 
25.08.2012 to 
22.11.2012 
Marked 
9. 6482 NIRMALA 27/F Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, Constipation,Infertility present 
31.08.2012 to 
28.11.2012 
Moderate 
10. 7146 PARVATHY 26/F Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, Constipation present 
05.09.2012 to  
3.12.2012 
Marked 
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CLINICAL STUDY ON NAVACHARA CHUNNAM  FOR  PCOS 
   Sl.No. O.P. No. Name Age/ Sex Symptoms 
 
Duration 
 
Results 
11. 7908 
DHANALAKSH
MI 30/F 
Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation,Infertility present 
06.09.2012 to 
07.12.2012 
Moderate 
12. 8767 KALADEVI 32/F 
Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation, Infertility present 
10.09.2012 to 
11.12.2012 
Marked 
13. 8827 PRIYANKA 20/F Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation, weight gain  present 
10.09.2012 to 
09.12.2012 
Marked 
14. 9110 
KRISHNAKUM
ARI 
27/F 
Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation present 
11.09.2012 to 
12.12.2012 
Moderate 
15. 168 SRIVALLI 38/F 
Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation present 
15.09.2012 to 
17.12.2012 
Marked 
16. 1221 KARPAGAM 30/F 
Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation present 
20.09.2012 to 
23.12.2012 
Marked 
17. 1371 ANITHA 29/F Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation present 
21.09.2012 to 
24.12.2012 
Marked 
18. 5201 DIVYA 20/F 
Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, weight 
gain present 
06.10.2012 to 
02.01.2013 
Mild 
19. 8395 SARALA 33/F 
Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Infertility Constipation present 
20.10.2012 to 
04.01.20113 
Marked 
20. 8825 
CAROLIN 
MERY 30/F 
Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation present 
23.10.2012 to 
30.12.2012 
Marked 
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CLINICAL STUDY ON NAVACHARA CHUNNAM FOR PCOS 
 
 
  
21. 7710 VASANTHI 28/F 
Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation present 
17.10.2012 to 
29.12.2012 
 
Moderate 
22. 6619 FATHIMA 24/F Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation present 
12.10.2012 to 
31.12.2012 
 
Marked 
23. 7779 AMUL 30/F 
Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation present 
17.10.2012 to 
28.12.2012 
 
Marked 
24. 8005 LATHA 22/F Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation present 
18.10.2012 to 
02.01.2013 
Poor 
25. 9657 
DHANALAKSH
MI 25/F 
Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation present 
27.10.2012 to 
03.01.2013 
Marked 
26. 341 RADHA 26/F 
Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation present 
31.10.2012 to 
30.12.2012 
Marked 
27. 1001 ARUNA 27/F Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation present 
03.11.2012 to 
04.01.2013 
Mild 
28. 1672 MEENALOKSI
NI 
26/F Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation present 
06.11.2012     to 
29.12 2012 
Marked 
29. 1523 AMBIKA 17/F 
Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation present 
06.11.2012   to  
02.01.2013 
Marked 
30. 1558 PIRAMILA 30/F 
Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation present 
06.11.2012 to 
04.01.2013 
Moderate 
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CLINICAL STUDY ON NAVACHARA CHUNNAM  FOR PCOS 
Sl.No. O.P. No. Name Age/ Sex Symptoms 
 
Duration 
 
Results 
31. 1528 SUGANYA 17/F 
Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation present 
06.11.2012 to 
28.12.2012 
Marked 
32. 1755 POWLIN 
SHANTHA 
23/F Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation,Acanthosis nigricans present 
07.11.2012 to 
02.01.2013 
 
Marked 
33. 1761 REJESWARI 31/F 
Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation present 
07.11.2012 to 
31.12.2012 
 
Poor 
34. 2082 SUBHASINI 35/F Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation present 
08.11.2012 to 
03.01.2013 
Moderate 
35. 2288 SARASWATHY 23/F 
Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation present 
09.11.2012 to 
31.12.2012 
Marked 
36. 2562 RADHIGA 25/F 
Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation present 
10.112012 to 
03.01.2013 
Moderate 
37. 2286 SOWMIYA 28/F 
Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation, hirsutism present 
09.11.2012 to 
04.01.2013 
Marked 
38. 2564 AISHWARYA 21/F Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation present 
10.11.2012 to 
29.12.2012 
Poor 
39. 2566 KAVYA 20/F 
Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation,Weight gain present 
10.11.2012 to 
30.12.2012 
Mild 
40. 2557 DEEPA 31/F 
Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation,infertility present 
10.11.2012 to 
02.01.2013 
Marked 
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Sl.No. I.P. No. Name Age/ Sex Symptoms 
 
Duration 
 
Results 
41. 664/6045 SUGANYA 19/F 
Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation, weight gain present 
12.06.2012 to 
28.06.2012 
Marked 
42. 1402/6801 SHANTHI 35/F Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation,Acanthosis nigricans present 
01.09.2012 to 
13.10.2012 
 
Marked 
43. 168/4474 NEELAMANI 25/F 
Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation present 
04.10.2012 to 
24.10.2012 
 
Marked 
44. 1035/5859 SELVARANI 20/F Irregular menstruation ,Oligomenorrhoea, Dysmenorrhoea, 
Constipation present 
18.07.2012 to 
28.08.2012 
Marked 
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Sl.
No. 
O.P. 
No. Name 
Age/ 
Sex 
 
BT 
& 
AT 
 
HAEMATOLOGICAL PARAMETERS URINE ANALYSIS  
 
TC 
CU/mm 
 
DC 
 
ESR 
 Hb(gm) 
 
B.S 
Mg/dl 
S.Cho 
Mg/dl 
 
ALB SUG DEP 
P L E ½ hr 1 hr 
1. 7349 DIANA 27/F 
 
BT 9000 58 37 5 5 10 10.0 85 214 
- - FPC 
AT 8100 56 39 6 6 12 12.5 90 172 - - - 
2. 3517 KALAIMAGAL 20/F 
BT 7600 52 42 6 8 16 9.0 95 178 -  - 
AT 5700 62 34 4 7 14 11.5 89 166 - - - 
3. 3182 VALARMATHI 16/F 
BT 6400 66 32 2 6 14 11.0 113 200 -  - 
AT 4900 54 40 6 5 12 11.5 98 179 - - FEC 
4. 7464 UMAMAHESWARI 37/F 
BT 6700 60 35 5 8 16 9.5 140 194 - - - 
AT 7800 63 35 2 7 14 11.0  98 167 
- - - 
5. 4189 RAJESWARI 27/F 
BT 5900 59 37 4 10 20 12.0 104 168 - - FPC 
AT 6700 58 36 6 5 10 12.5 84 172 - - - 
6. 2396 NITHYA 19/F 
BT 5700 66 31 3 6 12 10.0 92 173 - - - 
AT 6800 65 34 1 7 14 11.0 102 156 - - FPC 
7. 4283 DEEPAPRIYA 17/F 
BT 9800 63 32 5 6 12 12.5 86 165 - - - 
AT 8500  64 30 6 7 14 12.5 96 169 
- - - 
8. 5245 SUGANYA 26/F 
BT 6400 60 36 4 5 10 11.0 130 156 - - - 
AT 7800 62 33 5 8 16 12.0 104 164 - - - 
9. 6482 NIRMALA 27/F 
BT 9500 63 31 6 5 10 9.8 102 167 - - FEC 
AT 8100 65 35 0 7 14 12.2 98 178 - - - 
10. 7146 PARVATHY 26/F 
BT 5500 59 40 1 6 12 12.0 84 157 - - - 
AT 6100 65 34 1 7 14 12.0 95 162 - - - 
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Sl.N
o. 
O.P. 
No. Name 
Age/ 
Sex 
 
BT 
& 
AT 
 
HAEMATOLOGICAL PARAMETERS URINE ANALYSIS  
 
TC 
CU/mm 
 
DC 
 
ESR 
 Hb(gm) 
 
B.S 
Mg/dl 
S.Cho 
Mg/dl 
 
ALB SUG DEP 
P L E ½ hr 1 hr 
11. 7908 DHANALAKSHMI 30/F 
 
BT 980790 56 38 6 4 8 11.0 89 168 
- - - 
AT 8400 60 36 4 6 12 12.0 85 157 - - - 
12. 8767 KALADEVI 32/F 
BT 7600 64 31 5 7 14 9.8 96 179 - - - 
AT 8100 57 40 3 5 10 11.2 81 167 - - - 
13. 8827 PRIYANKA 20/F 
BT 5600 58 38 4 6 10 10.5 90 187 - - FEC 
AT 4900 60 35 5 5 12 12.4 98 165 - - - 
14. 9110 KRISHNAKUMARI /27F 
BT 7500 61 37 2 4 10 12.0 85 155 - - - 
AT 6500 64 35 1 8 16 12.2 84 167 - - - 
15. 168 SRIVALLI 38/F 
BT 8700 60 33 7 5 16 8.8 105 178 - - FPC 
AT 5600 55 40 5 4 8 11.5 86 165 - - - 
16. 1221 KARPAGAM 30/F 
BT 6300 60 39 1 5 10 11.0 112 230 - - - 
AT 7200 62 38 0 6 12 12.0 90 185 - - - 
17. 1371 ANITHA 29/F 
BT 6700 58 37 5 5 10 10.0 98 156 - - - 
AT 5800 56 37 7 7 14 12.0 87 176 - - - 
18. 5201 DIVYA 20/F 
BT 6900 64 36 0 5 10 10.4 79 178 - - FPC 
AT 8700 55 38 7 4 12 12.4 84 168 - - - 
19. 8395 SARALA 33/F 
BT 9200 51 45 4 6 14 11.4 80 198 - - FEC 
AT 6400 57 38 5 6 12 12.6 87 157 - - - 
20. 8825 CAROLIN MERY 30/F BT 7900 65 34 1 5 10 11.0 130 187 
- - - 
AT 6700 59 40 1 8 16 12.8 98 164 - - - 
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S. 
No. 
O.P. 
No. Name 
Age/ 
Sex 
 
BT 
& 
AT 
 
HAEMATOLOGICAL PARAMETERS URINE ANALYSIS  
 
TC 
CU/mm 
 
DC 
 
ESR 
 Hb(gm) 
 
B.S 
Mg/dl 
S.Cho 
Mg/dl 
 
ALB SUG DEP 
P L E ½ hr 1 hr 
21. 7710 VASANTHI 28/F 
 
BT 8700 57 38 5 4 12 12.0 98 165 
- - FEC 
AT 5400 63 37 0 6 16 12.4 95 154 - - - 
22. 6619 FATHIMA 24/F 
BT 4500 59 37 4 8 12 9.8 102 178 - - - 
AT 6800 65 35 0 5 14 12.2 86 167 - - - 
23. 7779 AMUL 30/F 
BT 9700 55 39 6 6 18 9.0 89 187 - - - 
AT 7600 66 30 4 8 15 11.5 92 165 - - FEC 
24. 8005 LATHA 22/F 
BT 5600 59 35 6 7 12 12.0 110 156 - - - 
AT 9100 60 37 3 4 18 12.6 94 178 - - - 
25. 9657 
DHANALAKS
HMI 25/F 
BT 5700 56 37 7 5 10 9.8 85 168 - - - 
AT 6700 60 34 6 6 12 11.8 79 155 - - - 
26. 341 RADHA 26/F 
BT 5700 65 30 5 8 14 11.4 88 178 - - - 
AT 5600 59 40 1 9 16 12.6 94 156 - - - 
27. 1001 ARUNA 27/F 
BT 5800 50 42 8 4 16 11.0 84 187 - - - 
AT 6800 67 40 3 5 14 12.4 81 164 - - - 
28. 1672 
MEENALOKSI
NI 26/F 
BT 6900 61 37 2 7 12 10.8 92 173 - - FPC 
AT 7800 62 34 4 6 15 11.5 80 162 - - - 
29. 1523 AMBIKA 17/F 
BT 7200 54 40 6 7 12 11.0 118 184 - - - 
AT 5600 66 34 0 4 8 12.8 95 161 - - - 
30. 1558 PIRAMILA 30/F 
BT 6900 61 33 6 8 16 10.8 130 164 - - - 
AT 6100 59 40 1 6 12 12.6 96 153 - - FEC 
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S. 
No. 
O.P. 
No. Name 
Age/ 
Sex 
 
BT 
& 
AT 
 
HAEMATOLOGICAL PARAMETERS URINE ANALYSIS  
 
TC 
CU/mm 
 
DC 
 
ESR 
 Hb(gm) 
 
B.S 
Mg/dl 
S.Cho 
Mg/dl 
 
ALB SUG DEP 
P L E ½ hr 1 hr 
31. 1528 SUGANYA 17/F 
 
BT 5400 62 34 4 5 10 11.5 86 165 
- - FEC 
AT 6300 57 37 6 6 15 12.0 78 155 - - - 
32. 1755 
POWLIN 
SHANTHA 23/F 
BT 7600 58 40 2 7 12 9.5 94 176 - - - 
AT 5200 59 36 5 8 16 11.5 84 165 - - - 
33. 1761 RAJESWARI 31/F 
BT 9100 56 32 6 5 10 9.8 76 187 - - - 
AT 6800 54 42 4 6 12 12.0 92 154 - - - 
34. 2082 SUBHASINI 35/F 
BT 7200 65 35 0 4 8 10.5 81 163 - - FPC 
AT 4500 61 38 1 9 18 12.2 86 172 - - - 
35. 2288 
SARASWATH
Y 23/F 
BT 5700 55 38 7 6 14 9.5 140 185 - - - 
AT 6700 52 42 6 4 10 11.8 98 163 - - - 
36. 2562 RADHIGA 25/F 
BT 4500 59 41 0 8 16 10.5 87 178 - - FEC 
AT 6200 53 41 6 9 18 11.6 96 169 - - - 
37. 2286 SOWMIYA 28/F 
BT 8200 63 37 0 5 10 11.0 84 167 - - - 
AT 8300 67 30 3 7 14 12.0 82 157 - - FPC 
38. 2564 AISHWARYA 21/F 
BT 9800 65 32 3 8 15 12.5 94 156 - - - 
AT 4500 56 41 5 5 12 12.6 96 172 - - - 
39. 2566 KAVYA 20/F 
BT 6800 58 36 6 5 10 11.6 82 170 - - FEC 
AT 7100 57 40 3 8 18 12.2 79 165 - - - 
40. 2557 DEEPA 31/F 
BT 9600 67 29 4 6 14 8.8 85 154 - - - 
AT 5700 57 37 6 9 20 11.0 84 150 - - - 
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S. 
No. O.P. No. Name 
Age/ 
Sex 
 
BT 
& 
AT 
 
HAEMATOLOGICAL PARAMETERS URINE ANALYSIS  
 
TC 
CU/mm 
 
DC 
 
ESR 
 Hb(gm) 
 
B.S 
Mg/dl 
S.Cho 
Mg/dl 
 
ALB SUG DEP 
P L E ½ hr 1 hr 
41. 664/6045 
SUGANY
A 19/F 
 
BT 5400 62 34 4 5 10 11.5 86 165 
- - FEC 
AT 6300 57 37 6 6 15 12.0 78 155 - - - 
42. 1402/6801 SHANTHI 35/F 
BT 7600 58 40 2 7 12 9.5 94 176 - - - 
AT 5200 59 36 5 8 16 11.5 84 165 - - - 
43. 168/4474 
NEELAM
ANI 25/F 
BT 9100 56 32 6 5 10 9.8 76 187 - - - 
AT 6800 54 42 4 6 12 12.0 92 154 - - - 
44. 1035/5859 
SELVAR
ANI 20/F 
BT 7200 65 35 0 4 8 10.5 81 163 - - FPC 
AT 4500 61 38 1 9 18 12.2 86 172 - - - 
144 
5. RESULTS AND DISCUSSION 
 
  The well known Siddha herbo – mineral drug Navachara Chunnam had been 
subjected to various studies to establish the works of Siddhars to be true. Literary 
collections, physicochemical and Elemental analysis, toxicological study, 
pharmacological study and clinical study are done to prove the activity of Navachara 
Chunnam in PCOS (Polycystic ovarian syndrome) 
 
Navacharam, the chief ingredient of the medicine Navachara chunnam, is 
indicated for soodhagakattu in Siddha literature. In addition Navacharam is used as key 
ingredient in medical formulations like Panchalavana dhravagam, Saara mezhugu, 
Kalingadhi mezhugu, Bojana sanjeevi legyam, which are indicated for soodhagakatti and 
soodhagavali. The adjuvant for Navachara chunnam is stated as sombu kudineer. Sombu 
kudineer as a separate medicine have the property of curing soodhagavayu. Hence 
navachara chunnam indication for soothagakattu is justified based on the composition and 
adjuvant. 
 
PHYSICO CHEMICAL ANALYSIS OF NAVACHARA CHUNNAM 
 
Parameter Mean Value 
Loss on Drying at 105°C NIL 
Total Ash 82.036 % 
Acid insoluble Ash 0.577 % 
Particle size 
Completely 
passes through 
sieve no.44 
ph 13.5 
 
 
Interpretation 
The stability of a drug and its shelf –life is dependent on moisture content. 
Determination of moisture (Loss on drying) in a drug is one of the important test in 
pharmaceutical analysis. (Dr.A.V. Kasture 2008) 
Physico chemical analysis of Navachara chunnam showed that Loss on drying 
(LOD) is nil which indicated that no moisture content present in the prepared medicine. 
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Increased Moisture content is the factor for instability of a drug and lesser shelf life of a 
drug. Since Navachara Chunnam was well prepared, it could get maximum stability and 
better shelf life. Longer shelf life for Chunnam said in Siddha literature is justified from 
the above observation. 
 
                      Preliminary Chemical Analysis of Navachara chunnam 
 
S.NO TEST FOR CHEMICALS RESULT 
1. Reducing sugar Absent 
2. Starch Absent 
3. Protein Absent 
4. Amino acid Absent 
5. Albumin Absent 
6. Phosphate Absent 
7. Sulphate Present 
8. Chloride Present 
9. Iron Present 
10. Calcium Present 
11. Sodium Absent 
12. Potassium Absent 
13. Zinc Present 
14. Magnesium Present 
15. Alkaloids Absent 
16. Tannic acid Absent 
 
From the result of preliminary chemical analysis shows that trial drug has Sulphate, 
chloride, Iron, Calcium, Zinc and Magnesium 
 
Interpretation 
 
CALCIUM  
Maturation of the immature oocyte and the activation and fertilization of the 
mature egg are two separate events. Both may be synchronized by changes in intracellular 
calcium.  
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Evidence now suggests that abnormalities in calcium regulation may understandably 
explain the clinical presentation of PCOS, Including the reproductive abnormalities and 
insulin resistance. This evidence is supported by several facts. 
Ø The significance of calcium in egg activation and in triggering meiotic resumption 
Ø The role of calcium in LH-induced meiotic maturation 
Ø The function of calcium and vitamin D in insulin resistance 
Ø The clinical evidence of abnormalities in calcium homeostasis in reproductive 
disturbance and in women with PCOS 
 Antagonizing the inhibitor with changes in calcium concentration can affect 
continuation of meiosis. Extra cellular stimulation of the oocyte with calcium, 
gonadotropins and various growth factors results in changes in intracellular calcium 
concentrations via transmembrane movements between cytosol and internal organelles, 
representing are important signalling mechanism. 
 Calcium homeostasis in the setting of various hormones and growth factors 
determines the ultimate biochemical pathway selected in the phosphoinositide or 
adenylate cyclase-dependent protein kinase C system of reproduction and oocyte 
maturation. 
 More recently, calcium has identified as an important mineral nutrient in fertility. 
Vitamin D receptor knockout mice have low serum calcium concentration and are 
infertile. (Connie M.Weaver et al 2006) 
 
Zinc and Reproduction 
Zn is essential for proper reproduction (Biochemistry-Sathyanarayana) 
 
Magnesium and insulin resistance 
Magnesium is necessary for the action of insulin and the manufacture of insulin. 
Recent studies shows that an association between insulin resistance and magnesium 
deficiency. Mg deficiency is relatively common in diabetic individual (Nancy Dunne et 
al). Insulin resistance is one of the most important clinical features of PCOS. 
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ELEMENTAL ANALTSIS OF DRUG 
 
Fourier Transforms Infrared Spectroscopy (FT-IR): 
 
 
                                                 Fig no-4   FT-IR analysis 
 
FTIR is the acronym for Fourier Transform Infrared Spectroscopy. FTIR is a 
spectroscopic technique that utilizes lower energy radiation to induce vibration and 
rational excitation of atoms and groups of atoms within molecules. Because of the variety 
of symmetry of atomic groups and their differences in atomic masses and electronic 
structure the absorption patterns for a specific species will be unique, which allows for 
their identification. Infrared spectroscopic technique used to recognize the functional 
groups in organic and inorganic compounds. 
 
Principle 
IR interacts with the sample and the bonds between atoms in the molecule stretch 
and bend, absorbing infrared energy and creating the infrared spectrum. It is of two types 
bending and stretching. 
FT-IR is a very useful tool in the detection of the functional groups of bio 
molecules, thus aiding in their structural elucidation, thereby confirming the presence of 
active molecules responsible for the therapeutic activity of Siddha drugs. 
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Navachara chunnam have following function groups. 
 
PEAK VALUES FUNCTIONAL GROUPS 
3883.5 Phenols and alcohols 
3643.2 Phenols and alcohols 
3586.1 Phenols and alcohols 
3429.7 Phenols and alcohols 
2924.2 Alkanes 
2515.6 Carboxylic acids 
1472.0 Alkanes 
876.5 Aromatic group 
 
Interpretation 
Phenolic groups act as an anti-oxidant (Modern uses for ancient medicine 2009). 
Increased oxidative stress and decreased antioxidant capability in women with PCOS 
could be a causative factor to the increased risk of cardiovascular disease in adding to 
typical risk factors as insulin resistance, hypertension, obesity and dyslipidemia.(Gabor 
Kovacs et al 2007).Navachara chunnam which has phenolic groups may be act as an anti-
oxidant and to prevent classical risk factors of PCOS like cardiovascular disease, insulin 
resistance, obesity, dyslipidemia and hypertension. 
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SCANNING ELECTRON MICROSCOPE (SEM): 
 
 
 
Fig No-5-SEM analysis 
 
Electron Microscopes are scientific instruments that use a beam of highly 
energetic electrons to examine objects on a very fine scale. This examination can yield 
information about the topography (surface features of an object) morphology (shape and 
size of the particles making up the objects) composition (the elements and compounds 
that the object is composed of the relative amounts of them) and crystallographic 
information (how the atoms are arranged in the object) 
 
Nanoparticles have valuable properties that can be used to improve drug delivery. 
Where larger particles would have been unfurnished from the body, cells take up these 
nanoparticles because of their size. Complex drug delivery mechanisms are being 
developed, together with the ability to get drugs through cell membranes and into 
cell cytoplasm. Effectiveness is important because many diseases depend upon processes 
within the cell and can only be impeded by drugs that make their way into the cell. 
(Bertrand N et al, 2011) 
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ACUTE AND SUBACUTE TOXICITY ON NAVACHARA CHUNNAM 
The results of haematological investigations revealed significant changes in the 
different parameters investigated compared with those of respective control. All the 
animals from control group were survived throughout the dosing period of 28 days but the 
Navachara Chunnam higher dose treated group showed toxic symptoms like itching, 
writhing and muscle paralysis with loss of gripping response. Two animals were died 
after 15 days of treatment. 
 
Animals from all the treated dose groups exhibited minimum body weight gain 
with that of controls throughout the dosing period of 28 days. Food consumption in 
treated animals was found to be reduced and water intake (Data not shown) was increased 
gradually at high dose group throughout the dosing period of 28days. Ophthalmoscopic 
examination, conducted prior to and at the end of dosing period on animals from control 
and all the treated dose groups did not reveal any abnormality. Functional observation 
tests conducted at termination revealed no abnormalities. Urine analysis, conducted at the 
end of the dosing period in week 4 revealed color and pH changes after treatment. 
  
Organ weight data of animals sacrificed at the end of the dosing period was found 
to be comparable except kidney, testis and liver with that of respective control. Gross 
pathological examination did not reveal any abnormality. Histopathological examination 
reveal as follows. In stomach with superficial erosion and congestion, Liver: shows 
marked dilatation of sinusoids, degeneration of hepatocytes, necrosis. Kidney: shows 
renal tissue with tubular epithelial damage. Testis: Giant cells were formed in the lumen 
of the seminiferous tubules and the spermatogenic cells degenerated. Lung: shows 
congestion, narrowed alveolar space and thickened alveolar wall. Ovary: shows increased 
ovarian follicles and corpus leuteum. Remaining organ architecture was found to be 
normal. 
These finding indicates that the Navachara chunnam has toxic effect upto 
50mg/kg onwards treated via oral route over a period of 28 days. So, it can be concluded 
that the Navachara Chunnam can be prescribed for therapeutic use in human with the 
dosage of upto maximum of 25mg/kg. body weight p.o. But for the long term use the 
dose reduction is recommended to prevent hepatic and renal complications.
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Toxicity profile of Navachara Chunnam 
 
 
 
 
 
 
 
 
Table 3: Dose finding experiment and its behavioral Signs of Toxicity 
No 
Dose 
mg/kg 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1. 500 + - - + - + - - - + - - - - - - - - - - 
2 1000 + + - + - + + + - + - - - - - - - + + + 
3 2000 + + - + - + + + + + + - - - - - - + + + 
1. Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch Response 7. Decreased Motor Activity 8. Tremors 
9. Convulsions 10. Muscle Spasm 11. Catatonia 12. Muscle relaxant 13. Hypnosis 14. Analgesia 15.Lacrimation 16. Exophthalmos 17. 
Diarrhoea 18. Writhing 19. Respiration 20. Mortality 
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Toxicity profile of Navachara Chunnam 
 
 
Table 4: Organ weights of rats in the sub acute toxicity study of the Navachara chunnam. 
Values are expressed as mean + S.E.M., n = 6; *p<0.05; **p<0.01 significantly different from 
control. 
  
Parameter Control  Navachara chunnam 
25mg/kg 50mg/kg 100mg/kg 
Brain 2.04±0.03 1.95±0.03 1.99±0.03 2.00±0.04 
Lungs 2.24±0.04 2.18±0.05 2.09±0.06 1.90±0.08* 
Heart 1.83±0.06 1.68±0.05 1.71±0.07 1.79±0.09 
Liver 18.50±0.53 14.68±0.44* 15.17±0.58* 13.50±0.56** 
Pancreas 1.99±0.18 1.77±0.13 1.70±0.12 1.74±0.14 
Spleen 1.10±0.07 1.04±0.02 1.04±0.04 1.06±0.03 
Ovary 1.03±0.04 1.15±0.02* 1.22±0.05** 1.26±0.02** 
Kidneys 1.90±0.05 1.80±0.03 1.61±0.04 1.37±0.07 
Testis 1.98±0.05 1.96±0.06 1.99±0.04 2.09±0.04 
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Toxicity profile of Navachara Chunnam 
 
 
Table 5: Effect of Navachara chunnam on Body weight of rats. 
Treat
ment 
Day 1 Day 4 Day 8 Day 12 Day 16* Day 
20** 
Day 
24** 
Day 
28** 
Contro
l 
158.02±
2.4 
162.00±
2.12 
164.11±
1.74 
166.51±
1.12 
167.12±
2.20 
168.54±2
.11 
168.05±
2.32 
170.14±
2.51 
25mg/k
g 
151.00±
1.2 
152.12±
1.4 
151.3±1
.2 
151.6±1
.82 
148.51±
1.20 
147.50±1
.2 
145.3±1
.3 
146.5±2
.2 
50mg/k
g 
150.02±
1.12 
152.20±
1.10 
151.7±1
.79 
150.04±
1.4 
152.41±
1.30 
140.25±2
.36 
140.20±
2.3 
135.06±
2.01 
100mg/
kg 
150.12±
1.34 
150.27±
1.42 
148.26±
3.25 
148.22±
2.02 
143.11±2.
7 
142.55
±1.6 
140.14±
1.10 
140.52±
0.32 
Values are expressed as mean + S.E.M., n = 6; *p<0.05; **p<0.01 significantly different from 
control. 
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Toxicity profile of Navachara Chunnam 
 
 
Table 6: Effect of Navachara chunnam on Heamatological and Biochemical profile of rats 
Parameter Treatment and Dose  
Control  Navachara 
Chunnam 
(25mg/kg) 
Navachara 
Chunnam 
(50mg/kg) 
Navachara 
Chunnam 
(100mg/kg) 
WBC(X103/µL) 11.4±3.1 10.72±2.4 10.10±2.2 10.16±2.5 
RBC(X1012/l) 7.14±0.38 7.92±0.46 8.12±0.52 7.00±0.50 
Hemoglobin(g/dl) 13.44±0.32 15.10±0.35* 14.52±0.40 15.11±0.44* 
MCV (fl) 53±0.47 53.52±3.20 52.55±6.42 60.17±8.07* 
MCHC (g/dl) 35.14±1.5 27.11±1.80** 37.20±1.58 30.10±1.40* 
MCH (pg) 20±0.2 23±0.1* 24±0.3** 25±0.3** 
Platelet count  
(X109/l) 
882.75±20.2 785.44±17.38* 784.40±28.12* 885.18±25.51 
Bilirubin 1.33±0.04 1.28±0.02 1.34±0.05 1.31±0.02 
ALT (µ/l) 35.38±2.2 24.50±1.40** 26.12±2.10** 27.00±1.43** 
AST (µ/l) 184.90±5.4 125.16±6.22** 130.69±6.20** 147.11±7.00** 
Creatinine (µ/l) 0.32±0.04 0.46±0.05** 0.40±0.06** 0.47±0.04** 
Cholesterol (mmol/l) 33.83±3.3 34.8±3.2 40.02±2.5 44.2±2.9** 
ALP 54.58±3.2 68.80±2.84** 63.60±3.28 66.60±4.29* 
Triglyceride 27.80±5.4 25.16±4.7 25.26±4.3 24.15±3.5 
BUN (mg/dL) 25.60±0.98 24.02±1.10 24.60±1.42 25.14±1.82 
Glucose (mg/dL) 99.30±3.72 99.10±5.37 99.70±8.22 98.57±7.33 
Values are expressed as mean + S.E.M., n = 6; *p<0.05; **p<0.01 significantly different from 
control. 
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Toxicity profile of Navachara Chunnam 
 
Table 7: Urine Analysis 
Parameters Control 25 mg/kg 50 mg/kg 100 mg/kg 
Colour Yellow Yellow Yellow Yellow 
Transparency Clear Slightly turbid Cloudy Turbid 
Specific gravity 1.010 1.010 1.010 1.010 
PH >7.2 >8.0 >8.0 >9.0 
Protein Nil 1+ 3+ 2+ 
Glucose Nil Nil Nil Nil 
Bilirubin -ve -ve -ve -ve 
Ketones -ve +ve +ve +ve 
Blood Absent Absent Absent Absent 
UROBILINOGEN Normal Abnormal Abnormal Abnormal 
Pus cells 0-cells/HPF 1-cell/HPF 2-cells/HPF 1-cell/HPF 
RBCs Nil Nil 0-1cells/HPF Nil 
Epithelial cells Nil 1-cell/HPF Nil 1-cell/HPF 
Crystals Nil Nil Nil Nil 
Casts Nil Nil Nil Nil 
Others Bacteria seen Bacteria seen Bacteria seen Bacteria seen 
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Fig 
No.6-Subacute toxicity of Navachara chunnam (Histopathology) 
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Fig.No.7- Subacute toxicity of Navachara chunnam (Histopathology) 
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Fig.No.8- Subacute toxicity of Navachara chunnam (Histopathology) 
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Fig.No.9 Subacute toxicity of Navachara chunnam (Histopathology) 
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EVALUATION OF OVULOGENIC EFFECT OF NAVACHARA CHUNNAM IN 
RATS 
RESULTS AND DISCUSSION 
 Polycystic ovary syndrome is an endocrine disorder that affects approximately 5% 
of all women. It occurs amongst all races and nationalities, is the most common hormonal 
disorder among women of reproductive age, and is a leading cause of infertility. The 
principal features are obesity, anovulation and/or menstruation, and excessive amounts or 
effects of androgenic hormones. The symptoms and severity of the syndrome vary greatly 
among women. While the causes are unknown, insulin resistance, diabetes, and obesity 
are all strongly correlated with PCOS. Based on symptomatology incidence varies 
between 4-5% to 21% (menstrual abnormalities) and 3.5 to 9% (hyperandrogenism). It is 
important to remember that, 40% of women with oligomenorrhoea, 84% of women with 
hirsutism and 100% of women presenting with severe acne, have PCOS as their etiology.  
 Due to the side effects of many chemical drugs, the alternative use of traditional 
medications has greatly increased within the past decade. Successful growth and 
differentiation of the ovarian follicle is known to be under the control of the follicle-
stimulating hormone (FSH) and luteinizing hormone (LH) produced by the pituitary. 
Many recent in vitro and in vivo studies have shown that the process of folliculogenesis is 
mediated by cAMP and is modulated by many local paracrine and autocrine factors in 
addition to the gonadotrophins themselves. These modulatory factors include steroid 
hormones and non-steroidal factors such as growth factors.  
 Although gonadotrophins are required for folliculogenesis, factors that regulate 
the cyclic appearance and atresia of dominant follicles and other follicles of variable size 
are of great significance. Various factors causing and regulating follicular atresia may 
include age, stage of the reproductive cycle, pregnancy, lactation, hormones of 
extraovarian or intraovarian sources.  
 Follicular growth is regulated by endocrine (FSH, LH and prolactin) and local 
(paracrine and autocrine) factors. The latter include steroid hormones (e.g., progestins, 
estrogens and androgens) produced by different cell types of the ovary and various non-
steroidal regulators (e.g., oocyte maturation inhibitor, luteinization stimulator, 
luteinization inhibitor, FSH inhibitor, insulin-like growth factors, transforming growth 
factors, epidermal growth factor, platelet-derived growth factor, inhibin, and activin). 
Many of the changes occurring during oocyte growth and maturation also appear to be 
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mediated or influenced by ions, hormones (especially gonadotrophins and steroids) and 
endogenous cytoplasmic factors such as maturation promoting factor and growth factors. 
 Treatment with doses of 25 and 50 mg/kg of Navachara Chunnam significantly 
increased the number of primordial follicles (p<0.05 for 25 mg/kg; p<0.01 for 50 
mg/kg;). This increase was also observed in the number of primary follicles, however it 
was significant only in the 50mg/kg group (p<0.01,). Treatment with 25 and 50 mg/kg 
dosages decreased the number of preantral and antral follicles, however, this decrease was 
significant only in the 50 mg/kg group (p<0.05). Different dosages of the Navachara 
Chunnam slightly increased the number of atretic follicles; a greater increase was 
observed at 50 mg/kg (p>0.05).  
 The treatment with both doses of Navachara Chunnam caused an  alterations in 
the amount FSH, which was statistically significant. Navachara Chunnam in the first 
stages of folliculogenesis strongly increased the number of primordial follicles. This 
increase was more pronounced at the 50mg/kg dose of the Navachara Chunnam acted as 
a stimulant, causing progression of folliculogenesis to the stage of primary follicle 
formation. However, at the next stage of folliculogenesis. Navachara Chunnam caused an 
increase in the number of growing follicles. The Navachara Chunnam also caused an 
increase in the number of atretic follicles, which confirmed the repressing effect of the 
Navachara Chunnam on the natural growth of follicles, which seems reasonable 
considering the slight decrease in the level of FSH. 
 
 The results of ovulation effect revealed the significant influence at the dose level 
of 25mg/kg and this marked effect was ensured with the histological evaluation of uterus 
of experimental rats also. Hence it may be concluded that the Navachara Chunnam is a 
excellent traditional medicine in the treatment for anovulatory conditions like PCOS and 
the effect may be attributed to the elevation of the ovulation stimulatory hormones in 
animal models. 
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Table-8: Effect of Navachara Chunnam on weight of uterus and ovary after 10 days 
treatment 
 
S.No Group Treatment and dose 
Weight of uterus 
(mg) 
Weight of ovary (g) 
1. Normal 2ml/kg 2% CMC 16.10±1.24 1.65±0.12 
2. Test-I 
Navachara Chunnam 
25mg/kg 
14.22±0.56 1.45±0.14 
3. Test-II 
Navachara Chunnam 
50mg/kg 
15.31±1.00 1.51±0.10 
4. Standard 
Clomiphene 
10mg/kg 
15.48±+0.68 1.72±0.15 
 
N = 6. Values are expressed as Mean±SEM. nsP>0.05 compared to normal control. 
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Table-9: Effect of Navachara Chunnam on Serum Concentration of reproductive 
hormones of female rats after 10 days treatment. 
 
S.N
o 
Group 
Treatme
nt and 
dose 
LH 
(IU/ml) 
FSH  
(IU/ml) 
Estrogen 
(pg/ml) 
Progestero
ne (pg/ml) 
Testestero
ne  
(ng/ml) 
1. 
Norma
l 
2ml/kg 
2% CMC 
0.31±0.
06 
0.36±0.0
4 
62.24±3.2 8.2±1.12 1.1±0.10 
2. Test-I 
Navachar
a 
Chunnam 
25mg/kg 
0.39±0.
08 
0.50±0.0
6 
45.27±2.2*
*,a 
7.1±1.00 
0.6±0.05**,
a 
3. Test-II 
Navachar
a 
Chunnam 
50mg/kg 
0.48±0.
08 
0.61±0.0
8* 
41.55±1.4*
*,a 
6.8±0.82 0.4±0.03** 
4. 
Standa
rd 
Clomiphe
ne 
10mg/kg 
0.56±0.
14 
0.67±0.1
0* 
30.62±1.0*
* 
6.2±0.61 0.3±0.02** 
 
N = 6. Values are expressed as Mean±SEM. *p<0.05;**p<0.01 Vs Normal control; ap<0.01 Vs Standard. 
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Fig.No.10. Ovulogenic activity of NC 
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4.5 CLINICAL ASSESMENT OF NAVACHARA CHUNNAM: 
44 women with PCOS, age between 16-38 year were selected for open label 
clinical trial. Among 44 patients 40 patients were treated as out-patients, 4 patients were 
treated as in-patients. The selection was based on the inclusion and exclusion criteria. 
They were clinically diagnosed on the basis of siddha principles with modern laboratory 
findings. 
 
Table No. 10-(Gradation result) 
 
S. NO LEVEL OF IMPROVEMENT NO.OF PATIENTS PERCENTAGE 
(%) 
1. Marked Response 32 72 
2. Moderate Response 6 14 
3. Mild Response 3 7 
4. Poor Response 3 7 
TOTAL 44 100 
 
 
 
 
Inference : 
32 patients had marked response 
6 patients had moderate response 
3 patients had mild response 
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Table No. 11- (Improvement in signs and symptoms) 
 
SL.NO SIGNS AND SYMPTOMS 
No of Patients 
BT AT IMP IMP % 
1. 
Irregular 
Menstruation 44 8 36 81 
2. Oligomenorrhoea 38 7 31 82 
3. Amenorrhoea 16 3 13 81 
4. Dysmenorrhoea 20 2 18 90 
5. Weight Gain 25 5 20 80 
6. Constipation 22 4 18 82 
7. Infertility 6 5 1 17 
8. Acanthosis nigricans 12 11 1 8.3 
9. Hirsutism 10 10 0 0 
 
 
 
Inference 
Among 44 patients, 
Ø 36 out of 44 patients were relieved from Irregular Menstruation. 
Ø 31 out of 38 patients were relieved from Oligo Menorrhoea. 
Ø 13 out of 16 patients were relieved from Amenorrhoea. 
Ø 18 out of 20 patients were relieved from Dysmenorrhoea. 
Ø 20 out of 25  patients were reduced weight. 
Ø 1 out of 6 patient was conceived. 
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USG-PELVIS 
 
 
Fig No.11- Polycystic appearance of ovary (Before treatment) 
 
 
 
 
                           Fig No.12-   After treatment 
 
 
 
 
STATISTICAL ANALYSIS 
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DESCRIPTIVE STATISTICAL FOR IMPROVEMENT IN SIGN & SYMPTOMS 
IN PCOS (POLYCYSTIC OVARIAN SYNDROME) PATIENTS 
 
PAIRED “t” TEST RESULT: 
BMI (BODY MASS INDEX) IN PCOS  PATIENTS 
 
Intermediate values used in calculations: 
   t = 23.3521 
  df = 43 
  standard error of difference = 0.141  
 
 
 
 
 
 
 
 
 
 
 
 
 
P value and statistical significance:  
The two-tailed P value is less than 0.0001 
By conventional criteria,this difference is considered to be extremely 
statistically significant.  
 
Confidence interval: 
The mean of Before treatment minus After treatment equals 3.295 
95% confidence interval of this difference: From 3.011 to 3.580  
 
Group Before treatment 
After 
treatment 
Mean 27.686 24.391 
SD 1.832 1.612 
SEM 0.276 0.243 
N 44 44 
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6. CONCLUSION 
 
Navachara Chunnam  is selected from the classical Siddha text Anubhoga Vaidhya 
Navaneetham for the evaluation of its therapeutic efficacy on Polycystic ovarian 
syndrome(Sudhagakatti).  
Physico chemically, Navachara chunnam with Nil  Loss on drying(LOD) has  
Longer shelf life.  Navachara chunnam contain Calcium which may  act in PCOS to 
regulate oocyte maturation and  the activation and fertilization of the mature egg. 
Navachara chunnam contains Zinc, which is essential for reproduction. Presence of Mg in 
Navachara chunnam  may be  useful in insulin action in PCOS. 
 SEM analysis revealed the size of the drug particle is in nanometer which implies 
that the drug could have potent drug delivery. FT-IR analysis disclosed the presence of 
Phenolic groups which could act as an anti-oxidant and prevent classical risk factors of 
PCOS like cardiovascular disease, insulin resistance, obesity, dyslipidemia and 
hypertension. 
The results of ovulation effect in Rats revealed the significant influence at the 
dose level of 25mg/kg and this marked effect was ensured with the histological evaluation 
of uterus of experimental rats also. Hence it may be concluded that the Navachara 
Chunnam is an excellent traditional medicine in the treatment for anovulatory conditions 
like PCOS and the effect may be attributed to the elevation of the ovulation stimulatory 
hormones in animal models. 
In Open clinical trial the drug has showed 72% marked response to PCOS. There 
were no new adverse drug reactions noticed during the course of the treatment. 
As all the studies about Navacharam chunnam add beneficiary values for the   
therapeutic efficacy for PCOS  it can be concluded that Navachara chunnam could be a 
scientifically validated and proven drug  of choice for the management of  
PCOS(Sudhagakatti). 
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7. SUMMARY 
The trial drug Navachara Chunnam is selected from the classical Siddha text 
Anubhoga Vaidhya Navaneetham for the evaluation of its therapeutic efficacy on 
Polycystic ovarian syndrome(Sudhagakatti). In the Introduction, the need to explore a 
new drug and the lacuna in present day management of  PCOS is signified.  
In  Drug review, Navacharam is viewed  in the field of   General characters, 
therapeutic action  and its presence in Siddha formulations indicated for female 
reproductive disorders. The uniqueness of Chunnam medicines expounded by siddhars 
are highlighted. Disease review explored the collection of Siddha literature as well as 
present  scientific view about PCOS. 
To standardize the drug, Physical and chemical study of the drug was done at 
SCRI, Arumbakkam, Chennai. Instrumental analysis for the drug was done at Anna 
University, Chennai. SEM analysis revealed the size of the drug particle is in Nanometer 
which implies that the drug could have potent drug delivery. FTIR analysis disclosed the 
presence of Phenolic groups which could act as an anti-oxidant and prevent classical risk 
factors of PCOS.  
. The results of ovulation effect in Rats revealed the significant influence at the 
dose level of 25mg/kg and this marked effect was ensured with the histological evaluation 
of uterus of experimental rats also. Hence it may be concluded that the Navachara 
Chunnam is an excellent traditional medicine in the treatment for anovulatory conditions 
like PCOS and the effect may be attributed to the elevation of the ovulation stimulatory 
hormones in animal models. 
In Clinical study, Open clinical trial was conducted in 44 patients at Arignar Anna  
Government Hospital of Indian Medicine and Homeopathy, Chennai. The drug has shown 
significant improvement in Polycystic ovarian patients.  
The final Discussion and conclusion chapters analyzed the dissertation. The 
conclusion chapter also provides a discussion of the verification and validity of the 
research results carried out. The most vital part of some experience of the findings in the 
dissertation is also discussed and thereafter invites the reader to further studies and future 
research possibilities. 
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                                M.D(S) - Branch  II (GUNAPADAM) 
Name of  the medicine : Aivaeli samoola chooranam  
Name of the disease     : Karappan (Eczema)  
Dose & Adjuvant         : 1 gm Bd after food with sugar  
O.P. NO : Date : Height : 
Name : Age/Sex : Weight : 
Address : 
 
BP : 
Occupation : Marital status : PR : 
 
    SIGNS&SYMPTOMS                                   WEEKS 
  0   1   2   3    4    5    6   7   8 
Itching          
Erythema          
Oedema          
Vesicles          
Pustules          
Oozing          
Scaling          
Lichenification          
Ulcer          
Pain and burning sensation          
Varicose vein          
Family H/O of EAHU          
Others 
 
         
Signature of AL/MO          
  
ASSESSMENT 
 Eczema Area and Severity  
   Index( EASI)Score 
         Before treatment          After treatment 
  
CALCULATION OF EASI SCORE 
EASI=0.1{Eh+Ih/Oh/Ph+Exh+Lh}(A)h+0.2{Eu+Iu/Ou/Pu+Exu+Lu}Au+0.3{Et+It/Ot/P
t+Ext+Lt}At+0.4{El+Il/Ol/Pl+Exl+Ll}Al 
 
Eh-Erythema of head 
Ih-Induration of head 
Oh-Oedema of head 
Ph-Papulation of head 
Exh-Excoriation of head 
Lh-Lichenification of head 
(A)h-Area of head 
Upper extremities-u 
Trunk-t 
Lower extremities-l 
E, I, O, P, Ex, and L are assessed according to a 3-point scale where 0=no symptoms, 
1=slight, 
2=moderate, 3=marked. A is assigned a numerical value based on the extent of lesions in 
a given anatomic site: 1=<10%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89% and 6=90-
100%. 
  
EASI SCORE= 
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  Before treatment After treatment 
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  Blood sugar   
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  Albumin   
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Specific patch test    
 
 SIDDHA SYSTEM OF EXAMINATION 
ENVAGAI THERVUGAL 
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Name of  the medicine : Navachara chunnam  
Name of the disease     : Soothaga katti(PCOS)   
Dose & Adjuvant         : As per literature 260mg to 780mg with Soembu kudineer 
                                      (Foeniculum vulgare). Dose will be fixed depending upon  
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O.P. NO : Date : Height : 
Name : Age/Sex : Weight : 
Address : 
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Acanthosis nigricans          
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Waist hip ratio          
Others 
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   Clinical features  Before treatment                      After treatment 
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Regularity of the cycle      
Length of the cycle      
Duration of 
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    Blood sugar   
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   FSH   
   Estradiol   
   Progesterone   
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                     GOVERNMENT  SIDDHA MEDICAL COLLEGE AND HOSPITAL. 
CHENNAI-  600 106. 
M.D (siddha) - BRANCH- II. GUNAPADAM 
CONSENT FORM 
CERTIFICATE BY INVESTIGATOR 
I certify that I have disclosed all details about the study in the terms readily understood by 
the patient and handed over a copy of the patient information sheet. 
 
Date:      Signature of the Investigator 
       Name: 
CONSENT BY PATIENT 
I have been informed to my satisfaction, by the attending physician, the purpose of the 
clinical trial and the nature of drug treatment and follow-up, including the laboratory 
investigations to be performed to monitor and safeguard my body functions. 
I am also aware of my right to opt out of the trial at any time during the course of trial 
without having to give the reasons for doing so. I, exercising my free power of choice, hereby 
give my consent to be included as a subject in the clinical trial of traditional remedy, namely 
Aivaeli samoola chooranam for the treatment of Karappan (ECZEMA). I understand that I may 
be treated with this drug for the disease. 
 
Signature of the attending Physician                                Name and Signature of the Patient  
 
Place :             Name and Signature of witness  
     
Date :             Relationship to patient:  
 
 
 
 GOVERNMENT  SIDDHA MEDICAL COLLEGE AND HOSPITAL. 
CHENNAI-  600 106. 
M.D (Siddha) - BRANCH- II. GUNAPADAM 
CONSENT FORM 
CERTIFICATE BY INVESTIGATOR 
I certify that I have disclosed all details about the study in the terms readily understood by 
the patient and handed over a copy of the patient information sheet. 
 
Date:      Signature of the Investigator 
       Name: 
CONSENT BY PATIENT 
I have been informed to my satisfaction, by the attending physician, the purpose of the 
clinical trial and the nature of drug treatment and follow-up, including the laboratory 
investigations to be performed to monitor and safeguard my body functions. 
I am also aware of my right to opt out of the trial at any time during the course of trial 
without having to give the reasons for doing so. I, exercising my free power of choice, hereby 
give my consent to be included as a subject in the clinical trial of traditional remedy, namely 
Navachara chunnam for the treatment of Sudhagakatti(Polycystic ovarian syndrome).                   
I  understand that I may be treated with this drug for the disease. 
 
Signature of the attending Physician                                Name and Signature of the Patient  
 
Place :             Name and Signature of witness  
     
Date :             Relationship to patient:  
 
 
 







 
